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Neurodegenerative and cerebrovascular diseases are frequent in elderly populations 
and comprise primarily of dementia (mainly Alzheimer disease (AD)), Parkinson disease 
(PD) and stroke. The prevalence of these neurological disorders rises with older age. 
From 55 years to 90 years and above, the prevalence of dementia increases from less 
than 1% to over 40%.1-3 For PD, the prevalence increases over the same age range 
from less than 0.5% to more than 4%,4,5 and for stroke from approximately 1% to 
nearly 10%.6,7 Similar age-related patterns are observed for incidence figures.8-11 In the 
Netherlands, the population of persons of 65 years and older is expected to increase 
from 2.4 million in 2007 to 3.9 million in 2050.12 At a global level, 2 billion persons 
above 65 years are expected by 2050.13 As a consequence of the aging population 
the incidence and prevalence of age-related neurological diseases will increase 
accordingly. Moreover, these neurological disorders all constitute highly disabling 
diseases, with appreciable impact on quality-of-life at the patient level, but also on 
society, both economically and socially.12,14-17 Currently, there is no effective cure for 
AD18, PD19 or the consequences of stroke.20 Hence, identification of determinants of 
these neurological diseases and development of preventive strategies is of paramount 
importance. This search is, in part, directed at currently available drugs which target 
established risk factors of neurological disease, or that have, in in vivo or in vitro 
studies, shown to interfere with more specific elements of the supposed pathogenic 
pathway of disease. Two drug groups commonly used by elderly are of interest, namely 
nonsteroidal anti-inflammatory drugs (NSAIDs) and cardiovascular medication. The 
general objective of this thesis was to study the role of these drugs as determinants of 
neurodegenerative and cerebrovascular diseases.
NoNSteroIDAl ANtI-INflAmmAtory DrugS (NSAIDS)
NSAIDs are among the most widely prescribed drugs worldwide owing to their anti-
inflammatory, antipyretic and analgesic properties.21 Registered indications relevant 
to the elderly population include mild to moderate pain and symptomatic relief in 
musculoskeletal and joint diseases. In the early 1970’s, a decade after their market 
introduction, it was discovered that NSAIDs mediate their anti-inflammatory effects 
through inhibition of the cyclooxygenase (COX) enzyme.21 COX is the enzyme required 
for the conversion of arachidonic acid to prostaglandins, a group of compounds with 
extensive functions in human physiology. At least two isoforms of COX to date have 
been identified, COX1 and COX2.22-24 NSAIDs differ with respect to relative selectivity 
Introduction
9
for either of the COX-enzymes.25 The ‘traditional’ NSAIDs are mostly non-selective 
and inhibit both COX-enzymes concurrently. Due to their inhibition of COX1, which 
is involved in gastric mucosal defence, the ‘traditional’ NSAIDs are known for their 
gastrointestinal adverse effects.26-28 In order to reduce these adverse events, the 
more recently developed compounds selectively inhibit COX2. However, in September 
2004, a COX2-selective NSAID was voluntarily withdrawn from the market as a result 
of concerns regarding its cardiovascular safety based on clinical trial data.29-31 It was 
thought that selective COX2-inhibition, without concomitant inhibition of COX1, causes 
platelet aggregation and thereby induces a prothrombotic state.32,33 Retrospective 
analyses of observational series and non-cardiovascular clinical trials suggested, 
however, that cardiovascular events may also occur with non-selective NSAIDs. Hence, 
it was debated whether the cardiovascular risk is restricted to the COX2-selective 
compounds.28,34-36 Furthermore, it is unclear whether NSAID use poses similar risks for 
different cardiovascular and cerebrovascular events. We investigated the association 
between NSAID use and risk of stroke in Chapter 1.1 and transient ischemic attack 
(TIA) in Chapter 1.2 and determined whether associations differed for the different 
NSAID groups, based on their COX-selectivity. 
NSAIDs have been a focus of pharmacoepidemiological research in neurodegenerative 
disease.37,38 Inflammation is a process that has been related to the onset of 
numerous neurodegenerative disorders.39,40 Findings from epidemiological studies 
have repeatedly suggested that anti-inflammatory drugs, particularly NSAIDs, could 
protect against AD and possibly against PD.37,41,42 Initially, it was thought that the 
anti-inflammatory properties of NSAIDs explain the protective effect of NSAIDs 
on AD and PD. However, NSAIDs also exhibit other effects potentially relevant to 
neurodegenerative disease. Of particular interest to researchers in the field of AD is the 
effect of NSAIDs on amyloid-β42-protein processing.43 In vitro and in vivo studies have 
shown consistently that a certain subgroup of NSAIDs lowers amyloid-β42 levels.44,45 
Amyloid-β42 protein is the major constituent of the senile plaques, a hallmark of 
Alzheimer pathology.46,47 If amyloid-β42 level lowering NSAIDs would protect against 
AD this would support a role of amyloid-β42 in the pathogenesis of AD. Moreover, it 
would provide a potential precursor for future drug development.48 In Chapter 1.3 
we examined the association between NSAID use and PD. Next, in Chapter 1.4, we 
investigated whether NSAIDs that lower amyloid-β42 peptide protect against AD. 
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CArDIovASCulAr meDICAtIoN
The presence of vascular risk factors, such as hypertension, hypercholesterolemia and 
diabetes mellitus places a patient at risk for cerebrovascular events. Hence, vascular 
risk management is a well-established strategy in the prevention of cerebrovascular 
events.49 In neurodegenerative disease the involvement of vascular pathology has 
long been recognized for vascular dementia, though this view is relatively new for 
AD.50,51 Despite the accumulating evidence that the elderly population may benefit 
from vascular risk management to prevent dementia, no such strategy currently 
exists. Two of these major vascular risk factors, of interest in Alzheimer research 
and for which pharmacological treatments are available, are hypertension and 
hypercholesterolemia.52 Cholesterol-lowering drug therapy nowadays consists mostly 
of statins.53 Antihypertensives are a group of diverse compounds that lower blood 
pressure though different mechanisms.54 The main pharmacological effects of these two 
drug groups on cholesterol levels and blood pressure were considered to be of potential 
value to AD.55 Alternatively, evidence from several lines of research suggests that 
other mechanisms of action or differences among the compounds within these drugs 
groups should not be precluded.56,57 A particular issue was raised for statins, since 
some statins are able to cross the blood brain barriers more easily than others, and the 
latter might therefore lack the ability to affect actual brain cholesterol homeostasis.58 In 
Chapter 2.1 we studied the association of statins and AD and evaluated whether there 
is a difference in the risk of AD for lipophilic statins and hydrophilic statins. In Chapter 
2.2 we investigated whether use of antihypertensives is associated with a reduced risk 
of dementia.
In neurodegenerative and cerebrovascular disorders clinical symptoms typically become 
manifest late in the disease course. The occurrence of clinical disease may therefore 
not reflect the underlying spectrum of disease-related pathology. Nowadays, non-
invasive imaging techniques, such as computed tomography and magnetic resonance 
imaging (MRI) allow for the investigation of pre-symptomatic brain pathology.59 Well-
studied markers of brain pathology are white matter lesions (WML).60,61 Cerebral white 
matter is important for transmission of impulses between different brain regions. WML 
are frequently observed on MRI scans in elderly persons and thought to result from 
vascular brain pathology.62 They have been associated with the risk of stroke, cognitive 
impairment and dementia.63-65 Besides their correlation with advanced age, several 
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cerebrovascular risk factors have been associated with the prevalence and progression 
of cerebral WML.66 Of these, increased blood pressure is the most widely recognized.67 
Consequently, control of blood pressure with antihypertensive agents was put forward 
as a possible strategy for the prevention of WML progression. Thus far, the evidence 
from two clinical trials and a study in healthy volunteers suggest that antihypertensive 
treatment protects against WML progression.68,69 In the general population, however, 
evidence on the relationship between antihypertensive use and progression of WML 
later in life is sparse. In Chapter 2.3 we studied whether antihypertensives could reduce 
the risk of WML progression.
MRI technology has advanced significantly over the years, contributing to its speed, 
sensitivity and spatial resolution. One area of research in neuroimaging that has 
benefited from these technical improvements is the research on cerebral microbleeds, 
another potential marker of vascular brain pathology.70,71 Cerebral microbleeds are 
hemosiderin deposits from red blood cells that presumably have leaked out of small 
brain vessels. The presence of cerebral microbleeds is associated with an increased 
risk of adverse neurological events in stroke patients.72,73 The etiology of cerebral 
microbleeds is largely unknown but is thought to resemble that of intracerebral 
hemorrhage. The clinical relevance of microbleeds has received particular attention in 
cardiovascular and cerebrovascular disease risk management, which often includes 
the decision to prescribe antithrombotic drugs to patients at risk for ischemic events. 
However, the use of antithrombotics was found to increase the risk of symptomatic 
hemorrhage74 and concerns are raised as to whether this also applies to microbleeds. 
A better understanding of the effect of antithrombotics on microbleeds is needed to 
aid in these clinical decisions. In the final chapter, Chapter 2.4, we thus explore the 
association between the use of antithrombotic medication and the presence of cerebral 
microbleeds. 
The studies presented in this thesis are based on the Rotterdam Study, an ongoing 
population-based study into causes and consequences of age-related diseases with 
detailed information on drug exposure from pharmacy prescription data during follow-
up. For our final study on antithrombotics and presence of microbleeds we included a 
randomly selected sample from the first expansion of the Rotterdam Study cohort of 
persons 60 years and older.75 
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AbStrACt
background: In clinical trials, cyclooxygenase (COX)-2-selective nonsteroidal anti-
inflammatory drugs (NSAIDs) were associated with an increased risk of thromboembolic 
events. We studied the association between NSAID use and risk of stroke in the 
prospective, population-based Rotterdam Study.
methods: We followed 7,636 persons free of stroke at baseline (1991-1993) for incident 
stroke until September 2004. Data on all filled prescriptions came from pharmacy 
records. With Cox regression models, we calculated crude and adjusted hazard ratios 
(HR) of stroke for time-dependent current use, compared with never use, of NSAIDs 
grouped according to COX selectivity (COX1-selective, nonselective, and COX2 
selective) and individual NSAIDs. 
results: At baseline, the mean age of the study sample was 70.2 years, and 61.3% 
were female. During 70,063 person-years of follow-up (mean, 9.2 years), 807 persons 
developed a stroke (460 ischemic, 74 hemorrhagic, and 273 unspecified). Current users 
of nonselective (HR 1.72; 95% confidence interval [CI], 1.22-2.44) and COX2-selective 
(HR 2.75; 95% CI, 1.28-5.95) NSAIDs had a greater risk of stroke, but not users of 
COX1–selective NSAIDs (HR1.10; 95% CI, 0.41-2.97). Hazard ratios (95% CIs) for 
ischemic stroke were 1.68 (1.05-2.69) for nonselective and 4.54 (2.06-9.98) for COX2-
selective NSAIDs. For individual NSAIDs, current use of the nonselective naproxen 
(HR 2.63; 95% CI, 1.47-4.72) and the COX2-selective rofecoxib (HR 3.38; 95% CI, 
1.48-7.74) was associated with a greater risk of stroke. Hazard ratios (95% CIs) for 
diclofenac (1.60 [1.00-2.57]), ibuprofen (1.47 [0.73-3.00]), and celecoxib (3.79 [0.52-
27.6]) were greater than 1.00 but were not statistically significant.
Conclusions: In the general population, we found a greater risk of stroke with current 
use of nonselective and COX2-selective NSAIDs. The risk of stroke was not limited to 
the use of COX2-selective NSAIDs.
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INtroDuCtIoN 
In clinical trials the use of cyclooxygenase (COX)-2-selective nonsteroidal anti-
inflammatory drugs (NSAIDs) has been associated with an increased risk of cardio-
vascular events and death.1-5 Most of the post hoc analyses of the trials focused on 
combined cardiovascular or cerebrovascular events as the end point, without further 
specification of the risk of stroke.
Moreover, few observational studies have investigated the association between NSAID 
use and the risk of stroke.6-11 Of these, one nested case-control study showed that 
current NSAID use was associated with a greater risk of ischemic stroke.7 In another 
nested case-control study, a greater risk of ischemic stroke was found for some COX2-
selective NSAIDs, but this was also found for the nonselective NSAID diclofenac.11 
Predominantly, null findings were reported in 4 studies that investigated the outcome of 
hemorrhagic stroke.6,8-10 It is supposed that selective inhibition of the COX2 enzymes 
by the COX2-selective NSAIDs induces a prothrombotic state, unlike NSAIDs that 
inhibit COX2 to a lesser degree and additionally inhibit COX1.12-14 However, the 
cardiovascular risk observed for the various COX2-selective NSAIDs has not been 
consistent in all clinical trials.15 In a recent placebo-controlled trial, the non-COX2-
selective NSAID naproxen sodium was associated with an increased cardiovascular 
risk.4 Evidence from observational studies has also shown that NSAIDs differ in their 
potential to cause cardiovascular events.16-18 In all, it remains inconclusive if the 
greater risk of cardiovascular events is specific for COX2-selective NSAIDs or whether 
other pharmacological properties of NSAIDs could cause these detrimental effects. 
We investigated the association between NSAID use and the risk of incident stroke 
in a large, prospective, population-based cohort study and whether any observed 
association was restricted to COX2-selective NSAIDs. 
metHoDS
Study population
The Rotterdam Study is a prospective, population-based cohort study of age-related 
disorders.19 The medical ethics committee of the Erasmus Medical Center, Rotterdam, 
the Netherlands, approved the study. Between 1990 and 1993, all persons 55 years 
or older living in Ommoord, a district of Rotterdam, were invited to participate. Of the 
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10,275 eligible persons, 7,983 (77.7%) signed informed consent. Of these individuals, 
7,722 were free of stroke at baseline. Follow-up examinations were conducted in 1993 
to 1994, 1997 to 1999, and 2000 to 2004. In addition, the cohort was continuously 
monitored for major disease outcomes and death through linkage with records from 
general practitioners and bimonthly updates from the municipality records. This resulted 
in a virtually complete follow-up for stroke. Nearly all persons (99.7%) were registered at 
1 or more of 7 automated pharmacies serving the Ommoord area. Of these pharmacies, 
records of all filled prescriptions were available as of January 1st, 1991. To ensure at 
least a 6-month history of medication use, we excluded 86 persons for whom follow-
up ended before July 1st, 1991. Consequently, the study population included 7,636 
persons. The end of the study period for this analysis was September 30th, 2004, on 
which date rofecoxib was withdrawn from the market after clinical trial data had shown 
an increased risk of thromboembolic events in the rofecoxib treatment arm. 
Drug exposure
Complete information on all filled prescriptions for all persons was obtained in auto-
mated format from the pharmacies. This included the product name, international 
nonproprietary name, Anatomical Therapeutic Chemical code, total number of delivered 
units (e.g., tablets or capsules), prescribed daily number of units, date of delivery, 
and drug dosage. The duration of a prescription was calculated as the total number 
of delivered units divided by the prescribed daily number of units. Drug dosage was 
defined by the defined daily dose (DDD), the recommended daily dosage of a drug 
taken by adults for the main indication of the drug. Based on data from in vitro and 
clinical studies, NSAIDs were classified as COX1 selective, nonselective, and COX2 
selective according to their relative selectivity for the COX1 and COX2 enzymes at 
therapeutic dosages (Table 1).20-26 For some NSAIDs, COX selectivity is unknown or 
equivocal (ie, benzydamine hydrochloride, tiaprofenic acid, tolfenamic acid, phenyl-
butazone, tenoxicam, and aceclofenac). 
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table 1. Classification of NSAIDs according to COX-selective properties and total person-
months exposure during follow-up
Type of NSAID Person-months exposure
CoX1-selective NSAIDs
Indometacine 2,181.0
Piroxicam 3,108.9
Ketoprofen 1,306.3
Flurbiprofen 222.4
Azapropazon 272.5
Non-selective NSAIDs
Diclofenac* 15,126.7
Naproxen 6,776.9
Ibuprofen 8,208.6
Nabumeton 1,008.2
Sulindac 467.6
CoX2-selective NSAIDs
Rofecoxib 1,882.2
Celecoxib 342.6
Meloxicam 767.0
Etoricoxib 49.8
Valdecoxib 12.6
*Includes combination products of diclofenac
Salicylates (ie, acetylsalicylic acid and carbasalate calcium) are pharmacologically 
related to NSAIDs and inhibit platelet aggregation via COX1; although, contrary to 
NSAIDs, their effects are irreversible.27,28 On these grounds, salicylates could be 
regarded as COX1-selective NSAIDs; however, they are mostly prescribed at a low 
dose as platelet inhibitors for the prevention of cardiovascular disease and stroke. 
We did not include salicylates in the COX1-selective NSAID group for the following 
reasons: (1) they are indicated for stroke prevention; (2) NSAID use is cautioned in 
persons already using salicylates because of the increased risk of gastrointestinal tract 
bleeding; and (3) some NSAIDs possibly antagonize the platelet inhibition induced 
by salicylates.27,28 This might obscure the protective effect of salicylates. Because of 
these potential sources of confounding by salicylates, all analyses were adjusted for 
the current use of salicylates, and the effect of salicylates on the association between 
NSAID use and stroke was studied through stratification.
Chapter 1
24
Diagnosis of stroke
A history of stroke at the time of enrollment into the Rotterdam Study was assessed by 
asking “did you ever suffer from a stroke, diagnosed by a physician?” Positive answers 
to this question were verified by reviewing the medical records. A history of transient 
ischemic attack was also assessed during the baseline interview. After enrollment into 
the Rotterdam Study, participants were continuously monitored for all major events, 
including cerebrovascular disease, through automated linkage of the study database 
with files from general practitioners. Information on vital status was obtained at regular 
intervals from the municipal authorities in Rotterdam. When an event or death had been 
reported, additional information was obtained from the general practitioner and from 
information in the hospital records (including brain imaging) and discharge letters in 
the case of admittance or referral. In addition, nursing home physicians’ files and files 
from general practitioners of participants who moved out of the district were scrutinized. 
Research physicians discussed information on all potential strokes and transient 
ischemic attacks with an experienced neurologist to verify all diagnoses while blinded 
to drug exposure. Subarachnoid hemorrhages were excluded. Subtyping of strokes 
in the Rotterdam Study has been extensively described previously.29 In brief, a stroke 
was subclassified as ischemic when a computed tomographic (CT) scan or magnetic 
resonance image (MRI) that was made within 4 weeks after the stroke occurred 
ruled out other diagnoses or when indirect evidence (eg, deficit limited to 1 limb or 
completely resolved within 72 hours and atrial fibrillation in absence of anticoagulants) 
indicated the ischemic nature of the stroke. Hemorrhagic stroke was diagnosed when a 
relevant hemorrhage was shown on a CT scan or MRI or when the patient permanently 
lost consciousness or died within hours after onset of focal signs. If a stroke could 
not be subclassified as ischemic or hemorrhagic as a consequence of a lack of the 
aforementioned data, it was classified as “unspecified”.29
other covariates
Potential confounders were chosen a priori. Baseline covariates included age, sex, 
systolic blood pressure, body mass index, total serum cholesterol level, and smoking 
status. Time-dependent covariates included myocardial infarction; atrial fibrillation; 
heart failure; transient ischemic attacks (TIA); coronary artery bypass graft (CABG); 
percutaneous transluminal coronary angioplasty (PTCA); diabetes mellitus; and use 
of antihypertensives, salicylates, and antithrombotics. Cardiovascular conditions were 
assessed at the baseline interview and follow-up examinations, together with a review 
of medical records. In addition, electrocardiography was performed to determine 
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myocardial infarction and atrial fibrillation.30 Sitting blood pressure was measured on the 
right upper arm using a random-zero sphygmomanometer. In the analyses, the mean of 
2 measurements, measured at 1 occasion, was used. Diabetes mellitus was defined as 
non-fasting serum glucose level exceeding 200 mg/dL (to convert to millimoles per liter, 
multiply by 0.0555) or the use of oral blood glucose-lowering drugs or insulin. Exposure 
to antihypertensives, salicylates, and antithrombotics was obtained from pharmacy 
records. 
Statistical analysis 
For all subjects, we calculated the duration of follow-up between the start of the study 
and the date of death, diagnosis of stroke, or end of the study period, whichever came 
first. We calculated the hazard ratio (HR) (and 95% confidence interval [CI]) of stroke 
with a Cox proportional hazards model (SPSS 11.01 software; SPSS Inc, Chicago, 
Illinois), in which calendar time was used as the time axis. Separate analyses were 
performed for all strokes, ischemic strokes, and hemorrhagic strokes. All analyses 
were adjusted for age and sex (crude model). In a second model, we adjusted for other 
potential confounders as previously described (adjusted model). During follow-up, at 
each time an event occurred, we determined the exposure to NSAIDs. Use of NSAIDs 
was classified as never, current, or past use of an NSAID and subsequently categorized 
into groups according to COX selectivity and as individual NSAIDs. Persons who had 
not used an NSAID before the date of an event were categorized as “never user”. 
Persons were considered current users of an NSAID if an event date fell between the 
start date and end date of a prescription. If a person had previously used an NSAID but 
no longer used the drug on an event date, they were considered a past user. Due to the 
initiation and cessation of prescribed drug use, persons can switch from the never to the 
current exposure category and from the current to the past exposure category or vice 
versa. Never use was the reference for all analyses. Simultaneous current use of 2 or 
more NSAIDs was rare (0.1%) and was excluded from the analyses. For the individual 
NSAIDs, we investigated a dose-effect relationship by dichotomizing the mean dose 
of current use as 1 DDD or less and greater than 1 DDD. We performed several sub-
analyses. First, we considered that noncompliance or a pharmacological “carryover” 
could affect the observed associations. Hence, in a sensitivity analysis we extended 
the risk window by 14 days after the end date of the prescription to see whether this 
altered our result. Second, the analysis was performed in a subcohort with a history of 
at least 1 NSAID prescription during follow-up to study the role of potential confounding 
by indication or contraindication. Third, previous studies have shown that COX2-
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selective NSAIDs are preferentially prescribed to persons with substantial comorbidity.31 
To investigate whether this played a role in our study population, we determined for 
all COX-selective NSAID groups whether a history of use was related to the risk of 
stroke. Finally, the effect of concomitant use of salicylates could affect our results for 
reasons described previously. We thus performed an analysis stratified by current use of 
salicylates.
reSultS 
Baseline characteristics of the cohort at risk are given in Table 2. At baseline, the mean 
age of the participants was 70.2 years, and the majority was female (61.3%). During 
70,063 person-years of follow-up, 807 persons developed a stroke. Of these individuals, 
460 were diagnosed as having an ischemic stroke and 74 as having a hemorrhagic 
stroke, while for 273 individuals the type of stroke could not be specified. The mean 
follow-up was 9.2 person-years. In our study population, 61 persons who experienced a 
stroke were current users of any NSAID at the time of the event, whereas 290 persons 
with a stroke had never used an NSAID during the study period.
table 2. Demographic and clinical characteristics of the study cohort at baseline
Characteristic
Age, y* 70.2 (± 9.6)
Female sex 4,684 (61.3%)
Smoking, ever 4,659 (60.9%)
Osteoarthritis in hand, knee or hip 595 (7.8%)
Diabetes mellitus 794 (10.4%)
Myocardial infarction 862 (10.8%)
Atrial fibrillation 339 (4.4%)
Transient ischemic attacks 207 (2.7%)
Percutaneous Transluminal Coronary Angioplasty 55 (0.7%)
Coronary artery bypass graft 164 (2.2%)
Heart failure 232 (3.0%)
Body Mass Index, kg/m2* 26.3 (± 3.7)
Total serum cholesterol, mmol/l* 6.6 (± 1.2)
Systolic blood pressure, mm Hg* 139 (± 22)
*Data are given as mean, ± SD
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As shown in Table 3, current use of any NSAID was associated with a greater risk 
of stroke compared with never use. Adjustment for confounders resulted in higher 
estimates. Associations were stronger if only ischemic strokes were considered. Use of 
any NSAID was related to the risk of hemorrhagic stroke (HR, 2.03; 95% CI, 0.81-5.11), 
albeit nonsignificant. Table 3 also shows that current users of nonselective NSAIDs and 
of COX2-selective NSAIDs had a higher risk of stroke compared with never users. We 
found no association for COX1-selective NSAID use with the risk of stroke. Current use 
of NSAIDs with unknown COX-selectivity on the index date was infrequent (0.02%) and 
thus not studied further. All associations were stronger if only ischemic strokes were 
considered (Table 3). There were no exposed cases in the class of COX2-selective 
NSAIDs for hemorrhagic stroke precluding comparison of the effect of different NSAIDs 
on the risk of hemorrhagic stroke.
As shown in Table 4, for individual NSAIDs, current use of the non-selective NSAID 
naproxen and the COX2-selective rofecoxib were associated with a greater risk of 
stroke. All but 1 person among the COX2-selective users, who experienced an event, 
used rofecoxib. Although HRs for current use of diclofenac (HR, 1.60; 95% CI, 1.00-
2.57), ibuprofen (adjusted HR, 1.47; 95% CI, 0.73-3.00), and celecoxib (adjusted HR, 
3.79; 95% CI, 0.52-27.6) were greater than 1.00, none of them reached the level of 
conventional statistical significance. The low number of events for celecoxib (n=1), 
as well as for all other individual NSAIDs, prohibited further investigation of these 
exposure categories. There was no clear dose-response effect, since doses of 1 DDD 
or less and greater than 1 DDD were both associated with a greater risk of stroke. 
However, analyses were compromised by low case numbers and unequal distribution 
of exposed cases across dosage categories. As for our subanalyses, the extension of 
the risk window by 14 days after the cessation of drug use attenuated the risk estimates 
(adjusted HRs [95% CIs] of stroke for current use of any current NSAID, 1.61 [1.20-
2.16]; for COX1-selective NSAIDs, 1.01 [0.37-2.72]; for nonselective NSAIDs, 1.55 
[1.11-2.16]; and for COX2-selective NSAIDs, 2.71 [1.26-5.86]). If we performed the 
analysis in a subcohort with at least 1 NSAID prescription during follow-up (517 events), 
we observed little change in HRs compared with the analyses in which never use 
was defined as the reference (data not shown). Past use of COX2-selective NSAIDs 
compared with never use was associated with a greater risk of stroke (adjusted HR, 
2.04; 95% CI, 1.34-3.09); no such association was observed for a history of any NSAID
 
Chapter 1
28
ta
bl
e 
3.
 H
az
ar
d 
ra
tio
s 
fo
r 
al
l s
tr
ok
e 
an
d 
is
ch
em
ic
 s
tr
ok
e 
w
ith
 c
ur
re
nt
 u
se
 o
f a
ny
 N
S
A
ID
 a
nd
 N
S
A
ID
s 
gr
ou
pe
d 
ac
co
rd
in
g 
to
 C
O
X
-
se
le
ct
iv
ity
A
ll 
st
ro
ke
Is
ch
em
ic
 s
tr
ok
e
N
SA
ID
 u
se
C
as
es
H
r
 (9
5%
 C
I),
 
cr
ud
e*
C
as
es
H
r
 (9
5%
 C
I),
 a
dj
us
te
d†
C
as
es
H
r
 (9
5%
 C
I),
 
cr
ud
e
C
as
es
H
r
 (9
5%
 C
I),
 
ad
ju
st
ed
N
ev
er
 u
se
29
0
1.
00
 (
re
f.)
22
2
1.
00
 (
re
f.)
15
6
1.
00
 (
re
f.)
12
8
1.
00
 (
re
f.)
A
ny
 N
S
A
ID
61
1.
58
 (
1.
19
-2
.0
8)
51
1.
77
 (
1.
29
-2
.4
1)
34
1.
74
 (
1.
20
-2
.5
3)
31
1.
92
 (
1.
29
-2
.8
7)
N
on
-s
el
ec
tiv
e 
N
S
A
ID
48
1.
58
 (
1.
16
-2
.1
5)
39
1.
72
 (
1.
22
 -
2.
44
)
24
1.
58
 (
1.
02
-2
.4
4)
21
1.
68
 (
1.
05
-2
.6
9)
C
O
X
1-
se
le
ct
iv
e 
N
S
A
ID
5
0.
95
 (
0.
39
-2
.3
1)
4
1.
10
 (
0.
41
-2
.9
7)
2
0.
78
 (
0.
19
-3
.1
6)
2
0.
99
 (
0.
24
-4
.0
1)
C
O
X
2-
se
le
ct
iv
e 
N
S
A
ID
7
2.
40
 (
1.
12
-5
.1
4)
7
2.
75
 (
1.
28
-5
.9
5)
7
4.
20
 (
1.
93
-9
.1
3)
7
4.
54
 (
2.
06
-9
.9
8)
A
bb
re
vi
at
io
ns
: C
I -
 c
on
fid
en
ce
 in
te
rv
al
, H
R
 -
 h
az
ar
d 
ra
tio
* 
S
ex
, a
ge
 a
dj
us
te
d
† 
A
dd
iti
on
al
ly
 a
dj
us
te
d 
fo
r 
sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e,
 B
M
I, 
to
ta
l s
er
um
 c
ho
le
st
er
ol
 a
nd
 s
m
ok
in
g.
 T
im
e-
de
pe
nd
en
t c
ov
ar
ia
te
s 
in
cl
ud
ed
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n,
 
at
ria
l fi
br
ill
at
io
n,
 h
ea
rt
 fa
ilu
re
, T
IA
, C
A
B
G
, P
T
C
A
, d
ia
be
te
s 
m
el
lit
us
 a
nd
 u
se
 o
f a
nt
ih
yp
er
te
ns
iv
es
, s
al
ic
yl
at
es
 a
nd
 a
nt
i-t
hr
om
bo
tic
s.
1.1 NSAIDs and risk of Stroke
29
ta
bl
e 
4.
 H
az
ar
d 
ra
tio
s 
of
 a
ll 
st
ro
ke
 a
nd
 is
ch
em
ic
 s
tr
ok
e 
w
ith
 c
ur
re
nt
 u
se
 o
f i
nd
iv
id
ua
l N
S
A
ID
s
A
ll 
st
ro
ke
Is
ch
em
ic
 s
tr
ok
e
N
SA
ID
 u
se
C
as
es
*
H
r
 (9
5%
 C
I),
 
cr
ud
e†
C
as
es
H
r
 (9
5%
 C
I),
 
ad
ju
st
ed
‡
C
as
es
H
r
 (9
5%
 C
I),
 
cr
ud
e†
C
as
es
H
r
 (9
5%
 C
I),
 
ad
ju
st
ed
‡
N
ev
er
 u
se
29
0
1.
00
 (
re
f.)
22
2
1.
00
 (
re
f.)
15
6
1.
00
 (
re
f.)
12
8
1.
00
 (
re
f.)
N
on
-s
el
ec
tiv
e 
N
SA
ID
s
D
ic
lo
fe
na
c
20
1.
35
 (
0.
86
-2
.1
3)
19
1.
60
 (
1.
00
-2
.5
7)
12
1.
61
 (
0.
89
-2
.9
0)
11
1.
70
 (
0.
91
-3
.1
7)
Ib
up
ro
fe
n
11
1.
32
 (
0.
72
-2
.4
2)
8
1.
47
 (
0.
73
-3
.0
0)
3
0.
76
 (
0.
24
-2
.4
0)
3
1.
02
 (
0.
32
-3
.3
2)
N
ap
ro
xe
n
15
2.
67
 (
1.
58
-4
.4
8)
11
2.
63
 (
1.
47
-4
.7
2)
7
2.
37
 (
1.
11
-5
.0
6)
6
2.
65
 (
1.
23
-5
.6
9)
C
o
X2
-s
el
ec
tiv
e 
N
SA
ID
s
R
of
ec
ox
ib
6
3.
24
 (
1.
42
-7
.3
7)
6
3.
38
 (
1.
48
-7
.7
4)
6
5.
73
 (
2.
48
-1
3.
2)
6
5.
56
 (
2.
38
-1
2.
9)
A
bb
re
vi
at
io
ns
: C
I -
 c
on
fid
en
ce
 in
te
rv
al
, H
R
 -
 h
az
ar
d 
ra
tio
* 
R
es
ul
ts
 a
re
 s
ho
w
n 
fo
r 
an
al
ys
es
 w
ith
 ≥
5 
cu
rr
en
t e
xp
os
ed
 c
as
es
 fo
r 
th
e 
ou
tc
om
e 
of
 a
ll 
st
ro
ke
. 
†  
S
ex
, a
ge
 a
dj
us
te
d
‡ 
A
dd
iti
on
al
ly
 a
dj
us
te
d 
fo
r 
sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e,
 B
M
I, 
to
ta
l s
er
um
 c
ho
le
st
er
ol
 a
nd
 s
m
ok
in
g.
 T
im
e-
de
pe
nd
en
t c
ov
ar
ia
te
s 
in
cl
ud
ed
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n,
 
at
ria
l fi
br
ill
at
io
n,
 h
ea
rt
 fa
ilu
re
, T
IA
, C
A
B
G
, P
T
C
A
, d
ia
be
te
s 
m
el
lit
us
 a
nd
 u
se
 o
f a
nt
ih
yp
er
te
ns
iv
es
, s
al
ic
yl
at
es
 a
nd
 a
nt
i-t
hr
om
bo
tic
s.
Chapter 1
30
use (HR, 1.13; 95% CI, 0.95-1.35) or for the other COX-selective groups (COX1-
selective NSAIDs, [HR, 1.13; 95% CI, 0.94-1.35]; and nonselective NSAIDs, [HR, 1.16; 
95% CI, 0.91-1.48]). Notably, almost all users of COX2-selective NSAIDs had used 
other types of NSAIDs earlier during follow-up and were, in general, long-term users 
of NSAIDs. Only 2 cases were current concomitant users of salicylates and NSAIDs; 
hence, stratification on concomitant use of salicylates could not be performed. 
DISCuSSIoN 
In the general population, we found an overall greater risk of stroke with use of NSAIDs, 
especially in the categories of nonselective NSAIDs and COX2-selective NSAIDs. The 
risk of stroke was most pronounced with COX2-selective NSAID use. 
Strengths of our study design included its prospective design, large number of partici-
pants, long follow-up period, and a general population-based setting, which makes 
selection bias unlikely. Information bias was prevented by prospectively collected and 
complete automated pharmacy records of all filled prescriptions and blinded adjudicat-
ion of cerebrovascular events. Certain limitations of our study, however, deserve 
comment. First, as with most of the clinical trials and observational studies performed to 
date, inferences must be interpreted in the context of small numbers despite a mean 
follow-up of more than 9 years. Second, although in the Netherlands long-term use of 
NSAIDs was fully reimbursed until the beginning of 2004, some misclassification might 
have occurred owing to intermittent use of “over-the-counter” NSAIDs. If this biased our 
results, however, it will have led us to underestimate an effect rather than overestimate 
the risk of stroke. Finally, “preferential prescribing” might have played a role in the 
COX2-selective NSAIDs group, since we observed a higher risk of stroke for past users 
of COX2-selective NSAIDs. This channeling bias with COX2-selective NSAIDs has 
been described previously in another Dutch patient population setting.31 However, since 
the risk estimates were higher for current use of COX2-selective NSAIDs than for past 
use, this type of confounding cannot fully explain the greater risk of stroke.
Our results are largely in agreement with the currently available data from randomized 
clinical trials. In the Alzheimer Disease Anti-inflammatory Prevention Trial (ADAPT), 
use of naproxen was associated with a similar 2-fold increased risk of stroke compared 
with placebo, which is in striking accordance with the results of the present study.4 
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This same study did not report an effect of celecoxib on the risk of stroke. In our study, 
no statistically significant effect was found for celecoxib either, although the effect 
size was similar to that of rofecoxib. Because of low numbers, however, an effect of 
celecoxib on the risk of stroke cannot be excluded. The similar occurrence of ischemic 
cerebrovascular events for the rofecoxib and the naproxen treatment arms of the Vioxx 
GI Outcomes Research (VIGOR) study corresponds with our finding of a greater risk 
of stroke for both these NSAIDs.1 However, because VIGOR did not include a placebo 
treatment, it does not provide evidence for the direction of the association.1 More 
compelling data consistent with an increase in the risk of stroke with rofecoxib use are 
provided by the results of the “Adenomatous Polyp Prevention on Vioxx trial,” in which a 
2-fold increased risk for cerebrovascular events was observed compared with placebo 
after 36 months of follow-up.2
Several other observational studies also investigated the use of NSAIDs on the risk of 
ischemic stroke. Our finding of an overall greater risk of ischemic stroke with current 
use of NSAIDs corresponds with the case-control study by Bak et al.7 However, 
direct information on potential confounders was not available in this study, and 
only concomitant drug use could be used as proxy for the presence of confounding 
conditions. Andersohn et al.11 found a greater risk of ischemic stroke for rofecoxib, 
etoricoxib, and diclofenac but not for celecoxib. The higher risk was most pronounced 
with COX2-selective NSAID use, which corresponds with our observations. In our 
study we observed similar odds ratios for celecoxib and rofecoxib. However, celecoxib 
was not introduced in the Netherlands until 2001, and the use among persons in our 
cohort was limited, precluding definite conclusions. Like Andersohn et al.11 our results 
also put forward a higher risk of stroke with the use of diclofenac, although statistical 
significance was not reached. These observational studies, including our own, suggest 
that an effect of NSAIDs on the risk of ischemic stroke is not restricted to the COX2-
selective compounds. 
The classification of COX selectivity used in the present study complies with the 
generally accepted labeling of NSAID selectivity. Nevertheless, some debate exists 
regarding the COX-selective properties of, mainly, diclofenac, celecoxib, and naproxen. 
Some have argued that diclofenac is COX2 selective, since diclofenac would not differ 
much from celecoxib in terms of its ability to inhibit COX2.32 However, therapeutically 
relevant COX2 selectivity will be difficult to attain, since the concentration of diclofenac 
necessary to achieve 80% inhibition of COX2 is expected to cause a similar inhibition 
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of COX1.22 For naproxen, relative selectivity for COX1, and hence a cardioprotective 
effect, has been suggested, since naproxen causes near-maximal inhibition of platelet 
aggregation similar to aspirin.26,33 However, clinical evidence does not suggest that 
relative COX1 selectivity is achieved.4,34 Despite the alleged differences in COX 
selectivity of these compounds, we found higher risks of stroke for both diclofenac 
and naproxen and also for celecoxib and rofecoxib. These findings do not necessarily 
exclude the possibility of an effect through a COX-related mechanism. Because 
selective inhibition of COX2 causes platelet aggregation, use of COX2-selective 
NSAIDs could, as suggested previously, cause a prothrombotic state.12-14 However, 
since both COX1 and COX2 are involved in vascular homeostasis, any pharmacological 
inhibition of the COX enzymes could be expected to disturb the thrombotic equilibrium, 
which would explain our observations. In addition, other COX mediated processes 
relevant to the pathophysiologic mechanisms of cerebrovascular events might be 
involved, such as inflammatory response and renovascular physiology.35,36 This could 
provide an alternative explanation for the cerebrovascular risk not being restricted to 
COX2-selective NSAIDs. 
In conclusion, our study suggests that the greater risk of stroke is not limited to the 
use of COX2-selective NSAIDs. Our risk estimates are in line with estimates from the 
literature. The existing knowledge regarding the effects of pharmacological interference 
of COX is currently incomplete. Evaluation of COX activity in vivo, together with post-
marketing surveillance and observational studies, will be essential to elucidate the 
potential mechanisms underlying the cerebrovascular effects associated with these 
drugs.
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AbStrACt
background: In clinical trials, cyclo-oxygenase (COX)-2-selective nonsteroidal anti-
inflammatory drugs (NSAIDs) were associated with an increased risk of thrombotic 
events. We studied the association between use of NSAIDs and risk of transient 
ischemic attack (TIA) in the prospective, population-based Rotterdam Study.
methods: We followed 7,392 persons free of TIA or stroke at baseline (1991-1993) 
for first incident TIA until September 2004. Data on all filled prescriptions came from 
pharmacy records. Persons were considered current user of a NSAIDs if the period 
of NSAID use overlapped the date of the event. With Cox-regression models, we 
calculated crude and adjusted hazard ratios (HR) of TIA for time-dependent current use, 
compared to never use, of any NSAID and of non-COX2-selective NSAIDs and COX2-
selective NSAIDs.
results: At baseline, the mean age of the participants was 70.1 years and the majority 
was female (61.4%). Persons were followed up to 15.1 years (average 9.4 years (± 
SD 4.0)), 330 persons developed a TIA. There were 22 current users of NSAIDs at the 
time of incident TIA: 19 non-COX2-selective NSAID users and 3 COX2 selective NSAID 
users. Current use of any NSAID was associated with an increased risk of TIA (sex, age 
adjusted HR 1.61 (1.02-2.54)). The HR for current use of non-COX2-selective NSAID 
use was HR 1.51 (0.93-2.45) and HR 2.85 (0.89-9.17) for COX2-selective NSAID use. 
Additional adjustments for potential confounders did not change the association by 
more than 5%. 
Conclusion: In the general population, we found a greater risk of TIA with current use 
of NSAIDs. 
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INtroDuCtIoN
In clinical trials, the use of cyclooxygenase-(COX)-2 selective NSAIDs has been 
associated with an increased risk of cardiovascular and cerebrovascular events 
and death.1-5 Subsequent analyses of observational series and non-cardiovascular 
clinical trials suggested that cardiovascular events may also occur with non-selective 
NSAIDs.6-9 Hence, it was debated whether the cardiovascular risk was restricted to the 
COX2-selective NSAIDs. Furthermore, there is limited knowledge on the risk of NSAID 
use for individual cardiovascular, but particularly, cerebrovascular events. Previously, 
we reported from the Rotterdam Study that the use of both non-selective and COX2-
selective NSAIDs was associated with a greater risk of ischemic stroke.11 An outcome 
which is strongly related to ischemic stroke is transient ischemic attack (TIA), which 
is essentially an ischemic attack of ‘transient’ nature.12 Like ischemic strokes, TIAs 
are caused by focal cerebral or retinal ischemia. Persons who suffered from a TIA 
are at increased risk of stroke, cardiovascular events and death.13-15 We studied the 
association between use of NSAIDs and risk of TIA in the Rotterdam Study, a large 
observational prospective population based study.16 
metHoDS
Study population
The Rotterdam Study is a prospective, population-based cohort study of age related 
disorders.18 The medical ethics committee of the Erasmus Medical Center approved the 
study.16 Between 1990 and 1993 all persons aged 55 years or older living in Ommoord, 
a district of Rotterdam, were invited to participate. Of the 10,275 eligible persons, 7,983 
(78%) signed informed consent. We excluded 455 persons with either prevalent TIA or 
stroke, as we considered that persons with a history of TIA or stroke have a different 
risk of incident TIA. Follow-up examinations were conducted in 1993 to 1994, 1997 to 
1999 and 2000 to 2004. In addition, the cohort was continuously monitored for major 
disease outcomes and death through linkage with records from general practitioners 
and bimonthly updates from the municipality records. Nearly all persons (99.7%) were 
registered at one or more of seven automated pharmacies serving the Ommoord area. 
Of these pharmacies, records of all filled prescriptions were available as of January 
1st 1991. To ensure at least six months of medication history, we excluded 86 persons 
for whom follow-up ended before July 1st 1991. Consequently, the study population 
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included 7,392 persons. The end of the study period for this analysis was September 
30th 2004, the date on which rofecoxib was withdrawn from the market after clinical trial 
data showed an increased risk of thrombotic events with rofecoxib treatment.
Drug exposure
Complete information on all filled prescriptions for all persons was obtained in 
automated format from the pharmacies. This included the product name; international 
non-proprietary name; Anatomical Therapeutic Chemical code17; total number of 
delivered units (e.g. tablets/capsules); prescribed daily number of units; date of delivery 
and drug dosage. Drug dosage was defined by the defined daily dose (DDD), the 
recommended daily dosage of a drug taken by adults for the main indication of the drug. 
NSAIDs were classified as non-COX2-selective NSAIDs and COX2-selective NSAIDs 
according to their selectivity for the COX2 enzyme at therapeutic dosages, based on 
data from in vitro and clinical studies (Table 1).18-24
table 1. Classification of NSAIDs
Non-CoX2-selective NSAIDs CoX2-selective NSAIDs
Diclofenac* Rofecoxib
Naproxen Celecoxib
Ibuprofen Meloxicam
Nabumeton Etoricoxib
Sulindac Valdecoxib
Indometacine
Piroxicam
Ketoprofen
Flurbiprofen
Azapropazon
*Includes combination products of diclofenac
Diagnosis of tIA
During the visit at the research center, a trained Rotterdam Study physician asked 
all participants, “Did you experience a short period with disturbances of sensibility 
in your face, arms, or legs, which lasted less than 24 hours over the last 3 years?” 
Similar questions were asked for disturbances in strength, speech, and vision. When 
answers were positive, time of onset, duration, and disappearance of symptoms and 
whether a general practitioner had been consulted were recorded. Additionally, a 
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detailed description of the symptoms in ordinary language was obtained.25 On the 
basis of this information, one of the investigators, a neurologist, classified events as 
TIA or no TIA.26 An attack was regarded as being a TIA according to the guidelines 
of the Ad Hoc Committee for the Classification and Outline of Cerebrovascular 
Disease12 : i.e., (1) weakness, clumsiness, or sensory alteration in one or both 
limbs on the same side, speech or language disturbance, loss of vision in one eye 
or part of the eye, or homonymous hemianopsia for symptoms that pertain to the 
carotid territory; (2) weakness or clumsiness (sometimes changing from one side to 
another), sensory alteration, complete blindness or homonymous hemianopsia, ataxia, 
imbalance, or unsteadiness not associated with vertigo; and/or (3) two or more of the 
following: diplopia, dysphagia, dysarthria, or vertigo for symptoms that pertain to the 
vertebrobasilar territory.27 Symptoms completely resolved within 24 hours. No clear 
evidence for the diagnosis of migraine, epilepsy, Ménière’s disease, hyperventilation, 
cardiac syncope, hypoglycaemia, or orthostatic hypotension was to be present. 
A reproducibility study in which 121 case histories were reclassified by the same 
neurologist, blinded for the initial diagnosis, revealed a weighted of κ0.77 (p<0.05), 
indicating a good reproducibility. Follow-up for all events was completed until January 
1st, 2005 for 96.2 % of potential person years. A second source of information on TIA 
came from those subjects who had replied affirmatively to the question “Did you ever 
suffer from a stroke?” Of these subjects, supplementary medical information, such as a 
copy of the hospital discharge records, was obtained from the general practitioner. On 
the basis of the available information, these subjects were also classified by the same 
neurologist as having had a stroke, a TIA but not a stroke, or neither a TIA nor a stroke. 
Diagnosis of strokes in the Rotterdam Study has been extensively described earlier.28
other covariates
Potential confounders were chosen a priori. Baseline covariates included age, 
sex, cardiovascular disease (myocardial infarction, atrial fibrillation, heart failure, 
coronary artery bypass graft, percutaneous transluminal coronary angioplasty) 
and the following cardiovascular risk factors; systolic blood pressure, total serum 
cholesterol, diabetes mellitus, current smoking, diabetes mellitus and use of 
salicylates. Sitting blood pressure was measured on the right upper arm using a 
random-zero sphygmomanometer. The average of two measurements, measured at 
one occasion, was used. Total serum cholesterol was measured in non-fasting blood 
drawn at baseline. Cardiovascular conditions were assessed at the baseline interview 
and follow-up examinations, together with a review of medical records. In addition, 
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an electrocardiogram was performed to determine myocardial infarction and atrial 
fibrillation. Diabetes mellitus was defined as non-fasting serum glucose level exceeding 
11.1mmol/l or the use of oral blood glucose lowering drugs or insulin. Exposure to 
salicylates was obtained from pharmacy records. 
Statistical analysis
During follow-up, at each date an event occurred, we determined the status of NSAID 
use for the person who suffered the event and for all persons in the remainder of the 
cohort and categorized NSAID use as never use, current use or past use. Persons 
were considered ‘current’ user of a NSAID if an event-date fell between the start-date 
and end-date of a prescription. If a person previously used a NSAID, but no longer 
used the drug on an event date, they were considered as ‘past’ users. The duration 
of a prescription was calculated as the total number of delivered units divided by the 
prescribed daily number of units. We also investigated a dose-effect relationship by 
dichotomizing the average dose of current use as ≤1DDD and >1 DDD. Never use was 
the reference for these analyses. However, since ‘never’ users of NSAIDs do not have 
an indication or may have a contraindication for NSAID use this could lead to bias due 
to confounding-by-indication or counfounding-by-contraindication.29 Therefore, we also 
performed an analysis in which we compared ‘current’ users to ‘past’ NSAID users. 
For all subjects, we calculated the duration of follow-up between start of the study and 
date of death, diagnosis of first incident TIA, or end of the study period, whichever 
came first. If a person suffered from a stroke during follow-up, persons were censored 
from the date of the stroke onwards. We calculated the hazard ratios (HR) (and 95% 
confidence intervals (CI)) of TIA with a Cox proportional hazards model30 (SPSS 
11.01 software) in which calendar-time was used as the time-axis. All analyses were 
adjusted for age and sex (Model I). In a second model, we adjusted for other potential 
confounders being cardiovascular disease, blood pressure, total serum cholesterol, 
current smoking, diabetes mellitus and salicylates (Model II).
reSultS
Baseline characteristics of the study population are shown in Table 2. At baseline, the 
mean age of the participants was 70.1 years and the majority was female (61.4%). 
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table 2. Demographic and clinical characteristics of the study cohort at baseline  
(n=7,392)
Characteristic
Age, y (± SD) 70.1 (± 9.6)
Female sex (%) 4,540 (61.4%)
Smoking, current (%) 1,601 (21.7%)
Diabetes mellitus (%) 756 (10.2%)
Cardiovascular disease (%) 1,107 (15.0%)
Myocardial infarction (%) 817 (11.1%)
Atrial fibrillation (%) 322 (4.4%)
Heart failure (%) 213 (2.9%)
Percutaneous transluminal coronary angioplasty (%) 53 (0.7%)
Coronary artery bypass graft (%) 153 (2.1%)
Total serum cholesterol, mmol/l (± SD) 6.6 (± 1.2)
Systolic blood pressure, mmHg (± SD) 139.1 (± 22.3)
Persons were followed up to 15.1 years (average 9.4 years (± SD 4.0)). During a total of 
64,435 person years of follow-up, 365 persons developed a TIA. Of these, 35 persons 
were censored based on incident stroke, leaving 330 TIA events in the analysis. There 
were 122 persons who experienced a TIA who had ‘never’ used an NSAID during 
follow-up, whereas 22 persons who experienced a TIA were current user of a NSAID at 
the time of the event. 
Current use of NSAIDs was associated with a greater risk of TIA compared to never 
use (Table 3). Current users of both non-selective NSAIDs and of COX2-selective 
NSAIDs had a higher risk of TIA than never users, but statistical significance was not 
reached. There was no clear dose-response effect as doses ≤1DDD and >1DDD were 
both associated with a greater risk of TIA. Neither of the individual covariates changed 
the risk estimates by more than 5% in sex-age adjusted models. In Model II concurrent 
adjustment for all covariates did not materially change the associations. 
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table 3. Hazard ratios for TIA with current use of any NSAID and NSAIDs grouped 
according to COX2-selectivity
risk of tIA
NSAID use Ncases Hr (95% CI), model I* Hr (95% CI), model II†
Never use 1.00 (ref.) 1.00 (ref.)
Current use of:
Any NSAID 22 1.61 (1.02-2.54) 1.59 (1.01-2.52)
≤1 DDD 11 1.68 (0.90-3.11) 1.67 (0.90-3.10)
>1 DDD 11 1.54 (0.83-2.87) 1.52 (0.82-2.84)
Non-COX2-selective NSAID 19 1.51 (0.93-2.45) 1.49 (0.92-2.21)
COX2-selective NSAID 3 2.85 (0.89-9.17) 2.80 (0.87-9.02)
Abbreviations; HR - hazard ratio, TIA - transient ischemic attack, NSAIDs - nonsteroidal anti-
inflammatory drugs, COX - cyclooxygenase, CI - confidence interval
* Sex, age adjusted. 
† Additionally adjusted for blood pressure, total serum cholesterol, current smoking, diabetes mellitus 
cardiovascular disease (myocardial infarction, atrial fibrillation, heart failure, coronary artery bypass 
graft, percutaneous transluminal coronary angioplasty systolic) and use of salicylates.
If, instead of never use, past use of NSAIDs served as reference, HRs attenuated by 
less than 10% (adjusted HR with current use of any NSAID 1.47; 95% CI 0.94-2.29, 
non-COX2-selective NSAIDs 1.39 95% CI; 0.83-2.23 and COX2-selective NSAIDs 2.58 
(0.81-8.20). Past use of NSAIDs compared to never use was not associated with the 
risk of TIA (adjusted HR with any past use of any NSAID 1.08 (95% CI 0.85-1.38), non-
COX2-selective NSAIDs 1.13 (95% CI 0.89-1.44), and COX2-selective NSAIDs 1.12 
(95% CI 0.88-1.38)).
DISCuSSIoN
In the general population, we found an overall greater risk of TIA with use of NSAIDs. 
Risk estimates with current use of non-COX2-selective NSAIDs and COX2-selective 
NSAIDs were both increased, though neither reached statistical significance. 
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Strengths of our study design included its prospective design, large number of 
participants, a general population-based setting and the long follow-up period. The 
availability of pharmacy records throughout follow-up allowed for an accurate estimation 
of NSAID exposure on the date of the event as opposed to baseline or periodic 
assessment of drug use. Also, compared to prescription records, pharmacy records 
provide certainty as to whether prescriptions are filled and when they are filled. One 
important limitation of our study is the small number of events. This prohibited extensive 
subanalyses and resulted in lack of statistical power, particularly in the analyses 
across subgroups of NSAIDs. Furthermore, the number of cases limits the number of 
covariates that can be adjusted for in a multivariate model. We showed that adjustment 
for each individual covariate did not materially change the risk estimates. Also in the full 
model, risk estimates were essentially unchanged. We also investigated the potential 
influence of confounding-by-indication or contra-indication by using past-use as a 
reference and found that this did not change our observations. Another limitation is that 
misclassification may have occurred in the identification of TIA during follow-up. Though 
we obtained information about TIA both by self-report and from medical records, people 
may underreport symptoms of TIA. This could have resulted in an underestimation of 
the true number of events. However, we have no reason to believe that misclassification 
of the outcome, if any, was different between users and non-users of NSAIDs and thus 
biased our observations. Finally, although in the Netherlands chronic use of NSAIDs 
was fully reimbursed until the beginning of 2004, some misclassification might have 
occurred due to intermittent use of ‘over the counter’ (OTC) NSAIDs. If this biased our 
results, however, it leads to underestimating an effect rather than overestimating the risk 
of TIA. 
Our findings fit our previous observation11 and those of others of an increased risk 
of cerebral events with NSAID use. Few studies have, however, reported on the 
association between NSAID use and risk of TIA in specific. In the Alzheimer’s Disease 
Anti-Inflammatory Prevention Trial (ADAPT)31 the use of the non-COX2-selective 
naproxen or the COX2-selective celecoxib was not associated with an increased risk of 
TIA compared to placebo based on 10 or less cases in exposure and reference group. 
In an analysis across 8 phase IIb/III osteoarthritis clinical trials, a higher rate of TIA was 
observed in the rofecoxib arm than in the placebo arm.32 No risk estimates were given. 
In a Taiwanese cohort study of long-term (≥180 days) NSAIDs users, patients with 
preexisting medical conditions had a 6-fold higher risk of TIA associated with the use 
of NSAIDs compared to patients without these conditions.33 Other studies included TIA 
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in a combined cerebrovascular endpoint.2,34 However, since this combined outcome is 
generally dominated by stroke events, these data are difficult to compare to our current 
findings. 
There is considerable overlap in underlying etiology of ischemic stroke and TIA events 
and in their risk factors.27,35,36 Our previous observation of an increased risk of stroke 
with NSAID together with our current findings strongly suggest that NSAIDs act on 
a common pathway leading to either of these events. Several hypotheses regarding 
the mechanism of the increased thrombotic risk of NSAIDs have been proposed. It 
was generally thought that selective inhibition of COX2 causes a prothrombotic state 
due to a disturbance in the COX2 and COX1 mediated balance of prostacyclin, which 
inhibits platelet aggregation, and respectively thromboxane, which facilitates platelet 
aggregation. More recent studies have suggested that prostacyclin may not only oppose 
prothrombotic effects of thromboxane but also acts as a general constraint on multiple 
thrombosis stimuli via different mechanisms of action. Additionally, other processes 
affected by NSAIDs relevant to the pathophysiology of cerebrovascular events might be 
involved, such as inflammatory response and renovascular physiology. Howevere these 
effects are less likely to lead to acute cerebrovascular events. 
In conclusion, in the general population we found a greater risk of TIA with current use 
of NSAIDs.
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AbStrACt
background: Several lines of evidence suggest a role of inflammatory processes in 
Parkinson disease, although it is still unclear whether inflammation is a cause or rather 
a consequence of neurodegeneration. 
methods: In a prospective population-based cohort study among 6,512 participants 
aged ≥55 years, with repeated in-person examination, we evaluated the association 
between cumulative use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the 
risk of Parkinson disease. Complete information on filled prescriptions was available 
from automated pharmacy records. Data were analyzed by means of Cox proportional 
hazards regression analysis, adjusted for age, sex, smoking habits and coffee 
consumption. 
results: After an average 9.4 years of follow-up, 88 incident cases of Parkinson 
disease were detected. No association was found between use of NSAIDs and the risk 
of Parkinson disease (adjusted hazard ratio for any NSAID use, 1.50; 95% confidence 
interval, 0.95-2.37). 
Conclusion: Our findings do not support the hypothesis that NSAIDs might decrease 
the risk of Parkinson disease.
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INtroDuCtIoN
The causes of the excessive dopaminergic cell death in Parkinson disease (PD) are 
still poorly understood. Activated glial cells and increased levels of proinflammatory 
cytokines have been observed in brains and cerebrospinal fluid of PD patients.1,2 Micro-
glial activation has also been observed in association with the loss of dopaminergic 
neurons in animal models of PD.3 However, the exact pathogenetic role of this immune 
response and whether it is a cause or rather a consequence of neurodegeneration is as 
yet unclear. Prospective studies on inflammatory markers in relation to PD have not yet 
been reported.
A causal role of inflammation in PD has been suggested by 2 large cohort studies in 
which self-reported baseline use of nonsteroidal anti-inflammatory drugs (NSAIDs) 
was associated with a decreased risk of incident PD.4,5 In these studies duration and 
cumulative dosage of NSAID use were also estimated based on data from repeated 
questionnaires. However, the main exposure being studied was self-reported baseline 
use, which is a crude measure that does not account for changes in use of NSAIDs 
during the follow-up period.6 We prospectively evaluated the association between 
NSAID use and incident PD taking into account cumulative use, in a large prospective 
population-based cohort study. 
metHoDS
The Rotterdam Study is a prospective population-based cohort study among 7,983 
persons aged ≥55 years in a district of Rotterdam, the Netherlands.7 Both at baseline 
(1990-1993) and 3 follow-up rounds (1993-1994, 1997-1999 and 2002-2004), all 
participants were interviewed and underwent extensive physical examination. We 
used a 2-phase design to identify subjects with PD.8 In the first phase, all participants 
were screened for parkinsonian signs (resting tremor, rigidity, bradykinesia or impaired 
postural reflexes) according to a standardized protocol. Those who screened positive 
received a structured clinical workup, comprising the motor examination of the Unified 
Parkinson’s Disease Rating Scale and neurological examination and history taking by 
a general physician specialized in research on neurological disorders or a resident in 
neurology, to establish parkinsonism and to classify subtypes. When PD was suspected 
or in case of doubt about the diagnosis, participants were invited for a further evaluation 
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by a neurologist, who decided on the final diagnosis. In addition to the in-person 
follow-up, the cohort was continuously monitored by computer linkage with the general 
practitioners’ automated medical record systems. Through this surveillance system, we 
were notified of incident cases of parkinsonism and had access to the subjects’ medical 
records. Medical records of all cases of incident parkinsonism detected through the 
computerized surveillance system were reviewed by a neurologist. The information 
obtained from the continuous monitoring system was also used for subjects who could 
not be reexamined in person at follow-up (due to death, migration, disease, logistic 
reasons or refusal). PD was diagnosed if ≥2 parkinsonian signs were present in a 
person not taking antiparkinsonian drugs, or if at least 2 signs had been present before 
starting medication and at least 1 sign improved after medication had been started, and 
when all causes of secondary parkinsonism could be excluded. 
Data on use of NSAIDs [including use of salicylates (i.e. acetylsalicylic acid and 
carbasalate calcium)] were derived from 7 fully automated pharmacies in which nearly 
all participants (99.7%) were registered. These pharmacies continuously provided 
details on all filled prescriptions from January 1st, 1991, including the product name, 
generic name, number of tablets, date of delivery, prescribed number of tablets and 
daily drug dosage. The duration of a prescription was calculated as the total number 
of delivered units divided by the prescribed daily number of units. Smoking status 
[classified as ever (current or former) or never smoking], self-reported use of NSAIDs at 
time of enrollment, coffee intake, and a diagnosis of osteoarthritis, rheumatoid arthritis 
or gout were assessed during the baseline interview. Baseline neurological screening 
was performed in 6,969 participants. We excluded participants diagnosed as having any 
parkinsonism (n=130) or dementia (n=273) at baseline and 54 persons for whom <6 
months of data on their history of medication use was available. This resulted in a study 
population of 6,512 participants at risk to develop incident PD. Data were analyzed by 
means of Cox proportional hazards regression, with calendar time as the time axis to 
account for differences in usage patterns and availability of NSAIDs during the study 
period. Analyses were initially adjusted for age and sex, and additionally for smoking 
habits and coffee consumption, as these were considered potential confounders.4,9 We 
also adjusted the analyses for self-reported diagnoses of osteoarthritis, rheumatoid 
arthritis or gout at baseline, being the main indications for NSAID treatment. First, we 
evaluated the association between self-reported NSAID use at baseline and the risk 
of incident PD. Subsequently, we investigated total use of NSAIDs during the study 
period as registered in the pharmacy records. Any use was defined as at least 1 filled 
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prescription of NSAIDs during the study period. Total cumulative use was calculated 
from the sum of all prescription durations filled during follow-up. We created 3 mutually 
exclusive time-dependent variables of cumulative use: no use, use ≤1 year (defined as 
total cumulative use ≤365 days) and use >1 year (total cumulative use >365 days). To 
examine potential bias due to changes in NSAID use in preclinical PD, we repeated the 
analyses after excluding the last 2 years before diagnosis. Participants who developed 
PD within the first 2 years after baseline were excluded from these analyses.
reSultS
After a total of 61,449 person-years of follow-up (mean= 9.4), we identified 88 partici-
pants with incident PD. Of those, 50 cases were detected through the structured workup 
at the research center and 38 through the computerized surveillance system. 
Table 1 shows the baseline characteristics of the study population. NSAID use was 
reported by 415 participants (6.4%) during the baseline interview. In total 4,654 
participants (71.5%) had used an NSAID during the study period, of whom 590 (9.1% 
of the study population) had a total cumulative use of >1 year. The median duration of 
filled prescriptions of NSAIDs was 22 days (interquartile range: 0-93). 
table 1. Baseline characteristics of the study population (n=6,512)
Characteristic
Age (yr), mean (SD) 68.7(8.6)
Women, no (%) 3,845 (59.0)
Ever smokers, no (%) 4,252 (65.3)
Coffee drinkers, no (%) 5,528 (84.9)
Osteoarthritis, no (%)* 1,149 (17.6)
Rheumatoid arthritis, no (%)* 165 (2.5)
Gout, no (%)* 28 (0.4)
Self-reported NSAID use at baseline, no (%) 415 (6.4)
* Self-reported diagnosis at baseline interview
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We found no association between self-reported NSAID use at baseline and risk of 
incident PD (age- and sex-adjusted hazard ratio= 1.04, 95% confidence interval= 0.45–
2.43). No significant association was seen between cumulative NSAID use and risk of 
PD, neither for any use nor for use <1 year or use >1 year. The results were unaltered 
after additional adjustments for smoking and coffee consumption (Table 2). Taking 
into account a 2-year lag time (including 74 incident PD cases in the analyses) even 
resulted in an association in the opposite direction of what had been expected, possibly 
as a result of small numbers. Adjustment for self-reported osteoarthritis, rheumatoid 
arthritis or gout at baseline did not substantially change the results (data not shown).
table 2. Cumulative duration of NSAID use and the risk of Parkinson disease
Hr (95% CI)
NSAID use
PD 
cases
Sex, age 
adjusted
full model* With 2-year 
lag time
Never use 34 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
Any use 54 1.47 (0.93-2.30) 1.50 (0.95-2.37) 1.70 (0.97-2.99)
≤1 year 48 1.44 (0.91-2.29) 1.48 (0.93-2.35) 1.66 (0.94-2.95)
>1 year 6 1.71 (0.70-4.20) 1.77 (0.72-4.35) 2.15 (0.77-5.96)
* Adjusted for age, sex, smoking, and coffee consumption
DISCuSSIoN
In this prospective, population-based study we found no significant beneficial effect 
of NSAID use on the risk of PD. In fact, the risk of PD associated with use of NSAIDs 
– if anything – appeared increased. Among the strengths of our study are the almost 
complete follow-up and intensive case finding methods using in-person screening, 
which minimizes the possibility of misclassification of disease status. Besides, instead 
of relying on questionnaires or doctor prescriptions, we drew data on filled prescriptions 
from pharmacy records, which is a more precise method of exposure assessment and 
reduces misclassification of drug use. A potential drawback of using computerized 
pharmacy data is the lack of information on use of over-the-counter medication. 
Theoretically, use of over-the-counter medication may differ between participants 
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with and without PD, due to socioeconomic or other differences. During the 1990s 
preparations of low dosages of ibuprofen and naproxen became available in the 
Netherlands as over-the-counter medication. However, until 1999 these drugs were fully 
covered by insurance companies, and after 1999 chronic use (i.e. >3 months) of these 
drugs remained reimbursed, if given on prescription. Only in 2004 did reimbursement 
of these drugs become restricted to higher-dosage forms. Regular users of NSAIDs are 
thus unlikely to have obtained their drugs over the counter during the study period, and 
misclassification because of occasional use of over-the-counter NSAIDs would only 
concern the lower-exposure categories. Therefore, we think that the effect of over-the-
counter medication on our findings is limited. Another potential limitation might be the 
discrepancy between prescribed medication and actual intake by the study participants. 
Nevertheless, in the current study filled prescriptions, i.e. medications that were actually 
collected at the pharmacy were taken into account, making this kind of misclassification 
less likely. We did not have data on use of NSAIDs before the start of the study period. 
We thus could not evaluate the effect of longer-term past exposure on the risk of PD. A 
final drawback of the current study is the limited power due to low numbers. The small 
number of participants who used NSAIDs for >1 year resulted in unstable estimates 
of the long-term effect of NSAID use. The relatively low number of 88 incident PD 
cases also precluded subanalyses, e.g. to compare the effects of non-COX2 selective 
NSAIDs versus COX2-selective NSAIDs, or to examine aspirin and non-aspirin NSAIDs 
separately. These kinds of subanalyses are potentially interesting, as recent evidence 
suggests that the hypothesized neuroprotective effects of NSAIDs might differ across 
subtypes.10 
There is growing evidence for a role of inflammation in PD pathogenesis.1,2,11 A pro-
fusion of microglia, the hallmark of inflammation in the brain, is present in the basal 
ganglia in PD and is associated with the loss of dopaminergic neurons.1 A beneficial 
effect of NSAIDs on PD risk has been hypothesized, given that NSAIDs inhibit the 
enzyme cyclooxygenase, which plays an important role in inflammation.4 In animal 
models, NSAIDs were found to attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
induced dopamine depletion and degeneration of dopaminergic neurons.1,4 Thus far, no 
studies have been reported that prospectively evaluated the association between direct 
markers of inflammation and the risk of PD. However, in a large prospective cohort 
study among 142,902 health professionals, regular use of non-aspirin NSAIDs was 
associated with a 50% lower risk of PD.4 A second large US-based prospective study 
demonstrated a significantly reduced risk of PD in users of ibuprofen.5 In both studies, 
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however, case ascertainment relied on self-reported diagnoses of PD (confirmed by 
review of medical records) and not in-person screening methods. More importantly, 
continuous automated pharmacy data were not available in these studies, and NSAID 
exposure was defined as self-reported use assessed through questionnaires. In a 
recent population based case-control study with recording of NSAID use through 
a computerized pharmacy database, no association was found between ever or 
cumulative use and the risk of PD, which fits our present findings.12 This study included 
206 cases and 383 controls, identified through registers of a health maintenance 
organization in the USA. A very large register-based nested case-control study from 
the UK, which included 1,258 PD patients, showed no significant association either. 
However, in this study, which was also based on computerized prescription data, 
stratified analyses indicated a higher risk of PD in women and a lower risk in men.13 
In conclusion, although an inverse association between NSAID use and the risk of 
PD has been suggested by 2 large cohort studies, the hypothesis that NSAIDs may 
lower the risk of PD could not be confirmed in our study, or in other studies based on 
automated pharmacy data. 
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AbStrACt
background: Observational studies suggested nonsteroidal anti-inflammatory drugs 
(NSAID) use might reduce the risk of Alzheimer disease (AD). Since then, in vitro and in 
vivo studies put forward that this protective effect may result from amyloid-peptide-β42 
(Aβ42)-level lowering properties of certain NSAIDs, rather than from a general anti-
inflammatory effect.
methods: We investigated the association between use of NSAIDs that lower Aβ42-
levels in vitro and in vivo and non-Aβ42-lowering NSAIDs, with the risk of AD in the 
prospective, population-based Rotterdam Study. We followed 6,992 participants from 
baseline (1990 -1993) until January 2005 for incident AD. Data on all filled prescriptions 
were obtained from pharmacy records. At each date of AD diagnosis, cumulative 
duration of NSAID use was calculated for both the person who was diagnosed with 
AD and the remainder of the cohort. Duration of use was categorized as: short- (≤1 
month), intermediate- (>1 and <24 months) and long-term use (≥24 months) for Aβ42-
lowering and non-Aβ42-lowering NSAIDs. Never-use of any NSAID was the reference 
in all analyses. Hazard ratios (HR) of AD were calculated with Cox-regression analyses, 
adjusting for age, sex and potential confounders. 
results: During 62,883 person years of follow-up, 582 persons developed AD. Long-
term use of Aβ42-lowering NSAIDs was associated with a decreased risk of AD 
compared to never-use (adjusted HR 0.42; 95%CI 0.21-0.83). Long-term use of non-
Aβ42-lowering NSAIDs was not associated with a reduced risk of AD (adjusted HR 1.15; 
95%CI 0.47-2.82). 
Conclusion: The reduced risk of AD associated with long-term use of NSAIDs is 
confined to NSAIDs with Aβ42-lowering properties. Our findings corroborate in vitro and 
animal studies which suggested that NSAIDs influence AD pathogenesis through an 
amyloid-processing related mechanism. 
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INtroDuCtIoN 
Alzheimer disease (AD) is the most common cause of dementia in the elderly.1 Neuro-
pathologically, AD is characterized by the abundant presence of senile plaques and 
neurofibrillary tangles in specific brain regions.2 A leading hypothesis regarding AD 
pathogenesis postulates a central role for amyloid peptide-β42 (Aβ42), the major 
constituent of senile plaques.3 Aβ42 can accumulate in the brain either as a result of 
increased production, aberrant processing of the amyloid precursor protein, or because 
of decreased clearance.4 Furthermore, brains of AD patients show signs of chronic 
inflammation, typically co-localized with the plaques. It has been suggested that a 
neuroinflammatory response may play a crucial role in AD pathogenesis.5 
Epidemiologic studies have indicated that the use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) might protect against AD.6-12 We previously reported from a follow-
up of the prospective cohort of the Rotterdam study until 1998, that long-term use of 
NSAIDs was associated with a reduced risk of AD.10 Initially, the assumed explanatory 
mechanism underlying the protective effect of NSAIDs was that this class of drugs 
would reduce the inflammatory response observed in AD.5 However, results from in vitro 
and in vivo mice model studies, that were published since, suggest that certain NSAIDs 
may have a more specific effect on Alzheimer pathology namely through interference 
with amyloid-β processing.13-16 If true, this would shed new light on the interpretation of 
trials that found no beneficial effect on AD.17,18 Thus far only one observational study 
distinguished between Aβ42- and non-Aβ42-lowering NSAIDs in relation to the risk of 
AD. The investigators found that the use of both Aβ42- and non-Aβ42-lowering NSAID, 
as obtained from annual interviews, was associated with a reduced risk of AD.11
In the Rotterdam Study we have detailed information on drug exposure from pharmacy 
dispensing records as well as on dementia outcomes.19 This allowed us to investigate 
the current hypothesis that the use of NSAIDs that lower Aβ42-levels in vitro and in vivo 
is associated with a reduced risk of AD whereas no such effect exists for use of non-
Aβ42-lowering NSAIDs. 
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metHoDS
Study population
The Rotterdam Study is a prospective, population-based cohort study of age related 
disorders.19 The medical ethics committee of the Erasmus Medical Center, Rotterdam, 
the Netherlands, approved the study. Between 1990 and 1993 all persons aged 55 
years or older living in Ommoord, a district of Rotterdam, were invited to participate. Of 
the 10,275 eligible persons, 7,983 (77.7%) signed informed consent. Of these, 7,528 
(94.3%) were screened for dementia and 7,046 were found to be free of dementia 
at baseline.20 Follow-up examinations, including screening and clinical workup for 
dementia, were conducted in 1993 to 1994, 1997 to 1999 and 2000 to 2004. In addition, 
the cohort was continuously monitored for major disease outcomes and death through 
linkage with records of general practitioners, the Regional Institute for Outpatient Mental 
Health Care and bimonthly updates from the municipality records. This resulted in a 
virtually complete follow-up for dementia until January 1st, 2005. Nearly all persons 
(99.7%) were registered at one or more of seven automated pharmacies serving the 
Ommoord area. Of these pharmacies, records of all filled prescriptions were available 
as of January 1st, 1991. To ensure at least six months medication history, we excluded 
persons for whom follow-up ended before July 1st, 1991. Consequently, the study 
population consisted of 6,992 persons. 
Drug exposure
Complete information on all filled prescriptions for all persons was obtained in 
automated format from the pharmacies. This included the product name; international 
non-proprietary name; Anatomical Therapeutic Chemical code;21 total number of 
delivered units (e.g. tablets/capsules); prescribed daily number of units; date of delivery 
and drug dosage. The duration of a prescription is calculated as the total number of 
delivered units divided by the prescribed daily number of units. 
NSAIDs were classified a priori as Aβ42-lowering or non-Aβ42 lowering NSAID based 
on their reported effects on Aβ42-levels in in vitro studies and in vivo mice model 
studies (Table 1).13-16,22 A separate category was made for NSAIDs with an unknown 
effect on Aβ42-levels; these drugs were infrequently prescribed (1%) and not further 
investigated. 
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table 1. Classification of the nonsteroidal anti-inflammatory drugs (NSAIDs) according to 
Aβ42-lowering properties, prescription frequencies and cumulative duration of use during 
follow-up
Type of NSAID 
Number of prescriptions 
(% of total NSAID 
prescriptions)
Cumulative duration of 
use in days * (% of total 
days of NSAID use)
Aβ42-lowering NSAIDs 33,171 (73.2%) 795,437 (71.3%)
Diclofenac 16,771 (37.0%) 347,722 (31.2%) 
Ibuprofen 9,209 (20.4%) 219,559 (19.7%) 
Diclofenac comb. 2,460 (5.4%) 60,029 (5.4%)
Piroxicam 2,437 (5.3%) 86,542 (7.7%)
Indometacin 1,771 (3.9%) 62,840 (5.6%)
Sulindac 403 (0.9%) 12,518 (1.1%)
Flurbiprofen 120 (0.3%) 6,227 (0.6%)
Non-Aβ42-lowering NSAIDs 11,638 (25.8%) 304,888 (27.4%)
Naproxen 7,765 (17.1%) 177,317 (15.9%)
Rofecoxib 1,446 (3.2%) 41,457 (3.7%)
Nabumeton 874 (1.9%) 30,914 (2.7%)
Ketoprofen 863 (1.9%) 32,805 (2.8%)
Meloxicam 574 (1.2%) 18,901 (1.7%)
Celecoxib 88 (0.2%) 2,872 (0.3%)
Phenylbutazone 13 (<0.1%) 337 (<0.1%)
Etoricoxib 12 (<0.1%) 234 (<0.1%)
Valdecoxib 3 (<0.1%) 52 (<0.1%)
Unknown effect on Aβ42† 441 (1.0%) 14,245 (1.3%)
* Since in the analysis exposure is time-dependent, the prescription overlap which is taken into 
account in the analysis, cannot be depicted in these descriptives
† No further specification because of small prescription frequency (includes azapropazon, tiaprofeic 
acid, aceclofenac, tolfenamic acid, tenoxicam, tolmetin, benzydamine). 
Salicylates (i.e. acetylsalicylic acid and carbasalate calcium) are pharmacologically 
related to NSAIDs. However, they are typically prescribed as platelet inhibitors in low 
dosages in which they have a negligible anti-inflammatory effect. Moreover, these drugs 
do not have Aβ42-lowering properties.13,14 Therefore, we did not categorize salicylates 
with NSAIDs but studied them separately in relation to the risk of AD.
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Diagnosis of dementia
The diagnosis of dementia was made following a three-step protocol.20 Screening 
was done with the Mini Mental State Examination (MMSE) and Geriatric Mental State 
schedule (GMS) organic level for all persons.23,24 Screen-positives (MMSE score <26 
or GMS organic level >0) underwent the Cambridge examination for mental disorders 
of the elderly.25 Persons who were suspected of having dementia underwent more 
extensive neuropsychological testing. When available, imaging data were used. In 
addition, the total cohort was continuously monitored for incident dementia through 
computerized linkage between the study database and digitalized medical records 
from general practitioners and the Regional Institute for Outpatient Mental Health Care. 
The diagnosis of dementia and subtype of dementia was made in accordance with 
internationally accepted criteria for dementia (DSM-III-R), AD (NINCDS-ADRDA), and 
vascular dementia (NINDS-AIREN) by a panel of a neurologist, neuropsychologist and 
research physician, blinded for drug exposure of the study population.26-28
other covariates 
Baseline covariates included age, sex, and level of education, diabetes mellitus and 
cardiovascular disease. Incident covariates included cumulative use of antihyper-
tensives, cumulative use of salicylates, newly diagnosed diabetes mellitus and cardio-
vascular disease. Education was assessed at the baseline interview and dichotomized 
into low education (including primary education only or low vocational training) and 
high education (including intermediate-level vocational training, secondary education 
or university). Diabetes mellitus was defined as antidiabetic medication use or a non-
fasting or 2-hour post load glucose level of ≥200 mg/dL or fasting glucose of ≥126 
mg/dL. Cardiovascular disease included myocardial infarction, coronary artery bypass 
graft, percutaneous transluminal coronary angioplasty, TIA, atrial fibrillation and heart 
failure. Data on antihypertensive and salicylate use was obtained from pharmacy 
records. Apolipoprotein E (APOE) genotyping was performed on coded DNA samples, 
and participants were classified according to presence or absence of at least one 
APOE-ε4 allele.29
Statistical analyses
At each date of AD diagnosis, cumulative duration of use was calculated for both the 
person who was diagnosed with AD and the remainder of the cohort. Conform our 
earlier study duration we subsequently categorized duration of use as: short- (≤1 
month), intermediate- (>1 and <24 months) and long-term use (≥24 months). This 
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was done for both Aβ42-lowering NSAIDs and non-Aβ42-lowering NSAID subtypes 
separately, and -to allow for comparison with earlier studies- also for use of any NSAID. 
A cohort member could contribute person-time to more than one category of duration of 
use with increasing NSAID use. Never use of any NSAID was the reference category for 
all analyses. For all subjects, we determined the duration of follow-up between start of 
the study and death, diagnosis of dementia, or end of the study period, whichever came 
first. We calculated the hazard ratio (HR) of AD (and 95% confidence intervals (CI)) 
with a Cox- proportional-hazards model (SPSS 11.01 software; SPSS Inc, Chicago, 
Illinois) in which calendar-time was used as the time-axis.30 All analyses were adjusted 
for age, sex and, in the analyses of Aβ42-lowering NSAIDs, for cumulative use of non-
Aβ42-lowering NSAIDs and vice versa (Model I). To adjust for potential confounders we 
additionally included level of education, cumulative use of antihypertensives, cumulative 
use of salicylates, diabetes mellitus and cardiovascular disease (Model II). 
We performed several additional analyses. First, patterns of NSAID use have changed 
over the years in that the use of non-Aβ42-lowering NSAIDs has increased relative to 
that of Aβ42-lowering NSAIDS after the year 2000 (Figure 1). We considered that if 
Aβ42-lowering NSAIDs decrease AD risk, but not non-Aβ42-lowering NSAIDs, the effect 
estimates for the risk of AD associated with the use of Aβ42-lowering and non-Aβ42-
lowering NSAIDs would remain stable over time, but the effect on AD risk associated 
with the use of any NSAIDs would decrease with increasing length of follow-up. We 
investigated this by calculation of the HR for any NSAID, and Aβ42-lowering and non-
Aβ42-lowering NSAIDs separately for each year after 1999. Second, we considered 
that persons in the prodromal phase of AD might change their drug use. To evaluate 
whether this biased our results we performed an additional analysis where we excluded 
the last two years before diagnosis.8 Third, we investigated the association between the 
use of salicylates and AD using the same methods, except that we here adjusted for 
cumulative use of NSAIDs. Finally, we investigated whether the association with AD was 
different for carriers and non-carriers of an APOE-ε4 allele by stratified analyses.
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figure 1. Proportions of cumulative use of NSAID subtypes calculated as the 
percentage of the total cumulative days of use of any NSAID per year from 1999 to 
2004
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reSultS
During 62,883 person years of follow-up (mean 9.0 years), 739 persons developed 
dementia, of whom 582 were diagnosed with AD, 81 with vascular dementia and 76 with 
other types of dementia. The total number of NSAID prescriptions during the complete 
follow-up was 45,250 representing a total of 1,114,569 cumulative days of use. 
Prescription frequencies and total cumulative duration of NSAID use are given in Table 
1. Baseline characteristics of the study population are shown in Table 2. At baseline, the 
mean age of the participants 69.4 years and the majority was female (60%). 
Compared to never use, long-term use of Aβ42-lowering NSAIDs was associated with a 
decreased risk of AD (HR adjusted for age, sex and use of other NSAIDs: 0.41 95%CI 
0.21-0.82). There was no difference in risk of AD with long-term use of non-Aβ42-
lowering NSAIDs compared to never use (HR adjusted for age, sex and use of other 
NSAIDs 1.19: 95%CI 0.48-2.90). Additional adjustment for other potential confounders 
did not change any of the estimates (Table 3).
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table 2. Baseline characteristics of the study population (n=6,992)
Characteristic
Age in years (mean, ± SD) 69.4 ± 9.1
Female (%) 4,195 (60.0%)
Primary education, low vocational training or less (%) 2,697 (38.6%)
Cardiovascular disease (%) 1,469 (21.0%)
Diabetes mellitus (%) 722 (10.3%)
APOE-ε4 allele present (%) 1,793 (25.6%)
Use of any NSAID at baseline (%)* 441 (6.3%)
Abbreviations: NSAIDs - nonsteroidal anti-inflammatory drugs
* Defined as any prescription filled within 90 days before or after start of study period
table 3. Hazard ratios of Alzheimer disease associated with the use of subtypes of 
nonsteroidal anti-inflammatory drugs (NSAIDs) according to Aβ42-lowering properties 
risk of Alzheimer disease
NSAID use
Number of
 cases 
Hazard ratio (95% CI), 
model I *
Hazard ratio (95% CI), 
model II †
No use 218 1.00 (ref.) 1.00 (ref.)
Aβ42-lowering NSAID use
≤1 month 141 0.92 (0.74-1.15) 0.92 (0.74-1.15)
>1 and <24 months 180 1.00 (0.81-1.23) 1.01 (0.82-1.24)
≥24 months 9 0.41 (0.21- 0.82) 0.42 (0.21-0.83)
Non-Aβ42-lowering NSAID use
≤1 month 84 0.89 (0.69-1.16) 0.89 (0.68-1.15)
>1 and <24 months 77 1.15 (0.87-1.52) 1.16 (0.88-1.53)
≥24 months 5 1.19 (0.48-2.90) 1.15 (0.47-2.82)
* Model I: adjusted for age, sex and cumulative use of other NSAIDs
† Model II: as model I and additionally adjusted for level of education, cumulative use of 
antihypertensives and salicylates, diabetes mellitus, cardiovascular disease
The utilization of NSAIDs changed during follow-up, in that there was a gradual shift 
towards more use of non-Aβ42-lowering NSAIDs relative to Aβ42-lowering NSAIDs after 
the year 2000 (Figure 1). The HR for long-term use of Aβ42-lowering NSAIDs and non-
Aβ42-lowering NSAIDs remained stable over the years (Figure 2). However, concurrent 
with the increasing proportion of use of non-Aβ42-lowering NSAIDs, the HR of AD for 
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long-term use of any NSAID gradually attenuated with increasing follow-up (Figure 2), 
becoming non-significant at maximum follow-up (adjusted HR of AD for long-term use of 
any NSAID 0.64 (95%CI 0.39-1.05), Figure 2). 
The exclusion of 2 years before diagnosis did not alter our findings. The HR for long 
term-use of Aβ42-lowering NSAIDs was 0.52 (95%CI 0.25-1.06) and for non-Aβ42-
lowering NSAIDs 1.41 (95%CI 0.52-3.84). In the categories of long-term use for Aβ42-
lowering as well as for non-Aβ42-lowering NSAIDs, only one case with an APOE-ε4 
allele was available, precluding additional analyses. Use of salicylates was not 
associated with risk of AD, regardless of duration of use (HR for short-term use 0.97: 
95%CI 0.61-1.54, intermediate-term use 1.10: 95%CI 0.87-1.39, and long-term use 
0.81: 95%CI 0.51-1.29).
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figure 2. Hazard ratios of Alzheimer Disease (AD) from 1999 to 2004 for long-term use of 
Aβ42-lowering NSAIDs (A), non-Aβ42-lowering NSAIDs (B) and any NSAIDs (C), before 
1999 no cases were available in Aβ42-lowering NSAID exposure categories
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DISCuSSIoN
In this large prospective population-based study, we found that long-term use of Aβ42-
lowering NSAIDs was associated with a significantly decreased risk of AD. Use of non-
Aβ42-lowering NSAIDs was not associated with the risk of AD. 
Strengths of our study include its prospective design, large number of participants, long 
follow-up period and population-based setting. The high response rate and virtually 
complete follow-up for dementia make selection bias very unlikely. A particular asset of 
our study is that we had complete pharmacy records of all filled prescriptions, providing 
us with very specific and detailed information on drug use. However, we cannot exclude 
some misclassification of drug exposure. First, we may have misclassified some 
NSAIDs with regard to their Aβ42-lowering properties. In determining the Aβ42-level 
modulating properties of NSAIDs much depends on the assay, cell culture and mice 
model being used. However, we based our classification mainly on a study by Eriksen 
et al who determined the Aβ42-modulating properties of almost all NSAIDs in a single 
assay.14 Where necessary, we added data from additional correlating assays.13,15,16 
If misclassification has occurred, this would have lead to a dilution of the observed 
protective effect. Second, we had no information on over-the-counter (OTC) drug 
use. During the 1990’s few preparations of low dosages of ibuprofen and naproxen 
became available OTC. However, in the Netherlands until 1999 these drugs were 
fully reimbursed, and after 1999 chronic use (>3 months) of these drugs remained 
reimbursed, if given on prescription. It was not until 2004 when reimbursement of these 
drugs was restricted to higher dosage forms. Therefore, it is unlikely that during the 
follow-up period of our cohort regular users of NSAIDs obtained their drugs OTC. Some 
misclassification may have occurred because of occasional use of OTC NSAIDs, but 
this was most likely non-differential as both Aβ42-lowering NSAIDs and non-Aβ42-
lowering NSAIDs were available OTC. To the extent that this has biased our results, 
it will have led us to underestimate an effect. Finally, prodromal AD might lead to 
changes in drug use. To examine whether the inclusion of persons with prodromal 
AD had biased our results, we performed an analysis where we excluded the last two 
years before diagnosis. Since this did not alter our results we do not think that this has 
played a major role, if any. Long-term use of Aβ42-lowering NSAIDs was associated 
with a decreased risk of AD, whereas no effect was observed for non-Aβ42-lowering 
NSAIDs. In an earlier analysis of our cohort after shorter follow-up we found that long-
term use of any NSAIDs was associated with a reduced risk of AD.10 By analyzing 
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our data with different lengths of follow-up we were now able to demonstrate that 
that could be attributed to the effect of Aβ42-lowering NSAIDs, which were the more 
frequently prescribed type of NSAIDs in the earlier years of follow-up of our cohort. 
The observation that the HRs for both Aβ42-lowering NSAIDs and non-Aβ42-lowering 
NSAIDs were stable over follow-up provides strong support for the protective effect that 
we observed for Aβ42-lowering NSAIDs being real. 
Numerous observational studies investigated the association between NSAIDs and 
risk of AD with conflicting results.6-12,31 An explanation for the inconsistencies between 
these previous studies can be the variation in the types of NSAIDs that were used, but 
this was not investigated. Whilst two more recent observational studies and a pooled 
cohort study again confirmed the protective effect of NSAIDs in AD, they did not provide 
support for a different effect of Aβ42-lowering and non-Aβ42-lowering NSAIDs in 
AD.18-20 The classification of NSAIDs was the same across studies and identical to our 
classification. However, there were considerable differences in study design, particularly 
in terms of source of information on drug exposure and exposure definition, which could 
explain the discrepancies. For example, the study by Szekely et al. relied on annual 
assessment of drug exposure which makes misclassification of drug exposure likely. 
Also, no consideration was given to the duration of use for the subtypes of NSAIDs.11 
Recent large randomized controlled trials did not provide evidence for a protective effect 
of long-term therapy of NSAIDs.17,18 Of note, the treatment regimens in neither of these 
trials included Aβ42-lowering NSAIDs. 
Our study is the first observational report to suggest a differential effect of subtypes 
of NSAIDs on AD risk based on their ability to modulate Aβ42-levels. Although we 
are unable to test whether these Aβ42-lowering NSAIDs actually lowered brain Aβ42-
levels, our results are in accordance with in vitro and in vivo mice model studies that 
consistently show an Aβ42-lowering effect for this specific subgroup of NSAIDs.13-16 
To our best knowledge the effect of the currently available NSAIDs on Aβ42-load of the 
brain has not yet been studied in humans under experimental conditions. 
By which mechanism NSAIDs can affect amyloid-processing and ultimately modulate 
Aβ42-levels in the brain remains to be elucidated. NSAIDs are pleiotropic drugs and 
numerous mechanisms have been suggested, such as those involving nuclear factor 
κB32, inhibition of Rho activity33, repression of β-secretase possibly via activation of 
proliferator-activated receptor-γ34, or modification of the activity or specificity of 
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γ-secretase.35,36 NSAIDs may also act on the level of Aβ42-aggregation in plaques.37 
Importantly, this Aβ42-lowering effect appears independent of inhibition of cyclooxy-
genase, the key target for the anti-inflammatory activity of NSAIDs.13 
In conclusion, long-term use of NSAIDs which lower Aβ42-levels in vitro and in vivo 
in mice models is associated with a decreased risk of AD. The protective effect was 
observed solely for this type of NSAID. Our findings suggest that these NSAIDs do 
not influence risk of AD through their anti-inflammatory effect, but rather through an 
amyloid-processing related mechanism.
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AbStrACt
background: Cross-sectional reports suggest that statin-users are less likely to have 
Alzheimer disease (AD). Prospective studies have provided inconsistent evidence. 
Moreover, it is unclear whether the association differs for lipohilic statins, those that 
could more easily pass the blood-brain-barrier, and hydrophilic statins. 
objectives: To prospectively evaluate whether use of statins is associated with the risk 
of AD, and to determine whether associations differ for lipophilic and hydrophilic statins.
method: We followed 6,992 participants of the prospective, population-based 
Rotterdam Study, from baseline (1990-1993) until January 2005 for incident AD. 
Data on all filled prescriptions came from pharmacy records. At each date an event 
occurred, cholesterol-lowering drug use for the person who experienced the event 
and all remaining persons in the cohort was categorized as ‘any’ or ‘never’ use. 
We distinguished between statin, lipophilic and hydrophilic statins, and non-statin 
cholesterol-lowering drugs. Data were analyzed with Cox-regression analysis, adjusting 
for sex, age and potential confounders. 
results: During follow-up (mean 9 years), 582 persons developed AD. Compared to 
never use of cholesterol-lowering drugs, statin use was associated with a decreased 
risk of AD (HR 0.57; 95%CI 0.37-0.90), but non-statin cholesterol-lowering drug use was 
not (HR 1.05; 95%CI 0.45-2.44). HRs were equal for lipophilic (HR 0.54; 95%CI 0.32-
0.89) and hydrophilic statins (HR 0.54; 95%CI 0.26-1.11). 
Conclusion: In the general population, use of statins, but not of non-statin cholesterol-
lowering drugs, was associated with a lower risk of AD compared to never use of 
cholesterol-lowering drugs. The protective effect of statins was independent of the 
lipophilicity of statins. 
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INtroDuCtIoN
Cross sectional observational studies have suggested an association between the 
use of cholesterol lowering drugs, particularly 3-hydroxy-3-methylglutaryl-coenzyme-
A-reductase inhibitors (statins), and the risk of Alzheimer disease.1-6 Thus far, the 
evidence from prospective studies for a protective effect of statins on the risk of 
Alzheimer disease is less clear and inconsistent.3,7-13 Important limitations of these 
studies, however, included use of interview data on drug exposure or cross-sectional 
exposure assessment, and short duration of follow-up. No clinical trial has yet been 
reported that investigated the efficacy of statin therapy in preventing Alzheimer disease 
in persons without cognitive impairment.14-16
The mechanism by which cholesterol-lowering drugs may affect Alzheimer pathogenesis 
is unclear. Since cholesterol is essential for normal function of the brain, the effect of 
these drugs on serum cholesterol was considered a potential underlying mechanism 
of action. However, brain cholesterol is synthesized in situ and exchange with the 
periphery is prevented by the blood-brain-barrier.17 Hence, it was debated whether 
lowering of serum cholesterol levels by these drugs could actually affect brain 
cholesterol homeostasis.17 This led to the hypothesis that only the lipophilic statins, 
those that could cross the blood-brain-barrier more easily, would affect brain cholesterol 
metabolism. 
The Rotterdam Study is a large prospective population-based cohort study with detailed 
information on drug exposure from pharmacy dispensing records, data on potential 
confounders and systematic assessment of dementia outcomes.18 We investigated 
whether the use of statins or other, non-statin, cholesterol-lowering agents, was 
associated with the risk of Alzheimer disease. In addition, we determined whether any 
observed associations differed between lipophilic and hydrophilic statins. 
metHoDS 
Study population 
The Rotterdam Study is a prospective, population-based cohort study of age related 
disorders.18 The medical ethics committee of the Erasmus Medical Center, Rotterdam, 
the Netherlands, approved the study. Between 1990 and 1993 all persons aged 55 
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years or older living in Ommoord, a district of Rotterdam, were invited to participate. 
Of the 10,275 eligible persons, 7,983 (78%) signed informed consent. Of these, 
7,528 (94%) were screened for dementia and 7046 were found to be free of dementia 
at baseline.19 Follow-up examinations, including screening and clinical workup for 
dementia, were conducted in 1993 to 1994, 1997 to 1999 and 2000 to 2004. In addition, 
the cohort was continuously monitored for major disease outcomes and death through 
linkage with records of general practitioners, the Regional Institute for Outpatient Mental 
Health Care and bimonthly updates from the municipality records. This resulted in a 
virtually complete follow-up for dementia until January 1st, 2005. Nearly all persons 
(99.7%) were registered at one or more of seven automated pharmacies serving the 
Ommoord area. Of these pharmacies, records of all filled prescriptions were available 
as of January 1st, 1991. To ensure at least six months medication history, we excluded 
persons for whom follow-up ended before July 1st, 1991. Consequently, the study 
population consisted of 6,992 persons. 
Drug exposure
Complete information on all filled prescriptions for all persons was obtained in auto-
mated format from the pharmacies. This included the product name; international 
non-proprietary name; Anatomical Therapeutic Chemical (ATC) code; total number of 
delivered units (e.g. tablets/capsules); prescribed daily number of units; date of delivery 
and drug dosage. The duration of a prescription is calculated as the total number of 
delivered units divided by the prescribed daily number of units. 
Cholesterol-lowering drugs were classified as statins (simvastatin, pravastatin, 
fluvastatin, atorvastatin, cerivastatin, rosuvastatin) or non-statin cholesterol lowering 
drugs (fibrates, bile acid binding resins or nicotinic acid and derivatives). Statins were 
further subdivided into lipophilic (simvastatin, atorvastatin, cerivastatin) and hydrophilic 
statins (pravastatin, fluvastatin, rosuvastatin) based on their relative lipid-solubility.20-23 
Lipophilic statins are thought to pass the blood-brain barrier more efficiently than 
hydrophilic statins, which could be relevant to their effect on Alzheimer pathology.24-26 
All drugs under study are available in the Netherlands only on prescription. In the 1998 
Dutch guidelines on the prevention of cardiovascular disease, simvastatin is the statin 
of first choice for treatment of hypercholesterolemia, followed by pravastatin.27 
2.1 Statins and risk of Alzheimer disease
79
Diagnosis of Alzheimer disease
The diagnosis of dementia was made following a three-step protocol. Screening was 
done with the Mini-Mental State Examination (MMSE) and Geriatric Mental State 
schedule (GMS) organic level for all persons. Screen-positives (MMSE score <26 or 
GMS organic level >0) underwent the Cambridge examination for mental disorders 
of the elderly.28,29 Persons who were suspected of having dementia underwent more 
extensive neuropsychological testing. When available, imaging data were used. In 
addition, the total cohort was continuously monitored for incident dementia through 
computerized linkage between the study database and digitalized medical records 
from general practitioners and the Regional Institute for Outpatient Mental Health Care. 
The diagnosis of dementia and subtype of dementia was made in accordance with 
internationally accepted criteria for dementia (DSM-III-R), AD (NINCDS-ADRDA), and 
vascular dementia (NINDS-AIREN) by a panel of a neurologist, neurophysiologist and 
research physician, blinded to drug exposure of the study population.30-32
other covariates 
Covariates included age, sex, education level, smoking, total serum cholesterol, 
body mass index, systolic blood pressure, diabetes mellitus and cardiovascular and 
cerebrovascular disease. Education was assessed at the baseline interview and 
dichotomized into low education (including primary education only or low vocational 
training) and high education (including intermediate-level vocational training, secondary 
education or university). Smoking status was also self-reported and categorized as 
ever or never smoker. Total serum cholesterol was measured in non-fasting blood 
drawn at baseline. Sitting blood pressure was measured on the right upper arm using 
a random-zero sphygmomanometer. Diabetes mellitus was defined as a non-fasting 
or 2-hour post load glucose level of ≥11.1 mmol/l or antidiabetic medication use at 
baseline. Cardiovascular disease included myocardial infarction, coronary artery bypass 
graft, percutaneous transluminal coronary angioplasty, atrial fibrillation and heart 
failure. Cerebrovascular disease included transient ischemic attacks and stroke. APOE 
genotyping was performed on coded DNA samples, and participants were classified 
according to presence or absence of at least one APOE-ε4 allele.
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Statistical analyses
For all subjects, we calculated the duration of follow-up between start of the study 
and death, diagnosis of dementia, or end of the study period, whichever came 
first. Prescription drug use was available on a day-to-day basis from the pharmacy 
prescription database. At each event-date, we were therefore able to determined 
cholesterol-lowering drug use for the person who suffered the event and for all persons 
in the remainder of the cohort. Subsequently, cholesterol-lowering drug use was 
categorized as either ‘any’ or ‘never’ use, depending on whether a person had used 
cholesterol-lowering drugs prior to or on that event-date, or not.33 Hence, if for a person 
cholesterol-lowering drug therapy was initiated at some point during follow-up, that 
person would then switch from the exposure category of ‘never’ use to ‘any’ use. In 
case two prescriptions overlapped, the use of the first drug was assumed to have been 
discontinued and treatment to have proceeded with the second drug. A cohort member 
could contribute person-time to more than one category of cholesterol-lowering drug 
use if a person had used more than one cholesterol-lowering drug during follow-up. 
Accordingly, the numbers of cases in the analyses of the statin subtypes do not add 
up to the numbers of cases in the analyses of statins as a group. ‘Never’ use of any 
cholesterol-lowering drug was the reference for all analyses. We distinguished between 
statin and non-statin cholesterol lowering drugs and between lipophilic and hydrophilic 
statins. In addition, we separately investigated the use of simvastatin, the most lipophilic 
statin prescribed and pravastatin, the most hydrophilic statin prescribed. We calculated 
the hazard ratio (HR and 95% confidence intervals (CI)) of the risk of Alzheimer disease 
associated with cholesterol-lowering drug use using a Cox-proportional-hazards model 
with time-dependent covariates (SPSS 11.01 software). Calendar-time was used as the 
time-axis in the model to account for changes in prescription guidelines and availability 
of cholesterol-lowering drug use over time. All analyses were adjusted for age and 
sex, and, if applicable, use of other cholesterol lipid-lowering drugs (model I). To adjust 
for potential confounders we additionally included baseline education, smoking, total 
serum cholesterol, body mass index, systolic blood pressure and diabetes mellitus 
and cardiovascular disease. In addition, we included cardiovascular disease as time-
dependent covariate in the model to adjust for cardiovascular disease diagnosed during 
follow-up.
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For statins, dose- and duration relationships were studied by dichotomizing statin use 
around the median of the cumulative duration of use (≤ and >2.9 years) and around 
the median of the defined daily dose (DDD), averaged over the total period of use used 
during follow-up (≤ and >0.89 DDD). 
We performed several additional subanalyses. First, we acknowledge that, even 
though cholesterol-lowering drug therapy is generally used chronically, persons could 
have stopped therapy, for example as a result of adverse events, non-compliance or 
a change in diet or life-style which rendered cholesterol-lowering therapy no longer 
indicated. To take this into account we performed an analysis where we restricted the 
exposure category of ‘any’ use to at least one prescription of cholesterol-lowering drugs 
filled in the year prior to the date of an event. Second, most of the preceding cohort 
studies enrolled persons of 65 years and older in the early 1990’s. Because statins were 
not widely used before the mid-1990s, it is likely that these persons did not use statins 
before the age of 65 contrary to our own study population. Therefore, we repeated the 
analysis for persons ≥65 years of age at baseline. Third, we considered that physicians 
might be less motivated to prescribe chronic preventive therapies to persons with mild 
cognitive impairment. To evaluate whether this biased our results we performed an 
analysis where we excluded the last two years before diagnosis. Fourth, in the main 
analyses we used calendar-time as time-axis in the COX-model. In an additional model 
we used age as time-axis, as was done in an earlier study on cholesterol-lowering drug 
use and Alzheimer disease.8 By using age as time-axis, no assumption is made on the 
functional form for the age-specific incidence rates. Finally, apolipoprotein E (APOE) 
is responsible for lipid metabolism and is the primary transport protein of cholesterol 
in the brain.34,35 Furthermore, it has been suggested that the response to statins is 
dependent on APOE-genotype.9,36 Therefore, for statins we determined whether any 
effect modification was observed due to the presence of an APOE-ε4 allele. 
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reSultS
In total 6,992 persons, free of dementia at baseline and with at least 6 months 
medication history, were included in the analysis. In Table 1 baseline characteristics of 
the study population are given. 
table 1. Baseline characteristics of the study population (n=6,992)
Characteristic
Age (± SD) in years 69.4 ± 9.1
Sex (% female) 4,195 (60.0%)
Smoking, ever (%) 4,386 (62.7%)
Diabetes mellitus (%) 722 (10.3%)
Systolic blood pressure (mmHg) 139.3 ± 22.3
Cardiovascular disease (%)* 1,877 (26.8%)
Cerebrovascular disease† 262 (3.7%)
Total cholesterol (mmol/L) 6.6 ± 1.2
Body-mass index, mean ±SD (kg/m2) 26.3 ± 3.7
Primary education, low vocational training or less (%) 2,697 (38.6%)
APOE-ε4 allele present (%) 1,793 (25.6%)
* Myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, 
atrial fibrillation and heart failure
† Stroke and transient ischemic attack
Persons were followed up to 15.3 years (average 9.2 years), with a total of 62,883 
person years of follow up. During follow-up 739 persons developed dementia, of whom 
582 were diagnosed with Alzheimer disease, 81 with vascular dementia and 76 with 
other types of dementia. The total number of filled prescriptions during follow-up was 
30,241. Prescription frequencies of statins and non-statin lipid lowering drugs and for 
individual statins are shown in Table 2. Simvastatin was the most frequently used statin, 
followed by pravastatin. 
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table 2. Prescription frequencies of cholesterol-lowering drug during follow-up
Cholesterol-lowering drug
Total number of filled prescriptions 
(% of total number of filled prescriptions, 
n=30,241)
Statins 27,713 (91.6%)
Lipophilic statins 21,855 (72.3%)
Simvastatin 17,742 (58.7%)
Atorvastatin 3,949 (13.0%)
Cerivastatin 164 (0.5%)
Hydrophilic statins 5,858 (19.4%)
Pravastatin 4,079 (13.5%)
Fluvastatin 1,735 (5.7%)
Rosuvastatin 44 (0.2%)
Non-statin-cholesterol-lowering drugs* 2,528 (8.4%)
* Fibrates, bile-acid binding resins or nicotinic acid and derivatives
We observed that use of statins was associated with a lower risk of Alzheimer disease 
than never use of cholesterol-lowering drugs. No protective effect was observed with 
use of non-statin cholesterol lowering drugs. Additional adjustment for other potential 
confounders did not change the estimates (Table 3).
The effect-sizes were equivalent for use of lipophilic statins and hydrophilic statins 
versus never-use (Table 3). Compared to non-use, we did not find evidence for 
a stronger protective effect for the lipophilic simvastatin than with the hydrophilic 
pravastatin (adjusted ORs: 0.61; 95% CI 0.36-1.03 and 0.38; 95% 0.15-0.99, 
respectively).
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table 3. Hazard ratios (HR) of Alzheimer disease with use of statins, lipophilic and 
hydrophilic statins separately, and non-statin cholesterol-lowering drugs 
Alzheimer disease
Cases* Hr (95% CI) Cases Hr (95% CI)
Cholesterol lowering drug use model I† model II‡
Never use 546 1.00 (ref.) 438 1.00 (ref.)
Statins 30 0.58 (0.38-0.88) 28 0.57 (0.37-0.90)
Lipophilic statins 25 0.55 (0.34-0.89) 23 0.54 (0.32-0.89)
Hydrophilic statins 9 0.52 (0.26-1.05) 9 0.54 (0.26-1.11)
Non-statin cholesterol lowering drugs§ 12 1.04 (0.45-2.40) 12 1.05 (0.45-2.44)
* The number of exposed cases for any statin differs from the sum of exposed cases for statin 
subtypes. This is because persons can contribute exposed person-time to more than one type of 
statin. 
†  Model I: Age, sex adjusted and use of other lipid-lowering drugs, if applicable.
‡ Model II: as Model I additionally adjusted education, systolic blood pressure, smoking, total serum 
cholesterol, body mass index, diabetes mellitus and cardiovascular and cerebrovascular disease. 
§ Fibrates, bile acid binding resins or nicotinic acid and derivatives. 
No dose-response relationship for statin use was detected, as dosages below and 
above the median were both associated with a decreased risk of Alzheimer disease 
(adjusted HR 0.57; 95% CI 0.32-1.00 for ≤0.89 DDD and HR 0.58; 95% CI 0.32-1.04 
for >0.89 DDD). Likewise, the protective effect was observed irrespective of duration of 
statin use (adjusted HR 0.44; 95% CI 0.25-0.80) for ≤2.9 years and adjusted HR 0.78; 
95% CI 0.44-1.32 for >2.9 years). 
Our findings were robust in all planned subanalyses. Restricting the exposure definition 
of ‘any use’ to at least one prescription in the year prior to the event date did not alter 
our findings: adjusted HR 0.51; 95% CI 0.31-0.83 for statin use and HR 1.55; 95% CI 
0.54-4.44 for non-statin cholesterol lowering drug use. Of the 30 persons who had used 
statins at time of Alzheimer diagnosis, 22 persons had filled at least 1 statin prescription 
in the year prior to diagnosis. For non-statin cholesterol-lowering drugs this was 5 out of 
12.
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When we restricted our analyses to participants of 65 years and older at baseline, the 
HRs for Alzheimer disease remained similar (adjusted HR for statin use 0.61; 95% 
CI 0.38-0.98, adjusted HR for non-statin cholesterol lowering drugs 1.14; 95% CI 
0.49-2.68). The exclusion of 2 years before diagnosis did not change the magnitude 
of the estimates either. The adjusted HRs were 0.60 (95% CI 0.39-0.92) for statin-use 
and 1.10 (95% CI 0.48-2.52) for non-statin cholesterol-lowering drug use versus never-
use. Likewise, if we used age as time-axis rather than calendar-time, the associations 
remained unchanged (adjusted HR for statin use 0.55; 95% CI 0.36-0.86, adjusted 
HR for non-statin cholesterol lowering drugs 1.17; 95% CI 0.52-2.64). Finally, in the 
analyses where we stratified on the presence or absence of an APOE-ε4 allele, the 
protective effect of statin use was similar for persons with an APOE-ε4 allele (adjusted 
HR 0.50; 95% CI 0.26-0.94) and for persons without an APOE-ε4 allele (adjusted HR 
0.61; 95% CI 0.32-1.18). 
DISCuSSIoN
In the prospective population-based cohort of the Rotterdam Study, we found that use 
of statins, but not of non-statin cholesterol lowering drugs was associated with a lower 
risk of Alzheimer disease compared to never use of cholesterol-lowering drugs. No 
difference was observed between the effects of hydrophilic and lipophilic statins. 
Strengths of our study include the active surveillance of incident dementia, including in 
person screening, together with the high response rate and virtually complete follow-up, 
which limited chances of selection or information bias. An important asset of our study 
is the availability of continuous pharmacy dispensing data on all members of the cohort. 
In terms of exposure misclassification this constitutes a major advantage compared 
to studies that have to rely on self-reported drug use and drug exposure obtained 
at baseline.11,12 Nevertheless, contrary to a clinical trial setting, treatment was not 
randomly assigned in our study and confounding by indication should be considered. In 
the case of lipid-lowering drugs, physicians might less readily prescribe these agents 
to individuals with early signs of cognitive impairment because of concerns regarding 
adherence, treatment complications and priorities in health-care resource allocation. 
However, the results did not change when we included a 2-year lag-period before 
diagnosis of Alzheimer disease, which suggested that this confounding by indication did 
not play a major role, if any, in our study. Finally, the number of exposed cases available 
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in the analyses limited extensive analyses of duration of use and in various patient 
groups. 
We found that statin use was associated with a reduced risk of Alzheimer disease. Our 
findings are in line with the cross-sectional reports, which showed a lower prevalence 
of dementia amongst statin users.1-3 Most of the prospective studies did not find a 
protective effect of statins or only for persons younger than 80 years of age.3,7-10,12,13 
Important limitations of these studies included the limited durations of follow-up, as 
short as 3 years12, and low number of incident Alzheimer cases.11,12 Moreover, several 
studies relied, in part, on (self) reported drug use at baseline, with persons who started 
statin therapy during follow-up consequently being classified as non-users.3,11,12 This 
may have led to misclassification of drug exposure and, hence, may have biased the 
risk estimates towards one. In the very large population database of United States 
Veterans Affairs (VA) medical system, a protective effect was specifically observed 
with the use of simvastatin, but not for other statins.37 The latter study is different 
from previous observational studies in that persons taking cardiovascular medication, 
excluding statins, were used as the comparator group. In our analyses adjustment for 
cardiovascular disease did not change the observed associations. Some clinical studies 
have studied the effect of statins on cognitive decline, but thus far none have reported 
on the prevention of Alzheimer disease with statins or other lipid-lowering drugs.14-16 
We did not find a duration-response relationship. Only few other observational studies 
investigating the use of statins and incident Alzheimer disease report on the duration-of 
statin use. Zamrini et al.7 reported a weakened protective effect among those with 12 
months of more use, whilst a post-hoc analysis of Zandi et al.12 observed a reduced risk 
for Alzheimer disease with more than 3 years of statin use. Further research would be 
required to investigate these aspects of statin use.
In our study both hydrophilic and lipophilic statins were associated with a reduced 
risk of Alzheimer disease. Two other prospective studies specifically investigated 
lipophilic and hydrophilic statins separately but found neither associated with a reduced 
risk of Alzheimer disease.10,13 As mentioned above, results from the VA database 
showed a protective effect for the lipophilic simvastatin, but not for other statins.37 Our 
observation of a protective effect regardless of the lipophilicity of statins challenges 
the hypothesis that only lipophilic statins would reduce the risk of Alzheimer disease. 
Various explanations could be given as to why no difference in effect for lipophilic and 
hydrophilic statins was observed. One, though many studies show that the ability of 
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statins to permeate the blood-brain barrier depends on their lipophilic or hydrophilic 
character 23,24,26, many other factors besides lipid solubility also determine a drug’s 
distribution in different tissues. These include pharmacokinetic properties and the 
affinity to specialized transport mechanisms.20,21,23,24 For example, though atorvastatin 
is lipophilic of nature, it is suggested that little of the drug is distributed beyond the liver, 
as had been expected.22 Two, if changes in endogenous cholesterol synthesis cause 
alterations of brain cholesterol metabolism the ability of statins to cross the blood-brain-
barrier might be irrelevant. This would also hold if statins act through a mechanism for 
which brain penetration might not be important at all. Besides inhibition of cholesterol 
synthesis, statins namely also affect physiological processes such as endothelial 
functioning, atherosclerosis and oxidative stress reactions.38 Many of these processes 
have also been associated with Alzheimer disease. Other effects, more typical to 
Alzheimer pathology, could include inhibition of amyloid synthesis and reduction of 
neurofibrillary tangle burden.13,39 At least for some of these mechanisms it is likely that 
brain penetration of statins is extraneous. 
The effect of statins on Alzheimer risk was not modified by APOE genotype. APOE 
is essential in cholesterol metabolism and it is suggested that the response to statin 
treatment varies with APOE genotype, though agreement in the literature is not 
complete.36 Our results comply with two other observational studies that did not find 
evidence for effect modification by APOE genotype.6,12 A recent report by Li et al found 
a lower risk of Alzheimer disease with statin use for persons with at least one APOE-ε4 
allele.9 Further investigations will be needed to provide conclusive results regarding a 
possible effect modification by APOE genotype.
In conclusion, use of statins is associated with a decreased risk of Alzheimer disease 
independent of their relative lipophilicity.
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AbStrACt
background: The evidence from prospective observational research for a protective 
effect of antihypertensive drug use on the risk of dementia is far from uniform. Duration 
of follow-up was limited and relied mainly on baseline drug exposure data without 
information on duration of use. We investigated the association between the duration of 
antihypertensive use and risk of dementia. 
methods: We followed 6,249 participants (mean 68.4 years, 60% women) of a 
prospective, population-based cohort from baseline (1990-1993) until 2005 for incident 
dementia. Continuous data on filled prescriptions came from pharmacy records. Total 
cumulative duration of antihypertensive use was expressed in years. We subtracted 
a latent 4-year period before the date of dementia diagnosis in the quantification 
of exposure duration to avoid potential bias in antihypertensive prescription due to 
prodromal changes in blood pressure or cognition. With Cox regression models, 
we calculated crude and adjusted hazard ratios (HRs) of all dementia and AD with 
antihypertensive use versus never use. 
results: Compared to never-use, antihypertensive use was associated with a reduced 
risk of all dementia (adjusted HR per year of use 0.95; 95% confidence interval (CI); 
0.91-0.99). We observed an 8% (95%CI -15% to -1%) risk reduction per year of use for 
persons ≤75 years, whereas for persons >75 years this was 4% (95% CI -11% to 4%). 
Equivalent estimates were observed for AD. No apparent differences were observed 
among different types of antihypertensives. 
Conclusions: Antihypertensive drug use was associated with 8% risk reduction of 
dementia per year of use for persons ≤75 years.
2.2 Antihypertensive drugs and risk of Dementia
93
INtroDuCtIoN
Hypertension is a risk factor for cerebrovascular disease and consequently for vascular 
dementia. The association between hypertension and Alzheimer disease (AD) is 
less clear.1 Follow-up studies generally showed that high blood pressure in midlife is 
associated with an increased risk of AD.2 In contrast, high blood pressure later in life 
appears to lower the risk of AD.3 It was also suggested that in the preclinical stage of 
AD blood pressure declines, possibly due to imminent disease.4 
Evidence for a protective effect of antihypertensives on the risk of dementia has 
been far from uniform (Table 1 and 2). With the exception of two studies,5,6 a major 
shortcoming of previous observational studies was the availability of merely baseline 
data on antihypertensive treatment. This considerably increases the chance of exposure 
misclassification during follow-up and, moreover, prohibits investigation of treatment 
duration. The intricate relation between blood pressure, age and dementia risk can 
also be responsible for the variance in the observed relationships. Furthermore, 
prodromal changes in blood pressure and cognitive decline could lead to changes in 
antihypertensive prescription or drug intake, both leading to bias.4,7 Hence, the years 
immediately preceding clinical onset of dementia may not provide the relevant risk 
period to investigate the effect of antihypertensives on dementia risk.
We investigated the association between duration of antihypertensive drug use and the 
risk of all dementia and AD in a large prospective population-based cohort study, taking 
into account a latent period in the quantification of treatment duration.8   
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metHoDS 
Study population
The Rotterdam Study is a prospective, population-based cohort study of age related 
disorders.9 The medical ethics committee at Erasmus MC, Rotterdam, the Netherlands, 
approved the study. Between 1990 and 1993 all persons aged ≥55 years living in 
Ommoord, a district of Rotterdam, were invited to participate. Of 10,275 eligible 
persons, 7,983 (78%) signed informed consent. Of these, 7,528 (94%) were screened 
for dementia and 7,046 were free of dementia at baseline.10 Follow-up examinations, 
including screening and clinical workup for dementia, were conducted in 1993-1994, 
1997-1999 and 2000-2004. In addition, the cohort was continuously monitored for major 
disease outcomes and death through linkage with records of general practitioners, the 
Regional Institute for Outpatient Mental Health Care and bimonthly updates from the 
municipality records. This resulted in a virtually complete follow-up for dementia until 
January 1st, 2005. 
Nearly all persons (99.7%) were registered at one or more of seven automated 
pharmacies serving the Ommoord area. Records of all filled prescriptions were available 
from January 1st, 1991. To ensure at least 6 months medication history, we excluded 
persons for whom follow-up ended before July 1st, 1991.  
Assessment of drug exposure 
Complete data on filled prescriptions was available on a day-to-day basis from the 
pharmacy prescription database in automated form. This included the product name; 
international non-proprietary name; Anatomical Therapeutic Chemical (ATC) code; total 
number of delivered units (e.g. tablets/capsules); prescribed daily number of units; date 
of delivery and drug dosage. The duration of a prescription is calculated as the number 
of delivered units divided by the prescribed daily number of units. 
In addition to overall antihypertensive use, we distinguished between the most 
commonly used types of antihypertensives in the Netherlands, as classified by ATC-
code. These included β-blocking agents, thiazides and high ceiling diuretics, calcium-
channel blockers, angiotensin-converting-enzym-(ACE)-inhibitors, angiotensin-2-(AT2)-
antagonists and other antihypertensives (centrally acting sympathicolytics, peripheral 
acting sympathicolytics and agents acting on arteriolar smooth muscle). 
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Diagnosis of Alzheimer disease
The diagnosis of dementia was made following a three-step protocol. Screening was 
done with the Mini Mental State Examination (MMSE) and Geriatric Mental State 
schedule (GMS) organic level for all persons.11,12 Screen-positives (MMSE score <26 
or GMS organic level>0) underwent the Cambridge examination for mental disorders 
of the elderly.13 Persons who were suspected of having dementia underwent more 
extensive neuropsychological testing. When available, imaging data were used. In 
addition, the total cohort was continuously monitored for incident dementia through 
computerized linkage between the study database and digitalized medical records from 
general practitioners and the Regional Institute for Outpatient Mental Health Care. The 
diagnosis of dementia was made in accordance with internationally accepted criteria for 
dementia (DSM-III-R), AD (NINCDS-ADRDA), and vascular dementia (NINDS-AIREN) 
by a panel of a neurologist, neurophysiologist and research physician, blinded to drug 
exposure of the study population.14-16
other covariates 
Covariates included age, sex, education level, systolic and diastolic blood pressure, 
current smoking, total serum cholesterol, body mass index, diabetes mellitus and 
cardiovascular and cerebrovascular disease. Education was assessed at the baseline 
interview and dichotomized into low education (primary education only or low vocational 
training) and high education (intermediate-level vocational training, secondary education 
or university). Smoking status was also self-reported and categorized as ever or 
never. Total serum cholesterol was measured in non-fasting blood drawn at baseline. 
Sitting blood pressure was measured on the right upper arm using a random-zero 
sphygmomanometer. The average of two measurements at one occasion was used. 
Diabetes mellitus was defined as a non-fasting or 2-hour post load glucose level of 
≥11.1mmol/l or antidiabetic medication use at baseline. Cardiovascular disease included 
myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary 
angioplasty and atrial fibrillation. Cerebrovascular disease included transient ischemic 
attack and stroke. Both prevalent and incident cardiovascular and cerebrovascular 
events were taken into account. APOE genotyping was performed on coded DNA 
samples, and participants were classified by presence of an APOE-ε4 allele.
Statistical analyses
We calculated the hazard ratio (HR and 95% confidence intervals (CI)) of the risk of 
all dementia and AD, associated with antihypertensive use using a Cox-proportional-
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hazards model with antihypertensive use as time-dependent covariate. Calendar-time 
was used as the time-axis in the model to account for changes in prescription guidelines 
and availability of antihypertensive drugs over time. For all subjects, we calculated 
the duration of follow-up between start of study and diagnosis of dementia, death or 
end of the study period, whichever came first. Because lowering of blood pressure 
and changes in cognition occur during the latent phase of disease, physicians might 
change antihypertensive treatment in the prodromal period of dementia. Calculating 
the cumulative exposure until the date of diagnosis would not take into account such 
disease-related changes in prescription and this might bias our risk estimates. To avoid 
this type of bias, we subtracted a potential latent period from the date of diagnosis, 
for quantification of exposure duration.8 Based on the current knowledge regarding 
the course of blood pressure1 and cognition in the latent phase of dementia17 we 
considered a 4-year prodromal phase for our main analysis. Consequently, at each date 
of diagnosis minus 4 years we determined cumulative duration of drug until that date 
for both the person who developed dementia as well as for all persons in the remainder 
of the cohort. Total cumulative duration of antihypertensive use was expressed in years 
and as categorical variable based on tertiles of total use at end of follow-up being: 
no use, <1.6 year use, from 1.6 to 5.3 years use and >5.3 years use. Never use of 
antihypertensive drugs was the reference in all analyses. In a sensitivity analysis we 
investigated whether associations differed if we subtracted 2 years from the date of 
diagnosis or if we used the original date of diagnosis.
We anticipated that the association might be modified by age, since the association 
between blood pressure and dementia appears to be different at older age. Therefore, 
we re-performed the analyses for persons ≤75 years and >75 years of age. Likewise, 
we investigated whether the associations were different for carriers and non-carriers 
of an APOE-ε4 allele, by adding an interaction term to a model, and by stratified 
analyses.18 Using the same exposure definitions, we also investigated the association 
between separate types of antihypertensive drugs and risk of dementia. A cohort 
member could contribute person-time to more than one class of antihypertensive drug if 
a person had used more than one antihypertensive drug during follow-up.
All analyses were adjusted for age, sex, systolic and diastolic blood pressure (Model 
I). To adjust for potential confounders we additionally included smoking, total serum 
cholesterol, education, body mass index, diabetes mellitus and cardiovascular and 
cerebrovascular disease (Model II). Missing values for continuous variables were 
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101
imputed with linear regression analyses using sex, age and dementia outcome as 
determinants. For categorical variables we used a missing indicator for missing values. 
Analyses were performed with SPSS 16.0 and SAS 9.1 software.
reSultS
In total 6,249 persons were included in the analysis. In Table 3 baseline characteristics 
of the study population are given. Persons were followed up to 13.3 years (average 8.0 
years), with a total of 49,829 person years of follow up. During follow-up 527 persons 
developed dementia, of whom 432 were diagnosed with AD, 50 with vascular dementia 
and 45 with other types of dementia. The total number of filled antihypertensive 
prescriptions during follow-up was 54,584. Of the 527 persons who developed dementia 
264 persons had used antihypertensive drugs during follow-up, whereas 263 persons 
never used antihypertensive drugs. 
table 3. Baseline characteristics of the study population
Characteristic (n=6,249)
Age (± SD) in years 68.2 (± 8.3)
Sex (% women) 3,749 (60%)
Smoking, ever (%) 3,985 (63.7%)
Diabetes mellitus (%) 574 (9.2%)
Systolic blood pressure (mmHg) 139.0 (± 21.6)
Cardiovascular disease (%)* 945 (15.2%)
Cerebrovascular disease (%) † 303 (4.8%)
Total cholesterol (mmol/L) 6.7 (± 1.2)
Body-mass index, mean ± SD  (kg/m2) 26.4 (± 3.6)
Primary education, low vocational training or less (%) 2,275 (36.4%)
* Myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, 
atrial fibrillation and heart failure
† Stroke or transient ischemic attack
Compared to never-use, antihypertensive use was associated with a reduced risk 
of all dementia. HRs for AD were nearly equivalent (Table 4). There was an evident 
duration-response relationship as the risk of all dementia decreased with longer 
duration of cumulative use, resulting in a 5% risk reduction per year of use (Table 
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4). Correspondingly, the strongest risk reduction was observed with long-term use of 
antihypertensives (>5.3 years), whereas short-term use of antihypertensives (<1.6 
years) was not associated with a reduced risk of dementia or AD. 
table 4. Hazard ratios of all dementia and Alzheimer disease with use of antihypertensives 
All dementia (n=527) Alzheimer Disease (n=432)
Cases Hr (95%CI) Cases Hr (95%CI)
model I† model II‡ model I† model II‡
Never use 263 1.00 (ref.) 214 1.00 (ref.)
Antihypertensive drug use:
 <1.6 years 126
0.94
(0.75-1.17)
0.90
(0.72-1.13)
102
0.92 
(0.73-1.18)
0.91 
(0.71-1.17)
From 1.6 to 5.3 years 98
0.77 
(0.60-0.99)
0.72 
(0.56-0.93)
83
0.75 
(0.57-0.98)
0.73 
(0.55-0.96)
 >5.3 years 40
0.71 
(0.49-1.03)
0.68 
(0.47-0.99)
33
0.70 
(0.47-1.05)
0.69 (0.46-
1.05)
Per year treatment 264
0.95 
(0.91-1.00)*
0.95 
(0.90-0.99)
218
0.95 
(0.90-0.99)
0.94 
(0.90-0.99)
† Model I: Age, sex, systolic and diastolic blood pressure adjusted
‡ Model II: as Model I additionally adjusted education, smoking, total serum cholesterol, body mass 
index, diabetes mellitus and cardiovascular and cerebrovascular disease. 
* Upper limit of the confidence <1.00, p-value <0.05
The association between antihypertensive use and dementia was modified by age 
(pinteraction=0.003). For persons ≤75 years, antihypertensive drugs reduced the risk of 
dementia with 8% per year of use (Table 5). For persons >75 years, we observed a risk 
reduction of 4% per year of use.  
Although the protective effect of antihypertensives on dementia risk seemed stronger 
for carriers of an APOE-ε4 allele, numbers across strata were low and the interaction 
between APOE-ε4 and antihypertensive drug use was not significant (pinteraction=0.9) 
(data not shown).  
No apparent differences among the various types of antihypertensives were observed. 
Adjusted HRs of all dementia per year of use were: 0.97 (95% CI;0.90-1.05) for thiazide 
diuretics; 0.89 (95% CI;0.78-1.01) for high ceiling diuretics; 0.93 (95% CI;0.87-1.00) 
for β-blockers; 1.00 (95% CI;0.91-1.09) for calcium channel antagonists; 1.07 (95% 
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CI;0.99-1.09) for ACE-inhibitors, 0.85 (95% CI;0.44-1.66) for AT2-antagonists and 1.04 
(95% CI;0.88-1.24) for other antihypertensives. Similar estimates were found for AD 
risk. 
table 5. Hazard ratios (HR) of all dementia and Alzheimer disease with use of 
antihypertensives across strata of age
All dementia Alzheimer Disease
Cases Hr (95%CI) Cases Hr (95%CI)
model I† model II‡ model I† model II‡
≤ 75 years of age
Never use 139 1.00 (ref.) 110 1.00 (ref.)
Antihypertensive use:
 <1.6 years 60
1.08 
(0.80-1.47)
1.03 
(0.75-1.41)
48
1.11 
(0.78-1.57)
1.11 
(0.78-1.56)
 1.6 to 5.3 years 42
0.72 
(0.50-1.03)
0.68 
(0.47-0.99)
32
0.66 
(0.44-1.00)
0.67 
(0.55-1.02)
 > 5.3 years 19
0.59 
(0.36-0.99)
0.56
 (0.33-0.95)
14
0.56 
(0.31-1.01)
0.57 
(0.41-1.04)
Per year treatment 121
0.93
 (0.87-0.99)
0.92 
(0.86-0.98)
94
0.91 
(0.85-0.98)
0.92 
(0.85-0.99)
> 75 years of age
Never use 124 1.00 (ref.) 104 1.00 (ref.)
Antihypertensive use:
 <1.6 years 66
0.81 
(0.60-1.10)
0.76 
(0.56-1.04)
54
0.79 
(0.56-1.10)
0.75 
(0.53-1.06)
 1.6 to 5.3 years 56
0.75
 (0.53-1.05)
0.68 
(0.48-0.96)
51
0.76 
(0.53-1.09)
0.70 
(0.48-1.02)
 > 5.3 years 21
0.89 
(0.52-1.52)
0.83 
(0.48-1.43)
19
0.90 
(0.51-1.59)
0.85 
(0.48-1.51)
Per year treatment 143
0.98 
(0.91-1.04)
0.97 
(0.90-1.04)
124
0.97 
(0.90-1.04)
0.96 
(0.89-1.04)
† Model I: Age, sex, systolic and diastolic blood pressure adjusted
‡ Model II: as Model I additionally adjusted education, smoking, total serum cholesterol, body mass 
index, diabetes mellitus and cardiovascular and cerebrovascular disease. 
Chapter 2
104
In the sensitivity analyses, estimates for risk of dementia gradually attenuated if shorter 
prodromal periods were considered. We observed a 4% risk reduction (0% to 7%, 
p=0.03) if 2 years were subtracted from the date of diagnosis to 3% (0% to 6%, p=0.03) 
per year of antihypertensive use if the original date of diagnosis was used. 
DISCuSSIoN 
In the general population, we found that the antihypertensive use was associated 
with decreased risk of all dementia and AD with 8% per year of use for persons ≤75 
years of age. No apparent differences were observed among the various types of 
antihypertensive drugs. 
Strengths of our study design included its prospective design, large number of 
participants, a general population-based setting and the long follow-up period of 
over 8 years average. Moreover, we used pharmacy records for the assessment of 
antihypertensive drug use. This greatly reduces the chance of exposure misclassifi-
cation as opposed to baseline exposure data or periodic re-assessment of drug use 
and allows for an accurate estimation of exposure duration. In an earlier study, we 
demonstrated that there was a high concordance between pharmacy filling data of 
cardiovascular drugs, and actual use according to a patient interview.19 Moreover, we 
were able to subtract 4-years from the date of clinical diagnosis of dementia to avoid 
potentially biased risk estimates as a result of changes in antihypertensive prescription 
due to blood pressure changes or cognitive decline in the prodromal phase of dementia. 
Nevertheless, some issues warrant consideration. First, the 4-year period is an average 
estimation of the prodromal period based on the available data from literature. There 
is, however, limited longitudinal data on the course of blood pressure prior to clinical 
dementia. Data from the Kungsholmen project shows that blood pressure markedly 
decreases over a 3-year period preceding diagnosis of dementia.20 The Göteborg 
longitudinal study revealed that a decline in systolic blood pressure between age 70 
and 75 was the only predictor of dementia with onset at age 75 to 79.21 Likewise, 
estimations of the intervals between cognitive decline and dementia vary from 1.5 years 
to up to 10 years, but generally suggest a more rapid decline in the last 2 to 3 years 
prior to diagnosis.22-24 In a sensitivity analysis, we also investigated the association 
of antihypertensive use and dementia subtracting only two years from the date of 
diagnosis for quantification of exposure duration, and also the date of diagnosis itself. 
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Though protective effects of antihypertensive use on dementia risk were still observed, 
the attenuation of the protective effect in these analyses suggests that, at least in part, 
the protective effect of antihypertensive may be obscured in the prodromal phase 
of dementia. Second, we have to consider potential bias due to confounding-by-
indication, since the indication for antihypertensive use, i.e. hypertension, is associated 
with the outcome of interest, i.e. dementia.7 However, given the complex association 
between hypertension and dementia, it is difficult to predict the direction of this effect. If 
hypertension increases the risk of dementia2, than our estimates would underestimate 
the true protective effect. Instead, if hypertension would protect against dementia 
in persons above ~75 years of age3, then confounding-by-indication could lead to a 
spurious protective effect on dementia for antihypertensives. However, this is refuted 
by our finding of no benefit of antihypertensive use on dementia risk for persons >75 
years. Finally, our analyses for the separate types of antihypertensive drugs must be 
interpreted in light of low numbers within the different antihypertensives categories. 
Since some antihypertensive drugs are preferred when certain comorbidities apply, 
the differences observed among the various antihypertensives, though small, may be 
explained by differences in underlying co-morbidity rather than by a true difference in 
physiological effect. Unfortunately, no data is available on the indication of drug use. 
Low numbers also prohibited further investigation across strata of age in the analyses of 
the separate antihypertensives.  
Numerous studies have investigated the association between antihypertensive use 
and the risk of dementia (Table 1 and 2). Thus far, findings have been inconsistent. 
Considerable methodological exist amongst studies. Clinical trials mainly included 
patients >60 years with, in 4 out of 5 trials, a systolic blood pressure of ≥160mmHg.25-30 
Some trials had significant number of patients who were lost to follow-up31 or allowed 
for usual antihypertensive treatment other than the study drug in the placebo group,28,31 
which further complicates the interpretation of their findings. The null-findings in 4 out 5 
trials have also been attributed to the limited duration of follow-up. 25,28-30 Nonetheless, 
in the Syst-EUR trial antihypertensive treatment reduced the risk of dementia by no 
less than 50% after a mere 2 years of follow-up26 and again in an open-label extension 
of the same trial after 3.9 years of follow-up.27 However, as with most of the studies 
previously performed, the Syst-Eur trial suffered from a small number of dementia 
endpoints. Besides the limited duration of follow-up, most observational studies 
relied on baseline data on antihypertensive treatment, which can lead to considerably 
misclassification of drug exposure during follow-up (Table 1). Furthermore, only 2 out of 
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8 of the prospective observational studies investigated whether associations depended 
on duration of antihypertensive use.6,32 In the Cache County Study, the protective 
effect of antihypertensives was observed regardless of duration of use as assessed at 
baseline.32 In a cohort of Japanese men the risk of dementia was reduced by 6% with 
each additional year of antihypertensive treatment, based on self-reported duration of 
drug use at the final examination.6 Considerable differences in both setting and design 
hamper a direct comparison of these findings to our study. Nevertheless, both studies 
suggest that the protective effect depends on the duration of antihypertensive use. Our 
observation of a stronger protective effect for persons ≤75 year of age corresponds with 
the view that an increased blood pressure earlier in life increases the risk of dementia, 
whereas high blood pressure in older persons may not necessarily put persons at 
higher risk for dementia.1 
The pathological processes through which hypertension is thought to influence 
dementia pathology are many. High blood pressure can result in severe atherosclerosis, 
leading to cerebral hypoperfusion.33 Changes in cerebral white matter can also occur as 
a result of sustained high blood pressure.34 Other than the blood pressure lowering 
effect of antihypertensives, it has been suggested that certain antihypertensives exert a 
more direct effect on dementia pathology. For example, the intracellular build-up of 
calcium in neurons can be neurotoxic and thus calcium channel blockers might result in 
neuroprotection.35 However, our findings do not support an advantage of one anti-
hypertensive over another. Other studies have also investigated the different types of 
antihypertensive in relation to dementia risk, but findings have been largely inconsistent. 
The types of antihypertensive for which reductions were shown included ACE-inhibitors, 
angiotensin-II-blockers, potassium-sparing diuretics, and dihydropyridine calcium 
channel blockers. The fact that, across both clinical and observational studies, various 
types of antihypertensive drugs have been identified as a having a particular beneficial 
effect on dementia suggests that this is the play of chance rather than that actual 
differences exist. Hence, we consider it more likely that effect of antihypertensive drugs 
on blood pressure in itself underlies the protective effect of these drugs. For future 
research, a more mechanistic approach, such as the use of imaging markers of cerebral 
pathology, would be desirable to understand the biological basis of the association 
between antihypertensives and dementia. 
Given the established benefit of antihypertensives on prevention of cardiovascular 
disease, we believe that current evidence constitutes a limited basis for advocating a 
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universal antihypertensive treatment policy for the sole purpose of dementia prevention. 
Further insight on the association between blood pressure and dementia and the effect 
of antihypertensives on this association could nonetheless provide us with important 
information on pathological pathways leading to dementia. 
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AbStrACt
background: Cerebral white matter lesions (WML) are frequently observed on MR-
images of elderly persons and are associated with an increased risk of stroke and 
dementia. Hypertension is a risk factor for presence and progression of WML. 
methods: We investigated the association between antihypertensive use and WML-
progression in non-demented participants from a prospective population-based cohort 
study. In 1995-1996, 563 participants (60-90 years; mean 72.1 years, 50% female) 
underwent cerebral MRI. After on average 3.3 years, 320 persons underwent a follow-
up MRI. Two independent raters assessed WML-progression in a blinded fashion by 
side-by-side scan comparison using a validated visual rating scale. Detailed information 
on drug use, from 1991 to baseline MRI, came from pharmacy records. We used age 
and sex adjusted analysis of covariance to compare baseline characteristics between 
persons with and without follow-up MRI. With logistic regression analysis, we calculated 
odd ratios (OR) and 95% confidence interval (CI) of WML-progression, adjusted for age, 
sex, blood pressure (BP) and other potential confounders. Analyses were re-performed 
across age strata (60-70, 70-80, and 80-90 years) and for persons with and without 
controlled BP (systolic BP>160mmHg or diastolic BP>95mmHg). 
results: Compared to non-users, users of antihypertensive had a lower risk of WML-
progression (OR 0.53; 95%CI 0.31-0.91). ORs were similar for periventricular and 
subcortical WML-progression. The association was modified by age and a statistically 
significant risk reduction was only observed in the youngest age stratum from 60 to 70 
years. Antihypertensive users with a controlled BP had a lower risk of WML-progression 
(OR 0.44; 95%CI 0.24-0.82), than persons with hypertension despite antihypertensive 
treatment (OR 0.81; 95%CI 0.39-1.69). 
Conclusion: The use of antihypertensives was associated with a reduced risk of WML 
progression. The protective effect was limited to persons <70 years of age and to those 
with controlled BP. 
2.3 Antihypertensive drugs and progression of White Matter Lesions
113
INtroDuCtIoN
Cerebral white matter lesions (WML) are frequently observed on magnetic resonance 
imaging (MRI) scans in elderly people.1-3 These lesions are associated with an 
increased risk of stroke, cognitive decline, and dementia.4-6 WML appear to progress 
gradually over time.7-11 Besides age, several vascular risk factors for WML have been 
identified, of which blood pressure is most recognized.12 Elevated blood pressure has 
consistently been associated with the presence and severity of WML in both cross-
sectional1,3,13 and longitudinal studies.14-18 The use of blood pressure lowering agents 
may modify this association as persons with uncontrolled hypertension were found to 
have a higher prevalence of WML than persons without hypertension or with controlled 
hypertension.1,15,16 Increased blood pressure has also been identified as a risk factor 
for WML-progression.2,7,17,19-21 Hence, it has been postulated that blood pressure 
lowering agents could protect against the progression of WML. This hypothesis has 
been examined in few studies, with conflicting results.8,17,20,22 Most of the previous 
studies were performed in the context of clinical trials or in healthy volunteers. We 
therefore investigated the association between the use of antihypertensives and the risk 
of WML-progression in a population-based prospective cohort of elderly. 
metHoDS
Study population
This study is based on the Rotterdam Scan Study, a large population-based cohort 
study in the Netherlands that aims to study the etiology and natural history of age-
related brain changes in the elderly.23 The study was approved by the medical ethics 
committee of the Erasmus Medical Center, Rotterdam. In 1995-1996, we randomly 
invited participants, aged 60 to 90 years, stratified by sex and 5-year age strata from 
two on-going population-based studies to participate in the Rotterdam Scan Study.24 
Participants, who were demented, were excluded based on a stepwise approach as 
used in the Rotterdam Study.25 After exclusion of individuals who were demented 
or had MRI contraindications, 563 participants from the Rotterdam Study gave their 
written informed consent to participate in the study, which included undergoing an MRI 
scan. In total, 320 persons underwent the follow-up MRI measurement in 1999. Other 
than refusal, non-participation at the follow-up MRI was mainly due to death (n=46), 
institutionalization (n=14) and contraindication for MRI (n=13, e.g. pacemaker). 
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Drug exposure
Complete information on all filled prescriptions for all persons was obtained in auto-
mated format from the pharmacies from January 1st, 1991 onwards. This included the 
product name; international non-proprietary name; Anatomical Therapeutic Chemical 
(ATC) code; total number of delivered units (e.g. tablets/capsules); prescribed daily 
number of units; date of delivery and drug dosage. The duration of a prescription is 
calculated as the total number of delivered units divided by the prescribed daily number 
of units. 
We studied exposure to antihypertensive drug as a group and, in addition, we 
distinguished between the various types of antihypertensives as classified by ATC-code. 
These included beta-blocking agents, diuretics, agents acting on the renin-angiotensin-
aldosterone-system (RAAS) (angiotensin-converting-enzym-inhibitors and angiotensin 
receptor-antagonists), calcium-channel blockers and other antihypertensives (centrally 
acting sympathicolytics, peripherally acting sympathicolytics and agents acting on 
arteriolar smooth muscle).
white matter lesion progression 
In 1995-1996, we made axial T1-, T2-, and proton density (PD)-weighted cerebral MR 
scans on a 1.5-Tesla scanner (MR VISION, Siemens).26 In 1999-2000, participants 
underwent a follow-up MRI on the MR VISION scanner using the same sequences. For 
measuring change of WML severity over time, we used a specifically developed and 
validated WML change scale.27,28 Two raters independently assessed the progression 
of WML severity on digital T2- and PD-weighted images by direct scan comparison. 
Raters were blinded to scans being baseline or follow-up and to all clinical information. 
To systematically evaluate the difference in WML severity, the raters independently 
scored differences in the three periventricular regions of both hemispheres 
(periventricular score range -6 to +6) and in the subcortical white matter of the four 
lobes of both hemispheres (subcortical score range: -8 to +8). Hyperintensities on PD- 
and T2-weighted images around an incident infarct were not considered as progression 
of WML. The rating showed good interobserver (intraclass correlation coefficient 
0.72–0.73) and intraobserver agreement (intraclass correlation coefficient 0.70–0.93). If 
raters disagreed on one point or less on the scale, the mean of the ratings was used; if 
more, a consensus meeting was held. Adjudication by consensus meeting was required 
in 9% of the periventricular and 11% of the subcortical WML ratings. WML-progression 
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was defined as an increase of one point or more in any region, and separately for the 
periventricular and subcortical region.27
other measures
Information on current health status was collected by interview and physical 
examination by trained examiners.5 Blood pressure was measured twice in sitting 
position on the right arm with a random-zero sphygmomanometer with the appropriate 
adult cuff size after 5 minutes rest. The average of the two values measured at one 
occasion was used. Hypertension was defined as a systolic blood pressure (SBP) 
above 160 mmHg or a diastolic blood pressure (DBP) above 95 mmHg according to the 
Dutch national guidelines at time of recruitment.29 Non-fasting serum total cholesterol 
was determined with an enzymatic procedure. Smoking habits were classified as never, 
former or current cigarette smoking. We considered diabetes mellitus to be present if 
the random glucose level was ≥11.1 mmol/l or if a person was taking oral anti-diabetics 
or insulin. Using automated MRI-analysis we measured volumes of WML at baseline 
MRI. Preprocessing steps and the classification algorithm have been described.13
Statistical analysis 
Use of antihypertensives at baseline was categorized as ‘any’ or ‘no’ use, depending 
on whether a person had used antihypertensive drugs between January 1st, 1991 
and date of baseline MRI (1995-1996), or not. We acknowledged that, even though 
antihypertensive treatment is generally used chronically, persons could have stopped 
therapy, for example as a result of adverse events, non-compliance or a change in 
life-style which rendered antihypertensive treatment no longer indicated. Therefore, we 
additionally defined ‘current’ use as at least one prescription of antihypertensive drugs 
was (re)filled ≤4 months prior to baseline MRI. No-use of any antihypertensive drug 
was the reference category for all analyses. A person could contribute to more than one 
exposure category of antihypertensive use if that person had used different types of 
antihypertensives prior to baseline.
We used age and sex adjusted analysis of covariance to determine whether base-line 
characteristics, including antihypertensive use, differed between persons with and 
without a follow-up MRI assessment. Logistic regression models were used to study 
the association between antihypertensive drug use and any progression of WML (total) 
and separately for periventricular and subcortical WML-progression. All analyses were 
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adjusted for age, sex, systolic and diastolic blood pressure (Model I). In a second model 
we additionally adjusted for the following cardiovascular risk factors; diabetes mellitus, 
total serum cholesterol, body mass index, and smoking (Model II). Subsequently, in 
Model III, we additionally adjusted for baseline WML volume. 
We performed several subanalyses. First, we considered that the association might 
be biased by selective attrition, since hypertension, the underlying indication of 
antihypertensive treatment, is related to mortality. This could be of particular concern 
in elderly participants. We addressed this issue by performing the analysis in three 
equal age strata (60-70 years, 70-80 years and 80-90 years).16 Second, in persons 
treated with antihypertensives adequate blood pressure control is not always achieved. 
Previously, it was shown that the severity of WML is higher in poorly controlled 
hypertensive patients than in successfully treated patients.1,16 Hence, we categorized 
persons according to antihypertensive use and blood pressure status into 3 categories; 
(1) no use of antihypertensive drugs (reference), (2) antihypertensive use and controlled 
blood pressure (defined as <160mmHg SBP and <95mmHg DBP according to Dutch 
national guidelines at time of recruitment), (3) antihypertensive use and uncontrolled 
blood pressure (defined as ≥160mmHg SBP or ≥95mmHg DBP). Finally, we studied 
whether any observed effects depended on the duration of drug use by dichotomizing 
total duration of antihypertensive use around the mean duration of use. Analyses were 
done using SPSS 11.0.1, IL, USA for Windows.
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reSultS
Baseline characteristics of participants with and without a follow-up MRI assessment 
are presented in Table 1 and 2. Persons without a follow-up MRI were on average older 
at baseline, more frequently diabetic, less frequently smokers and had a higher baseline 
WML load than those who had a follow-up MRI assessment. However, after adjusting 
for age and sex, there were no statistically significant differences between participants 
with or without MRI at follow-up for these baseline characteristics. Notably, there was 
no difference in the WML-volume for persons with and without a follow-up MRI (Table 
1). The mean follow-up period between the first and follow-up MRI was on average 3.3 
years (SD ± 0.3 years).
table 1. Baseline characteristics of the study population, n=563
Characteristic
Participants with 
a 2nd mrI at 
follow-up (%)
Participants 
without a 2nd mrI 
at follow-up (%) p-value*
Number 320 243
Age (years, ± SD) 72.1 (7.8) 75.5 (7.7) <0.00
Sex (% female) 160 (50.0) 121 (49.8) 0.90
Systolic blood pressure (mm Hg, ± SD) 145.6 (20.4) 146.7 (20.5) 0.55
Diastolic blood pressure (mm Hg, ± SD) 76.5 (11.4) 76.6 (11.5) 0.62
Body Mass Index (kg/m2, ± SD) 26.2 (3.7) 26.5 (3.4) 0.26
Serum total cholesterol (mmol/l, ± SD) 5.9 (1.0) 5.8 (1.1) 0.80
Smoking (% current smokers) 62 (19.9) 36 (14.9) 0.43
Diabetes mellitus (%) 13 (4.1) 17 (7.0) 0.31
White matter lesion volume (%-ICV, ± SD) 1.2 (1.4) 1.5 (1.6) 0.92
Abbreviations: MRI - magnetic resonance imaging, SD - standard deviation, ICV - intra cranial volume
* p-value for sex, age adjusted differences, if applicable
Table 2 shows the baseline characteristics of antihypertensive use. Antihypertensive 
use at baseline was comparable between persons with and without a follow-up MRI in 
the age of 60 to 70, but proportionally greater in persons above 70 without a follow-up 
MRI and those with controlled blood pressure. 
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table 2. Antihypertensive drug use at baseline for persons with and without a follow-up 
MRI
Antihypertensive drug use
Participants with a 
follow-up mrI 
at follow-up
 (%)
Participants 
without a follow-up 
mrI at follow-up 
(%) p-value*
Any use of antihypertensive drugs 134 (41.9) 141 (58.0) 0.01
60 to 70 years 53 (38.1) 28 (43.1) 0.50
70 to 80 years 43 (38.7) 51 (54.8) 0.02
80 to 90 years 38 (54.3) 62 (73.9) 0.02
With controlled BP§ 87 (31.9) 96 (48.5) 0.03
Without controlled BP 45 (14.4) 46 (18.5) 0.10
Beta blocking agents 81 (25.3) 75 (30.9) 0.34
Diuretics 58 (18.1) 88 (36.2) <0.00
Agents acting on RAAS 45 (14.1) 55 (22.6) 0.05
Calcium channel blockers 36 (11.2) 59 (24.3) <0.00
Other antihypertensives 4 (1.3) 8 (3.3) 0.15
Abbreviations: MRI - magnetic resonance imaging, RAAS - renin-angiotensin-aldosterone system, 
SBP - systolic blood pressure, DBP - diastolic blood pressure
* p-value for sex, age adjusted differences
§  Systolic blood pressure ≥160mmHg or diastolic blood pressure ≥95 mmHg, according to Dutch 
national guidelines at time of recruitment
A total of 132 persons of the 320 persons who underwent follow-up MRI, showed 
progression of WML compared to baseline MRI. Of these, 51 persons had used 
antihypertensives between 1991 and baseline MRI (1995-1996).
In Table 3, the results are shown for any antihypertensive use and the risk of WML-
progression. Compared to non-use, the use of antihypertensive drugs at baseline was 
associated with a reduced risk of WML-progression at follow-up (Table 3). 
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The odds ratios were equivalent for periventricular and subcortical WML-progression 
and effect sizes were comparable to the overall estimate. The association was modified 
by age and the statistically significant risk reduction was only observed in the youngest 
age stratum from 60 to 70 years, while in the higher age categories the risk was non-
significantly reduced, or not present at all. Users of antihypertensives with a controlled 
blood pressure had a reduced risk of WML-progression, whereas persons who had 
hypertension despite antihypertensive treatment did not (Table 3). Additional adjustment 
for baseline WML did not alter the odds ratios (data not shown). Similar odds ratios 
were observed when restricting the exposure definition to current users who had filled 
at least one prescription ≤4 months prior to baseline MRI (OR 0.59 95% CI (0.33-
1.04). This was applicable for 42 of the 51 exposed cases at baseline. Here, ORs for 
the different age strata were 0.27 95% CI (0.09-0.83) for 60 to 70 years, 0.91; 95% CI 
(0.34-2.43) for 70 to 80 years and 1.19; 95% CI (0.27-5.26) for 80 to 90 years. 
Between January 1st 1991 and date of first MRI the mean duration of antihypertensive 
use was 3.2 years (±1.8 years). Compared to no use, we observed that persons with 
less than 3.2 years of use prior to baseline had a lower risk of WML-progression (OR 
0.33; 95%CI 0.16-0.68) than persons who had used antihypertensives for more than 
3.2 years (OR 0.78; 95%CI 0.41-1.47). The limited number of exposed cases, however, 
prohibited further stratification across age or achieved blood pressure control for the 
separate duration categories. 
There were only slight differences among the various types of antihypertensives, 
although the risk reduction was only statistically significant for beta-blockers and RAAS 
inhibitors (Table 4).
2.3 Antihypertensive drugs and progression of White Matter Lesions
121
table 4. Odd ratios (OR) of white matter lesion (WML) progression with any use of the 
individual types of antihypertensives
Progression of wml
Antihypertensives drug use N* or (95% CI), model I† or (95% CI), model II‡
Never use 186 (81) 1.00 (ref.) 1.00 (ref.)
Any use of: §
β- blocking agents 81 (27) 0.51 (0.28-0.93) 0.52 (0.28-0.96)
Diuretics 58 (28) 0.56 (0.27-1.17) 0.63 (0.31-1.28)
Agents acting on RAAS 45 (15) 0.38 (0.17-0.82) 0.37 (0.17-0.81)
Calcium channel blockers 36 (11) 0.45 (0.19-1.04) 0.43 (0.18-1.03)
RAAS - renin-angiotensin-aldosterone system
* Total number of persons with follow-up MRI-measurement. The number of persons with WML-
progression in the exposure category is shown between brackets. 
† Model I: adjusted for sex, age, systolic and diastolic blood pressure
‡ Model II: as Model I and additionally adjusted diabetes, total serum cholesterol, body mass index, 
and smoking 
§ There were no persons with WML-progression in the exposure category of other antihypertensives. 
DISCuSSIoN
 
In the general elderly population, we found a protective effect of antihypertensive use on 
the progression of WML. The protective effect was limited to persons younger than 70 
years of age and to those with controlled blood pressure.
 
Strengths of our study include the population-based setting, and the large sample size 
of elderly persons aged 60 years and older. A particular asset of our study is that we 
had complete pharmacy records of all filled prescriptions, providing us with very specific 
and detailed information on drug use. In an earlier study, we demonstrated that there 
was a high concordance between pharmacy filling data of cardiovascular drugs, and 
actual use according to a patient's interview.30 In view of the observational nature of 
our study, we should consider the possibility of selection bias and confounding. First, 
progression of WML could only be assessed in persons with a follow-up MRI. For the 
youngest age stratum of 60 to 70 years of follow-up we showed that antihypertensive 
use was unrelated to non-participation at follow-up and, hence, this could not have 
confounded the observed risk reduction for WML-progression. For the age groups 
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above 70 years of age, users of antihypertensive were less likely to have a follow-up 
MRI. Individuals in these age groups who did have a follow-up MRI may thus pertain 
to a ‘healthier’ selection of this study population. We can not exclude that selective 
participation biased our risk estimates in these higher age groups, although such a 
bias would tend to lead to a decreased risk. Second, we have to consider potential bias 
due to confounding-by-indication, since the indication for drug use, i.e. hypertension, 
is associated with the outcome of interest, i.e. progression of WML. The fact that we 
did not find an increased but decreased risk of progression indicates the absence of 
confounding by indication. Would the risk estimates still be confounded by the indication 
of hypertension, it would mean that the true protective effect is even higher than 
we measured. Third, WML-progression was rated visually, which gives less precise 
estimates of total lesion progression than a volumetric measurement but these were 
unavailable in our study.31 Independent validation showed, however, that our visual 
rating scale had good correlation with volumetric measurements.27,28 Finally, the 
indication of drug use is unknown in our study. Certain types of antihypertensives are 
preferred when certain comorbidities apply, such as beta-blockers in the case of angina 
pectoris. Hence, from our study we cannot conclude whether the differences observed 
among the various antihypertensives, though small, may be explained by differences in 
underlying co-morbidity or by a true difference in physiological effect. Our observations, 
particular for the individual antihypertensive drugs, should be interpreted in context of 
limited case numbers.
 
Our finding of a protective effect of antihypertensive use on WML-progression is 
compatible with three earlier studies that reported a lower risk of more severe WML 
among users of antihypertensive drugs, particularly also among persons with controlled 
blood pressure.1,15,16 Only few studies have prospectively investigated the effect of 
antihypertensive treatment on the progression of WML. Differences in study 
populations, imaging techniques, lesion ratings and assessment of drug exposure limits 
the comparison of previous studies to our results. Sachdev et al. investigated the course 
of WML-progression over 3 years in 51 healthy volunteers and found no association 
between the use of antihypertensives and change in WML volume.8 However, only 17 
users of antihypertensives were available in the analysis and no distinction was made 
between persons with controlled and uncontrolled blood pressure. Within the cohort of 
the Cardiovascular Health Study investigators found that the use of diuretics was 
associated with a worsening of WML grade.17 Two studies on antihypertensive use and 
WML-progression were performed in the context of two clinical trials; the Study on 
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COgnition and Prognosis in the Elderly (SCOPE)20 and the Perindopil Protection 
Against Recurrent Stroke Study (PROGRESS).22 Both studies found a reduced risk of 
WML-progression with the use of either an angiotensin receptor blocker20 or an ACE-
inhibitor with or without a diuretic compared to placebo.22 However, in the treatment and 
control groups the study protocol of both studies allowed for usual antihypertensive 
treatment, not containing the study drug. In both studies lower blood pressure levels 
were attained in the treatment groups for which the risk of WML-progression was 
reduced. In our study, we did not observe a difference in the effect of antihypertensive 
use on periventricular and subcortical WML-progression. This observation is in line with 
the results from a previous report from our cohort that showed that increased blood 
pressure was associated with both periventricular and subcortical WML.16 In all of the 
previous investigations on the association between antihypertensives and WML-
progression, none distinguished between periventricular and subcortical WML-
progression.
 
Contrary to what would be expected, persons with shorter duration of antihypertensives 
use had a lower risk of WML-progression than persons with longer duration of 
antihypertensive use. We speculated that persons who have required antihypertensive 
treatment for longer periods of time are also long-standing hypertensive patients and 
adequate blood pressure control may not be achieved at all times. Hence, though 
antihypertensive treatment might slow down the process that leads to increasing WML 
volume, with time the effect of increased blood pressure surpasses the protective effect 
of antihypertensives. Furthermore, hypertension treatment guidelines were introduced 
in the early 1990s and persons who started antihypertensive therapy more recently may 
have had better surveillance of their hypertension from the start of therapy. Limited case 
numbers prohibited further stratification across other characteristics, such as age or 
blood pressure, to study whether these may have played a role.
Antihypertensives may offer potential therapeutic possibilities in preventing the risk of 
cerebrovascular events and dementia associated with WML-progression. Confirmation 
of our findings by other studies is needed. Furthermore, insight into the mechanism by 
which antihypertensive drugs prevent WML-progression will help us better understand 
and substantiate these observations. Future studies could also focus on whether 
differences among the various types of these drugs exist or who might particular benefit 
from antihypertensive use. 
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AbStrACt
background: Cerebral microbleeds are hemosiderin deposits in the brain that are 
indicative of microangiopathy. Microbleeds in strictly lobar brain locations have been 
related to cerebral amyloid angiopathy, a bleeding-prone state. 
objective: To investigate the relation between antithrombotic drug use and presence of 
cerebral microbleeds, especially those in strictly lobar locations.
Setting: The Rotterdam Scan Study, a population-based imaging study in a general 
elderly community in the Netherlands.
Participants: A population-based sample of 1,062 persons from a longitudinal cohort, 
aged 60 years and older, free of dementia. 
Design: Population-based cross-sectional analysis. We used magnetic resonance 
imaging (MRI) to assess presence and location of microbleeds. Complete information 
on outpatient use of platelet aggregation inhibitors and anticoagulant drugs prior to MRI 
was obtained from automated pharmacy records.
results: Compared to non-users of antithrombotic drugs, cerebral microbleeds were 
more prevalent among users of platelet aggregation inhibitors (adjusted odds ratio (OR) 
1.71; 95% confidence interval (CI) 1.21-2.41). We did not find a significant association 
for anticoagulant drugs and microbleed presence (OR 1.49; 95%CI 0.82-2.71). Strictly 
lobar microbleeds were more prevalent among aspirin users (adjusted OR compared 
to non-users 2.70; 95%CI 1.45-5.04) than among persons using carbasalate calcium 
(adjusted OR 1.16; 95%CI 0.66-2.02). This difference was even more pronounced when 
comparing persons who had used similar dosages of both drugs.
Conclusions: In this cross-sectional study, we show that use of platelet aggregation 
inhibiting drugs is related to presence of cerebral microbleeds. Furthermore, our data 
suggest that aspirin use and carbasalate calcium use may differently relate to presence 
of strictly lobar microbleeds.
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INtroDuCtIoN
Cerebral small vessel disease is common in the elderly, and well-studied markers 
on magnetic resonance imaging (MRI) include lacunar infarcts and white matter 
lesions. In the past decade, cerebral microbleeds have become acknowledged as 
new markers of small vessel disease in the brain. These microbleeds, consisting of 
hemosiderin deposits in macrophages,1 can be visualized on T2*-weighted gradient-
recalled echo (GRE) MRI as small areas of hypointensity. Generally, microbleeds are 
thought to occur on the basis of either cerebral amyloid angiopathy2 or arteriolosclerotic 
microangiopathy.3 There is accumulating evidence that microbleed location in the brain 
is reflective of their underlying etiology. Microbleeds in deep or infratentorial locations 
are thought to be suggestive of hypertensive or arteriolosclerotic microangiopathy, 
whilst those occurring in strictly lobar brain sites are indicative of cerebral amyloid 
angiopathy.4 Cerebral amyloid angiopathy is characterized by accumulations of amyloid 
in the vessel wall, causing degeneration of smooth muscle cells resulting in vessels 
that are more susceptible to ruptures and haemorrhages.5 This suggests that especially 
strictly lobar microbleeds may be indicative of the presence of bleeding-prone brain 
vessels.2 In cerebral amyloid angiopathy, the use of platelet aggregation inhibitors and 
anticoagulants has been found to be related to increased occurrence of symptomatic 
hemorrhage.6-8 In parallel, the development of asymptomatic lobar microbleeds in these 
persons may perhaps also be accelerated by use of these antithrombotic drugs.
We hypothesized that microbleeds, especially those in strictly lobar locations, occur 
more often in persons using antithrombotic drugs. We therefore studied the association 
between the use of platelet aggregation inhibitors or anticoagulant drugs, with presence 
of microbleeds in different brain locations in a large elderly population.
metHoDS
Study population
The study population was derived as described previously.4 In short, we randomly 
selected 1,073 members of the first cohort expansion of the Rotterdam Study and in 
addition invited all Rotterdam Study participants who underwent brain imaging in the 
context of a previous round of the Rotterdam Scan Study (n=302).9 Of these, a total 
of 1,229 persons were eligible, of whom 1,114 participated and gave written informed 
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consent (response 91%). A total of 1,098 complete MRI examinations were performed 
between August 2005 and August 2006, of which 36 scans had to be excluded because 
of artifacts,4 leaving a total of 1,062 scans to be analyzed.
brain mrI and rating of cerebral microbleeds
We performed a multi-sequence MRI protocol on a 1.5-Tesla MRI scanner (General 
Electric Healthcare, Milwaukee, USA) as described previously,4 including a T1-
weighted, proton density weighted and fluid-attenuated inversion recovery (FLAIR) 
sequence. For microbleed detection, we used a high-resolution 3-dimensional T2*-
weighted gradient recalled echo (3D T2* GRE) sequence,10 optimized to increase the 
conspicuity of cerebral microbleeds (repetition time= 45 ms, echo time= 31, matrix 
size= 320*224, flip angle= 130, field-of-view= 25 x 17 cm2, parallel imaging acceleration 
factor= 2, 96 slices encoded with a slice thickness of 1.6 mm zero padded to 192 slices 
of 0.8 mm, acquisition time 5 minutes 55 seconds).
All 3D T2* GRE scans were reviewed as described before4 by one of two trained raters
(MWV, MAI), who recorded the presence, number and location of cerebral microbleeds.
Microbleeds were defined as focal areas of very low signal intensity on the 3D T2* 
GRE scan,11-13 and they were categorized into one of three locations: lobar (cortical 
grey and lobar white matter), deep (deep grey matter: basal ganglia and thalamus, 
and white matter of internal/external capsule and corpus callosum), and infratentorial 
(brainstem and cerebellum).4,11-13 All potential cerebral microbleeds were reviewed with 
an experienced neuroradiologist (AvdL). Intra-observer and inter-observer reliabilities 
for microbleed detection were very good.4
Antithrombotic drug use
Participants were registered at one or more of seven community pharmacies serving the 
study area. Of these pharmacies, complete records of all outpatient filled prescriptions 
in automated format were available as of January 1st, 1991. This included the product 
name; international non-proprietary name; Anatomical Therapeutic Chemical (ATC) 
code; total number of delivered units (e.g. tablets/capsules); prescribed daily number of 
units; date of delivery and drug dosage. 
We determined the use (categorized into yes/no) of antithrombotic drugs from January 
1st 1991 onwards. We classified antithrombotic drugs based on the ATC system 
according to pharmacological subgroup into platelet aggregation inhibitors and 
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anticoagulant drugs. Anticoagulant drugs were furthermore classified according to 
chemical subgroup (vitamin K antagonists and heparins). Among platelet aggregation 
inhibitors, we distinguished between aspirin and carbasalate calcium preparations. 
Carbasalate calcium has a lower risk of gastrointestinal mucosal damage and bleeding 
than aspirin.14 Though this bleeding-risk difference is generally attributed to differences 
in local effects on gastrointestinal mucosa,14 a recent report postulated that there may 
be differences in systemic effects between aspirin and carbasalate calcium.15 We 
therefore hypothesized that aspirin and carbasalate calcium may differentially relate 
to microbleed presence. To take into account that aspirin and carbasalate calcium can 
also be used as pain medication, we concluded whether these drugs were used for 
inhibition of platelet aggregation on the basis of prescribed dose and regimen. National 
guidelines dictate the use of aspirin and carbasalate calcium up to 80 mg and 100 mg, 
respectively, for the purpose of platelet aggregation inhibition.16 The dosage criterion 
was overruled only if the regimen clearly indicated the indication of use or if used 
as loading dose at start of therapy 3.4% of all prescriptions). Dosages of aspirin or 
carbasalate calcium around 30 or 38 mg, respectively, are generally specifically advised 
in case of previous cerebrovascular events (‘neuro dosage’), whereas dosages around 
80 mg to 100 mg, respectively, are considered cardiac dosage’.16
Confounding by indication
Associations between drug use and certain outcomes may be confounded by the 
indication for which the drugs are prescribed. Antithrombotic drugs are usually 
prescribed in persons at risk for, or with a history of, ischemic cardiovascular or cerebro-
vascular disease, which in turn can be related to the risk of cerebral microbleeds. We 
therefore assessed cardiovascular risk factors as potential confounders. Furthermore, 
we determined whether persons had a known history of cerebrovascular disease. 
Finally, we recorded the presence of infarcts and the volume of white matter lesions on 
MRI, as these are known markers of ischemic cerebrovascular disease, and therefore 
more likely to be influenced by confounding by indication.
Cardiovascular risk factors
For cardiovascular risk factors, we used information that was obtained by interview, 
laboratory and physical examination at the preceding regular visit of study participants 
to the research center.4 We computed the Framingham Risk Score for each participant 
using age, sex, systolic and diastolic blood pressure, serum total cholesterol, serum 
HDL cholesterol, presence of diabetes and smoking status.17
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History of cerebrovascular disease
A known history of cerebrovascular disease was assessed as follows. Upon entry in 
the Rotterdam Study, history of stroke is assessed.18 Subsequently, participants are 
continuously monitored for incident stroke through automated linkage of the study 
database with files from general practitioners and hospital discharge information. All 
reported events are validated by an experienced neurologist.19
Infarcts and white matter lesions on MRI
Infarcts were rated on FLAIR, PD-weighted and T1-weighted sequences by the two 
raters who had scored the cerebral microbleeds, as described previously.20 All infarcts 
were reviewed in a consensus meeting with an experienced neuroradiologist. For white 
matter lesion volume quantification, we used a validated tissue classification technique.
In brief, we used the k-nearest neighbor classifier22 to automatically segment MRI 
scans into grey matter, white matter, CSF and white matter lesions. White matter lesion 
volumes were calculated by summing all voxels of the white matter lesion-class across 
the whole brain, to yield volumes in milliliters.
Statistical analysis
We categorized persons based on the location of their microbleeds as described 
previously.4 In short, we made a category of persons who had one or more microbleeds 
restricted to a lobar location (‘strictly lobar’). Persons who had at least one microbleed 
in a deep or infratentorial brain location were assigned to the category ‘deep or 
infratentorial microbleeds’.
We analyzed the relation between exclusive use of platelet aggregation inhibitors and 
anticoagulants prior to MRI and the presence of microbleeds using multiple logistic 
regressions. We redid these analyses for microbleeds in specific locations (strictly 
lobar and deep or infratentorial) and in addition studied all separate drug types (aspirin, 
carbasalate calcium, vitamin K antagonists and heparins). Non-users of antithrombotic 
drugs served as reference, unless specified otherwise. All analyses were adjusted 
for age and sex. To adjust for cardiovascular risk without overfitting the model,23 we 
additionally adjusted all analyses for the Framingham risk scores. For comparison we 
also studied the association between antithrombotic drug use and presence of brain 
infarcts and volume of white matter lesions (dichotomized at the 75th percentile). We 
redid all analyses excluding persons with a known history of cerebrovascular disease. 
Furthermore, we tested whether the mean daily dose that was prescribed for aspirin and 
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carbasalate calcium differed. To control for differences in dosage of these drugs, and 
thus for possible differences in indication,16 we performed a direct comparison between 
users of aspirin or carbasalate calcium who had only been prescribed so-called ‘cardiac 
dosages’ (>50 mg/day). All analyses were performed using the statistical software 
package SPSS, Illinois, USA, version 11.0.1 for Windows.
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reSultS
Population characteristics are shown in Table 1. Mean age of the population was 
69.6 years (range 60.7-96.7 years) and 543 (51.5%) were women. There were 363 
persons (34.2%) who had used any kind of antithrombotic drug in the years prior to MRI 
scanning. Of these, 245 persons (23.1%) had exclusively used platelet aggregation 
inhibitors and 61 (6.3%) had exclusively used anticoagulant drugs. Platelet aggregation 
inhibitors comprised aspirin (n=67) and carbasalate calcium (n=141). Anticoagulant 
prescriptions were mainly for vitamin K antagonists (n=51), and only few persons had 
used heparin (n=5). No prescriptions for other antithrombotic drugs were filled at any of 
the community pharmacies.
Users of antithrombotic drugs significantly more often had cerebral microbleeds than 
non users of antithrombotic drugs (Table 2). This was especially true for persons using 
platelet aggregation inhibiting drugs (age- and sex-adjusted OR for users compared 
to non-users 1.68; 95% confidence interval (CI) 1.20-2.35). There was no significant 
association between anticoagulant drug use and presence of microbleeds (Table 2). 
Use of antithrombotic drugs was also related to presence of brain infarcts and to high 
white matter lesion volume (Table 2). Additional adjustment for cardiovascular risk did 
not change any of the associations (Table 2). Exclusion of persons with a known history 
of cerebrovascular disease (n=36) attenuated the associations between antithrombotic 
drug use and infarcts or white matter lesions, but did not alter the relation with cerebral 
microbleeds (data not shown).
When analyzing antithrombotic drug use in relation to microbleed location, we found 
that aspirin users more often had strictly lobar microbleeds (adjusted OR 2.70; 95%CI 
1.45-5.04) than non-users. This was not seen for users of carbasalate calcium (OR for 
presence of strictly lobar microbleeds 1.16; 95%CI 0.66-2.02); Table 3). In contrast, 
both aspirin and carbasalate calcium were equally strongly related to presence of 
deep or infratentorial microbleeds (Table 3). The pattern for infarcts and white matter 
lesion load was reversed: users of carbasalate calcium more often had infarcts (OR 
2.64; 95%CI 1.52-4.95) or high white matter lesion load (OR 1.80; 95%CI 1.16-2.79) 
than non-users; but this was not true for aspirin users (OR of aspirin users compared 
to no-users, for infarcts 1.73; 95% CI 0.78-3.83) and for white matter lesions OR 1.01; 
95%CI 0.52-1.95). Further investigation of anticoagulant drugs into exposure to vitamin 
K antagonists versus heparin was less informative due to low numbers of heparin 
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users; though use of vitamin K antagonists seemed related to deep or infratentorial 
microbleeds, but not to strictly lobar microbleeds (Table 3).
table 1. Characteristics of the study population (n=1,062)
Characteristic
Age, years 69.6 ± 7.2
Women 543 (51.1)
Cerebral microbleeds 250 (23.5)
Strictly lobar 146 (13.7)
Deep or infratentorial* 104 (9.8)
Any use of antithrombotic drugs 363 (34.2)
Exclusive use of platelet aggregation inhibitors 245 (23.1)
Aspirin 67 (6.3)
Carbasalate calcium 141 (13.3)
Exclusive use of anticoagulant drugs 61 (5.9)
Vitamin K antagonists 51 (4.9)
Heparin 5 (0.5)
Systolic blood pressure, mmHg 144.4 ± 18.7
Diastolic blood pressure, mmHg 80.2 ± 10.3
Current smoker 310 (29.7)
Past smoker 445 (42.6)
Diabetes 95 (8.9)
Total serum cholesterol, mmol/l 5.7 ± 1.0
HDL-cholesterol, mmol/l 1.4 ± 0.4
Known history of cerebrovascular disease 36 (3.4)
Infarcts on MRI 119 (11.2)
WML volume, ml† 3.4 (2.0-7.3)
Values are numbers (%) or means ± standard deviation, unless 462 specified otherwise.
* With or without microbleeds in a lobar location.
† Median (interquartile range).
Data missing for: smoking (n=17) and for use of anticoagulant drugs (n=24).
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Among users of platelet aggregation inhibitors, the mean prescribed daily dose of 
aspirin was higher than the dose of carbasalate calcium (89.0 mg versus 72.2 mg 
(equivalent to 57.8 mg aspirin), p< 0.001). This was mainly due to carbasalate calcium 
being more often prescribed in low doses (‘neuro dosage’)16: 56% of persons using 
carbasalate calcium had been prescribed at any time a low dose preparation (<50 
mg daily dose), versus none of the persons using aspirin. Restricting our analysis to 
users of high dosages (‘cardiac dosage’)16 of either aspirin or carbasalate calcium, 
we found an even more marked difference between aspirin use and carbasalate use 
and presence of strictly lobar microbleeds (Table 4), whilst mean prescribed daily dose 
did no longer differ significantly (89.0 mg for aspirin versus 102.8 mg for carbasalate 
calcium (equivalent to 82.2 mg aspirin)). This again indicated that aspirin users more 
often had strictly lobar microbleeds compared to users of carbasalate calcium. Again, 
this discrepancy was not present for microbleeds in deep or infratentorial locations or 
for infarcts and high white matter lesion load.
table 4. Use of cardiac dosage aspirin or carbasalate calcium and cerebral microbleeds, 
infarcts and white matter lesions
odds ratio (95% CI)
Antithrombotic 
use
Any 
microbleed
Strictly lobar 
microbleeds
Deep or 
infratentorial 
microbleeds
Infarct High wml 
volumea
Use of carbasalate 
calcium in “cardiac” 
dose (n=61)
1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
Use of aspirin in 
“cardiac” dose 
(n=66)
Model I
2.05 
(0.94-4.49)
4.02 
(1.34-12.04)
1.00 
(0.36-2.76)
1.28 
(0.43-3.83)
0.53
(0.22-1.29)
Model II
1.88 
(0.84-4.18)
3.83 
(1.25-11.70)
0.95 
(0.34-2.68)
1.26 
(0.42-3.82)
0.59 
(0.24-1.47)
Model I = adjusted for age & sex. 
Model II = adjusted for age, sex and Framingham Risk Score.17
DISCuSSIoN 
We found that cerebral microbleeds were more prevalent in persons who had used, 
or were using, platelet aggregation inhibitors. Furthermore, our data show a higher 
prevalence of strictly lobar microbleeds among aspirin users than among people using 
carbasalate calcium.
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Before discussing the implications of our findings, we need to address some methodo-
logical considerations. Firstly, our study was not prospective, limiting our ability to draw 
conclusions regarding cause and effect. Presence of cerebral microbleeds on MRI 
does not provide information on when these bleeds actually occurred, as hemosiderin 
deposits can remain visible in the brain for an undefined period of time. Therefore, it is 
possible that some of the microbleeds we assessed actually occurred prior to use of 
antithrombotic drugs. If this occurred, this may have influenced our results. Secondly, 
there is the issue of confounding by indication. As cerebral microbleeds may be related 
to presence of cardiovascular or cerebrovascular disease in general, it may be that 
antithrombotic drugs are more often prescribed to persons with an increased risk to 
develop microbleeds, confounding our results. We have tried to minimize confounding 
by indication by adjusting our analyses for cardiovascular risk and furthermore by 
excluding persons with a known history of cerebrovascular disease from our analyses. 
We found that anticoagulant drug use was not significantly related to presence of micro-
bleeds, whilst platelet aggregation inhibitor use was. Lack of statistical significance 
for anticoagulants can be due to the lower number of anticoagulant users in our popu-
lation. Alternatively, it could be speculated that this difference can be explained by 
the different pathways of action on haemostatis of anticoagulant versus antiplatelet 
drugs. Platelet aggregation inhibiting drugs interfere with the intravascular aggregation 
of platelets into haemostatic plugs at the site of fissures or ruptures in atherosclerotic 
plaques or vessel walls.24 Anticoagulant drugs such as vitamin K antagonists or 
heparins act on inhibiting the cascade of enzymatic reactions that ultimately stabilize 
the platelet clot. It may be that microbleed formation is more dependent on the sealing 
of small vessel wall defects by platelet aggregation than it is on clot stabilization.
We furthermore found a differential relation between use of aspirin or carbasalate 
calcium and presence of strictly lobar microbleeds, microbleeds which are thought to 
be indicative of cerebral amyloid angiopathy.2,4 This difference is not likely caused by 
confounding by indication as we did not observe such a difference for deep or infra-
tentorial microbleeds or for infarcts and white matter lesions, all of which are known 
to be more strongly related to vascular risk than strictly lobar microbleeds.4,25,26 The 
difference was even more pronounced when comparing persons who had used only 
the ‘cardiac dosage’ of these drugs, indicating that prescribed doses did not play a 
role either. Though it is possible that this is a chance finding, it may also be that this 
difference is caused by an underlying biological mechanism. Replication of this finding 
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is needed to further evaluate, though we could speculate that aspirin and carbasalate 
calcium may perhaps differentially affect bleeding-risk or microbleed development in 
cerebral amyloid angiopathy. Although aspirin and carbasalate calcium have the same 
active component, acetylsalicylate, (i.e. carbasalate calcium is a complex of calcium 
acetylsalicylate and urea), it has been described that under certain circumstances 
bioavailability of aspirin may differ from carbasalate calcium27 or from other salt-forms 
of acetylsalicylate28 and that both drugs may not have similar systemic effects.15 
Hypothetically, a difference in (time to) peak concentration of active acetylsalicylate, 
or a difference in plasma concentrations of the drug, for example, could cause aspirin 
to achieve a critical level of inhibition of platelet aggregation and induce leakage 
of blood from amyloid-laden vessels, whilst this may not occur using carbasalate 
calcium at similar dosages. Alternatively, it may be that the mode of administration of 
aspirin and carbasalate calcium, for example in effervescent tablets or enteric-coated 
tablets, influences the (differences in) plasma concentrations and biological effect.29 
Unfortunately, our data set lacked power to investigate whether mode of administration 
may have played a role in our observations. Thus, more research is needed to 
explore the difference in microbleed prevalence we assessed between both chemical 
substances. There is currently major interest in bleeding-risks of antithrombotic or 
thrombolytic treatment in persons who have microbleeds on MRI,30-35 as this may 
affect clinical management in patients with cardiovascular or cerebrovascular disease. 
Our data show an association between use of platelet aggregation inhibitors and 
presence of cerebral microbleeds. The cross-sectional design of our analyses prohibited 
to investigate whether persons with cerebral microbleeds are at increased risk of 
symptomatic hemorrhage when using platelet aggregation inhibitors. Of note is that the 
beneficial effects of well-indicated antithrombotic drugs in persons at risk of myocardial 
infarction or ischemic cerebrovascular disease should not be disregarded, as these 
have shown to outweigh any risks of bleeding.36 Nevertheless, it may be that in selected 
persons, e.g. those with signs of cerebral amyloid angiopathy, this risk-benefit ratio may 
differ for certain drugs (e.g. aspirin), thus influencing treatment decisions. The cross-
sectional associations between antithrombotic drugs and microbleeds in the general 
population that we report on would therefore justify further longitudinal research into this 
relation. 
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The general objective of this thesis was to study the effects of nonsteroidal anti-
inflammatory drugs (NSAIDs) and cardiovascular drugs on neurodegenerative and 
cerebrovascular disease. In this discussion, the main findings are summarized in the 
context of recently published evidence. Next, the methodological issues of these studies 
will be discussed, focusing on specific aspects of pharmacoepidemiological research 
that may have consequences for an accurate interpretation of our findings. Finally, the 
potential (clinical) implications of our observations will be discussed and suggestions for 
future research are given.
mAIN fINDINgS AND INterPretAtIoN
NSAIDs, Stroke and transient Ischemic Attack
In the general population, we found an increased risk of ischemic stroke with current 
use of any NSAID. The increased risk was observed with current use of COX2-
selective and non-selective NSAIDs.1 Transient ischemic attack (TIA) is an outcome 
strongly related to ischemic stroke and essentially considered an ischemic stroke of 
‘transient’ nature also caused by focal cerebral or retinal ischemia. Concordantly, we 
also observed an overall greater risk of TIA with the use of NSAIDs. Our observations 
are largely in agreement with previous findings from clinical trials and observational 
investigations which also showed an increased risk with use of NSAIDs of (ischemic) 
cerebrovascular endpoints.2,3 The mechanism by which NSAIDs induces thrombotic 
events is yet unclear. It was initially thought that selective inhibition of COX2 caused 
a prothrombotic state due to a disturbance in the COX2 and COX1 mediated balance 
of prostacyclin, which inhibits platelet aggregation, and respectively thromboxane, 
which facilitates platelet aggregation and acts as a vasocontrictor.4,5 But, since both 
COX-enzymes are involved in this vascular homeostasis it could also be that any 
inhibition of COX could disturb this equilibrium.6-8 Alternatively, the stroke hazard across 
COX-classes might be plausibly explained by effects of NSAIDs that are not unique 
to selective COX2-inhibition, such as increased blood pressure.9,10 In conclusion, we 
should be critical of the widespread idea that only COX2-selective NSAIDs increase the 
risk of cardiovascular and cerebrovascular events. 
NSAIDs and Parkinson disease
In the Rotterdam Study we did not find evidence for a protective effect of NSAIDs 
in Parkinson disease (PD). This was contrary to the hypothesis that NSAIDs may 
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protect against PD based on the results from human postmortem and animal studies 
which suggested a role for inflammatory processes in PD pathogenesis.11 Previous 
observational studies also found that NSAID use was associated with a reduced risk 
of subsequent PD.12,13 Several explanations can be given for the null finding in our 
study. For instance, it is likely that the effect is related to the duration of exposure. 
Unfortunately, in our study the relatively low number of exposed incident PD cases 
resulted in unstable estimates in the category of long-term users of NSAIDs. For the 
same reason, analyses across subtypes of NSAIDs were not possible, whereas in 
reality differences among subtypes may exist.14 It could also be that inflammation 
is not a cause but a consequence of neurodegeneration in PD. Only recently it was 
prospectively examined whether human plasma concentrations of inflammatory 
biomarkers assessed before PD diagnosis were predictive of future risk of the 
disease.15 A positive association was observed for interleukin-6 (IL-6), but not for 
C-reactive protein, fibrinogen, or tumor necrosis factor-α receptors. The specific role of 
IL-6 in PD pathogenesis is as yet unclear. Furthermore, the lack of associations with 
other inflammatory biomarkers prevented a solid conclusion about a role of inflammation 
and PD. These recent findings do not contradict our observations from the Rotterdam 
Study. 
NSAIDs and Alzheimer disease
In Chapter 1.4 we reported that long-term use of amyloid-β42 (Aβ42)-lowering NSAIDs 
was associated with a decreased risk of AD, whereas this was not observed for non-
Aβ42-lowering NSAIDs. Amyloid-β42 protein is the major constituent of the senile 
plaques, a hallmark of Alzheimer pathology.16 Our observations suggest that NSAIDs 
influence the risk of AD through an amyloid-processing related mechanism. These 
findings could explain why recent trials using non-Aβ42-lowering NSAIDs found no 
beneficial effect on the prevention of AD17 and may have important consequences 
for the development of preventive drugs for AD. Whilst two more recent observational 
studies and a pooled cohort study again confirmed the protective effect of NSAIDs in 
AD, they did not provide support for a different effect of Aβ42-lowering and non-Aβ42-
lowering NSAIDs in AD.18-20 The classification of NSAIDs was the same across studies 
and identical to our classification. However, there were considerable differences in study 
design, particularly in terms of source of information on drug exposure and exposure 
definition, which could explain the discrepancies. No clinical trial has tested Aβ42-
lowering NSAIDs for the prevention of AD nor has the effect of NSAIDs on Aβ42-load in 
the human brain been studied. 
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Statins and Alzheimer disease
We found that use of statins but not of other cholesterol-lowering drugs was associated 
with a 43% lower risk of AD compared to never use of cholesterol lowering drugs. The 
protective effect was observed regardless of lipophilicity of statins. The therapeutic 
benefit of these agents in AD prevention is the topic of much controversy in the litera-
ture. Cross-sectional observational studies have suggested an association between 
the use of cholesterol lowering drugs, particularly statins, and the risk of AD.21-26 Thus 
far, prospective studies provided inconsistent evidence for a protective effect of statins 
on the risk of AD.23,27-30 Important limitations of these studies, however, included use 
of interview data on drug exposure or cross-sectional exposure assessment, and 
short duration of follow-up. Furthermore, it has been hypothesized that only lipophilic 
statins, that cross the blood-brain-barrier more easily, would affect the risk of AD.31 Our 
observation of a protective effect of statins regardless of lipophilicity could be explained 
by the fact that properties other than lipophilicity also determine their tissue distribution 
or that passage of the blood-brain-barrier is irrelevant to exert their effect. Randomized 
controlled clinical trials of cholesterol lowering agents to date have not revealed a 
reduction in the incidence of dementia in patients on statins.32,33 However, these 
studies were not designed to identify dementia or AD. We await the results of primary 
prevention trials to provide conclusive results as to whether statins reduce the risk of 
AD.
 
Antihypertensives and Alzheimer disease
We found that the use of antihypertensive drugs was associated with 8% risk 
reduction of dementia per year of use for persons below 75 years of age. The effect 
of antihypertensive drug use on the risk of dementia or AD has been investigated in 
several prospective observational studies and clinical trials with conflicting results.34 
However, duration of follow-up in these studies was limited and observational studies 
relied mainly on baseline data on drug exposure without information on duration of 
use. By using continuous information on antihypertensive use from pharmacy records 
we limited the chance of potential misclassification of drug exposure. Furthermore, 
to avoid potential bias in antihypertensive prescription due to prodromal changes in 
blood pressure35 or cognition as a result of developing disease, we subtracted a 4-year 
latent period before the date of dementia diagnosis in the quantification of exposure 
duration. Our observation of a stronger protective effect for persons below 75 year 
of age is in line with the view that increased blood pressure earlier in life increases 
the risk of dementia36,37, whereas high blood pressure in older persons may not 
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necessarily put persons at higher risk for dementia.38,39 Since there were no apparent 
differences among the various types of antihypertensive drugs, we consider it likely 
that the class effect of lowering blood pressure underlies the protective effect of these 
drugs. We conclude that the currently available evidence for a protective effect of 
antihypertensives on AD constitutes a rather limited basis for advocating a universal 
antihypertensive treatment policy for the sole purpose of dementia prevention. 
Antihypertensives and Progression of White Matter Lesions 
In Chapter 2.3 we studied the use of antihypertensives in relation to progression of 
cerebral white matter lesions (WML) and observed that users of antihypertensives had 
a lower risk of WML-progression. Cerebral WML are frequently observed on magnetic 
resonance imaging (MRI) scans in elderly people.40,41 These lesions are associated 
with an increased risk of stroke, cognitive decline, and dementia.42-44 Hypertension is 
the most recognized risk factor for the presence, severity and progression of WML.45 
We investigated the association between antihypertensive use and WML-progression 
in a sample of 563 non-demented participants from our cohort who underwent MRI. For 
320 persons follow-up MRI measurements were available to asses WML-progression. 
Compared to non-users, users of antihypertensive had a 50% risk reduction of WML-
progression at follow-up, particularly in the age group of 60 to 70 years. For persons 
older than 70 years of age our analyses were compromised by selective attrition due 
to which a spurious protective effect could be expected. However, we did not observe 
a protective effect of antihypertensive users above 75 years of age, which suggests 
that selective attrition may not have played a major role, if any, in this age group. 
Furthermore, we found that users of antihypertensives with controlled blood pressure 
(<160 mmHg) had a lower risk of WML-progression, than persons with elevated 
blood pressure despite antihypertensive treatment. Control of blood pressure with 
antihypertensive agents could provide a possible strategy for the prevention of WML 
progression.
Anticoagulants and cerebral microbleeds 
In Chapter 2.4, we hypothesized that microbleeds, especially those in strictly lobar 
locations, occur more often in persons using antithrombotic drugs. We studied the 
association between antithrombotic drug use and presence of cerebral microbleeds in 
1,062 persons from the population-based Rotterdam Scan Study. We found that use of 
antithrombotic drugs, particularly platelet aggregation inhibitors, was related to presence 
of cerebral microbleeds.
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Furthermore, we observed that aspirin users significantly more often had lobar 
microbleeds than users of carbasalate calcium, suggesting that these drugs may 
differently relate to presence of strictly lobar microbleeds. Cerebral microbleeds are 
emerging as a very important topic in neurology research as well as clinical practice; 
not in the least because their clinical relevance is still largely unknown, yet considered 
potentially high. In stroke patients, microbleed presence has been associated with an 
increased risk of stroke recurrence or hemorrhagic transformation of ischemic brain 
areas.46 Very little is known on risk factors and prognosis of microbleeds in the general 
population. Recently, we reported that microbleed prevalence in the general elderly 
population is as high as 18% in persons aged 60-70 years, and increases up to 38% in 
those over the age of 80.47 There is accumulating evidence that microbleeds in strictly 
lobar brain locations are indicative of cerebral amyloid angiopathy,48 a bleeding prone 
state, in which antithrombotic drug use was shown to increase the risk of symptomatic 
brain hemorrhage.49,50 In parallel, the development of asymptomatic lobar microbleeds 
in these persons may perhaps also be accelerated by use of antithrombotic drugs. 
The cross-sectional nature of this final study does not allow for the assessment of a 
temporal relationship between drug exposure and occurrence of microbleeds. Also, 
confounding-by-indication is likely to have played a role since persons with cardio-
vascular disease are more likely to have microbleeds and, at the same time, are also 
more prone to receive antithrombotic treatment. Therefore, our findings should be 
regarded as exploratory and confirmation by prospective studies is needed. 
 
methodological considerations
Experimental clinical research is the corner stone for studying benefit and harm of 
drug therapy. However, for ethical and practical reasons, experimental clinical research 
cannot always be employed and observational research may provide an alternative 
and, in certain instances, better tool. In contrast to experimental clinical research, 
observational research draws inferences about the effect of a treatment in a population 
where the assignment of subjects into a treated versus a control group is outside the 
control of the investigator.51,52 Treatment selection is done on the basis of clinical need 
or preference, which can result in differences in clinical outcomes solely because of 
differences between those who do and do not receive treatment. Major challenges in 
conducting observational research are therefore to draw inferences that are acceptably 
free from influences from these biases, but also, in first instance, to assess and define 
drug exposure.53,54 
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The studies described in this thesis are based on the prospective cohort of the 
Rotterdam Study.55 Methodological strengths include its general population based 
setting, the large number of participants and long-duration of follow-up. A particular 
asset of the Rotterdam Study cohort in the context of the current thesis is the availability 
of information on drug exposure from community pharmacy records. From January 
1st 1991 onwards we had detailed information on all dispensed drugs in automated 
format, collected irrespective and independent of the outcome under study. The 
source, methods of collection and completeness makes information and selection bias 
for these data unlikely. Also, pharmacy derived data on drug exposure considerably 
reduces the chance of exposure misclassification as opposed to studies in which (self-
reported) baseline drug exposure data, periodical assessment of drug exposure or 
prescription records are used.56 Furthermore, the filled prescription data provided us 
with information on drug use at each point in time during follow-up. This is important 
information because, unlike constantly present determinants such as gender or history 
of stroke, exposure to drugs changes constantly over time due to initiation, stopping 
and switching of medication. By using a Cox-regression model with time-dependent 
variables for our prospective analyses we were able to take changes in exposure 
status into account.57 In addition, this model allowed us to investigate timing of drug 
use in relation to the occurrence of the event, i.e. the ‘risk-window’. An appropriate 
‘risk-window’ would capture the relevant period of increased or decreased risk of an 
outcome following an exposure.58,59 The ‘risk-window’ depends on the pharmacological 
effect of the drug and on the induction and latency period of the disease under study. 
Selection of an appropriate risk-window results in exposure misclassification and 
thereby underestimation of the true association. In our first report we studied the effect 
of NSAIDs on stroke, for which inhibition of COX-enzymes appears relevant. The effect 
of NSAIDs on the COX-enzymes is considered reversible. With cessation of the drug, 
the effect on COX-subsides as the drug is cleared from the body and the physiological 
balance of COX-mediated processes re-establishes. Since stroke is also of acute 
onset, a causal relationship is therefore only plausible if the event occurs during periods 
of drug intake or shortly after cessation of the drug. This is in contrast to the effect 
of NSAIDs on amyloid-β42 processing where every period of drug use is thought to 
impede the accumulation of amyloid-β42-protein and adds up to a sum of period of 
protection, delaying the onset of AD. In this study we thus calculated cumulative use 
during a theoretical life-time risk-window as exposure. Yet other considerations for 
the exposure definition had to be born in mind when we investigated the associations 
between both statins and antihypertensive on the risk of AD. As with the effect of 
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NSAIDs on COX, the main effects of these drugs on human physiology, i.e. decreasing 
blood pressure and cholesterol reduction respectively, are not considered permanent. 
Nevertheless, if during each period of use the process to disease is halted or slowed, 
users of these drugs will have a lower risk of disease than non-users, despite the 
fact that they may not use continuously. Hence, in these studies our main analyses 
pertained to cumulative use. However, in subanalyses we excluded persons who did not 
refill their prescription in certain time-periods prior to diagnosis to take into account that 
the risk may return to the background incidence rate after cessation of drug use. 
Despite the many advantages of pharmacy prescription records to determine drug 
exposure, assumptions are still required. For example, if two of more prescriptions 
for similar medications overlap and it is unlikely that a person would use these 
drugs simultaneously, one has to assume discontinuation of one of the drugs. These 
assumptions may not always represent the actual situation of drug use. Furthermore, 
pharmacy data on filled prescriptions do not provide the guarantee that a drug is 
actually taken. Drug compliance is a general issue in efficacy research and influenced 
by many factors. Compliance can differ from person to person, but also depends 
on the drug itself (adverse effects, ease of administration and regimen) making it 
difficult to predict the magnitude of non-compliance. By varying exposure definitions 
we attempted to determine whether and how this affected our findings. Fortunately, 
for chronically taken medication timely refill at the pharmacy mostly means that the 
patient is compliant. For incidental medication, such compliance checks can not 
be performed with pharmacy data. This applies to NSAIDs, which besides being 
chronically used, such as for arthritis, are also used incidentally. Another limitation is 
that pharmacy registrations do not include ‘over-the-counter’ (OTC) drugs, i.e. drugs for 
which prescriptions are not required. If investigating prescription drugs that are (also) 
available as OTC drugs, like NSAIDs and aspirin, this can lead to misclassification of 
exposure. Exposed persons can be incorrectly classified as unexposed, or the true 
cumulative duration of exposure may be underestimated. During most of our study 
periods, OTC available medication was reimbursed in the Netherlands if prescribed 
for chronic conditions and it is thus safe to assume that outside of chronic indications, 
OTC drugs are used incidentally. Under this assumption, lack of information on OTC 
drug use may have limited consequences for studies were long-term use is required 
for the drug to have an effect, such as in our study of NSAIDs and AD. However, this 
may have implications for the acute effect of NSAIDs in stroke. There we may have 
randomly missed exposure in some of the cases and non-cases and thereby caused an 
underestimation of the true risk. 
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In non-experimental research the allocation of treatment is by definition not random.54 
If drug prescription is rational and, for the sake of argument we ignore undertreatment, 
the indication of the drug will only be present in treated persons and not in non-treated 
persons. Unavoidably, this results in an imbalance in prognostic factors between those 
with and without the indication for treatment. Two forms of bias that typically originate 
from the indication of drug use are confounding-by-indication (or contra-indication) 
and protopathic bias.60 Confounding-by-indication occurs if the indication of the drug 
under investigation is also an independent risk factor for the outcome. Essentially, the 
conceptual basis of our studies on antihypertensives and cholesterol-lowering drugs 
and risk of AD and WML progression lies in the association between the indication 
of these drugs and the outcomes, as both hypertension and cholesterol-levels are 
thought to be related to the outcomes under investigation. Since in these associations 
confounding-by-indication leads to increased risk estimates and because we found a 
risk reduction, we apparently underestimated the true protective effect. Contrary, in our 
study the effect of confounding-by-indication on anticoagulants and risk of microbleeds 
could lead to spuriously increased risk estimates, since users of anticoagulants are at 
risk for vascular disease, which in turns increases the risk of microbleeds. To minimize 
confounding-by-indication, we adjusted our analyses for the Framingham risk score 
and furthermore by excluding persons with a known history of cerebrovascular disease 
from our analyses. For our studies on NSAIDs and AD or PD confounding-by-indication 
is less likely to have played a role since the indications of pain or joint disease are 
generally not considered risk factors for AD or PD. However, during the prodromal 
phase of these diseases preferential prescribing or change in drug use behavior may 
have occurred. If, like in these studies, not the drug’s indication acts as a confounder 
but the early symptoms of the outcome is the reason for prescribing the drug, this bias is 
referred to as ‘protopathic bias’. To avoid protopathic bias in our studies on AD and PD 
we subtracted a four year period before the date of diagnosis from the potential period 
for exposure assessment to ensure that changes in drug use patterns due to preclinical 
signs of the disease are not erroneously associated with the disease of interest .61 
Finally, we must consider the possibility that the indication of a drug can give rise to 
selection bias if the use of the drug of interest differs among study participants and 
non-participants at baseline or follow-up. In our cross-sectional study on antithrombotics 
and microbleeds we anticipate that the response rate among users of antithrombotics is 
lower than among non-users. Again, since antithrombitic use is related to cardiovascular 
morbidity, which in turn is related to microbleeds, this may have biased our estimates. 
The magnitude of this bias is, however, difficult to predict since no imaging data are 
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available for these participants. The same holds for our study on antihypertensives and 
WML-progression, where we showed that the non-response observed in the older age 
groups at follow-up was related to the drug under investigation. However, this did not 
result in a spurious protective effect as we would have expected. 
(Clinical) implications 
In general, the extent to which our findings may have (clinical) implications depends in 
part on the direction of the observed associations, i.e. benefit or harm. In this thesis, the 
drugs for which we observed a potential beneficial effect on neurological disease have 
all been studied in relation to outcomes outside their currently registered indications 
and clinical use. For drugs to be imbedded in clinical practice guidelines, registration 
for these indications is essential. However, the registration of a drug for a particular 
indication is a time-consuming and intensive process and, by legislation, generally 
requires evidence from randomized clinical trials. Hence, the direct clinical implications 
of these findings will be limited, at least on the short-term. For the drugs that we found 
to have adverse effects on neurodegenerative and cerebrovascular disease, the 
immediate clinical relevance is more obvious.
We showed that the use of non-selective and COX2-selective NSAIDs increases the 
risk of stroke. In response to the previous reports on the cardiovascular risks of COX2-
selective NSAIDs certain measures have already been put into effect by national and 
international authorities to prevent future events. This involved changes in drug labeling 
and ‘dear health care professional letters’, which have been less stringent for non-
selective NSAIDs than for COX-selective NSAIDs.2,62 Our data, and those of others, 
suggest that with respect to cardiovascular risk, similar labels are appropriate for all 
NSAIDs. Also, OTC availability of NSAIDs may need reconsideration. 
Besides the potential harm of NSAIDs we also observed that a certain subgroup, 
namely Aβ42-lowering NSAIDs, seems to reduce the risk of AD. However, the know-
ledge regarding the thrombotic risk of NSAIDs and their risk of gastro-intestinal 
bleeding makes it very unlikely that they will be of clinical importance in the prevention 
of AD. Likewise, this also limits the feasibility of future clinical trials of NSAIDs in AD 
or experimental studies in humans. Questions, such as whether and how NSAIDs 
affect amyloid-β in humans may thus not easily be answered in experimental settings. 
However, our findings do provide an indication for future drug development that thera-
peutics targeted at Aβ42 can be worthwhile. 
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We found that both statins and antihypertensives may protect against AD. Currently, 
both drugs are extensively used in vascular risk management. Based on our findings, 
vascular risk management could also be viewed in the light of preserving ‘neurological 
health’. The question, of course, remains if these drugs are also of value to AD 
prevention outside their current indication areas and if specific patient groups could 
be recognized who would benefit most. Our study on antihypertensives and WML-
progression suggests that presence of WML could prove to be one of the indication 
areas of interest. 
The final report in this thesis actually resulted, in part, from clinical questions regarding 
antithrombotic treatment in persons with microbleeds on MRI. Our finding of a higher 
prevalence of cerebral microbleeds among users of platelet aggregation inhibitors has 
no direct consequence for clinical practice yet. One, because of the cross-sectional 
nature of the study does not allow for causal inference. Two, because the beneficial 
effects of well-indicated antithrombotic drugs in persons at risk of myocardial infarction 
or ischemic cerebrovascular disease have thus far shown to outweigh any risks of 
bleeding. 
future reSeArCH
Despite the substantial re-evaluations and continuing flow of evidence from clinical 
and epidemiological studies regarding the thrombotic risk of NSAIDs, various issues 
remain which hamper adequate treatment and regulatory decision making. Among 
others, this concerns the lack of exact knowledge about the risk of each individual 
NSAID for the various thrombotic events, particularly for cerebrovascular events. 
Also, we should gain better insight into dose-dependency and timing of risk and 
whether certain patient groups are at higher risk than others. Unraveling these 
details will require large population numbers not usually available in single medical 
databases or from prospective cohort studies. In general, the late recognition of the 
cardiovascular risk associated with NSAID use also raised concerns as to whether 
current pharmacovigilance systems, which are based on spontaneous reporting from 
physicians and patients, are able to detect adverse events rapidly enough. Current 
initiatives to combine population databases to attain a more rapid detection system of 
adverse drug reactions are in progress. At the same time, these extensive databases 
can also be deployed for more detailed investigation of the aforementioned issues on 
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the cardiovascular safety of NSAIDs. The feasibility of such studies will rely on the 
available data to control for confounding, the outcomes of interest and, foremost, timing 
and details on drug exposure. 
Consensus is growing that Aβ-peptide has a role in AD pathogenesis. Our work on 
Aβ42-lowering NSAIDs and risk of AD again provides indirect support hereof. Pharma-
ceutical industries are already pursuing a variety of other amyloid-based therapeutics 
for the prevention and treatment of AD.63,64 Only few of the newly developed com-
pounds have reached the stage of human testing and, unfortunately, success has yet 
failed to materialize. One of these compounds under study for the prevention of AD 
progression, and of particular relevance to our study, concerns the R-enantiomer of the 
NSAID flurbiprofen. R-flurbiprofen is a potent reducer of amyloid-β levels but without 
COX-inhibiting properties.65 Initial results based from a Phase III trial looked promising, 
but the investigators recently concluded that the drug had no beneficial effects on AD 
progression.66 Though lack of effect on progression of AD would not exclude efficacy 
in the prevention of AD, the development of the drug was nevertheless halted. Another 
approach that had reached the clinical trail stage comprised that of passive or active 
immunization with amyloid antibodies.67 Preliminary results showed that patients with 
a higher antibody titer had a slowing of the progression of cognitive loss. However, 
the program was discontinued prematurely after signs of aseptic meningoencephalitis 
developed in some treated patients.68 Despite these setbacks, hopes for amyloid 
directed therapy in AD are high. Future research directed to unravel the AD pathology, 
will be necessary to clarify whether amyloid-β remains a rational target for future drug 
development in AD. 
Though our studies showed that there may be a role for statins and antihypertensives 
in the prevention of AD, there is still limited evidence available from primary prevention 
trials. Most trials performed to date did not include a systematic clinical cognitive 
assessment or did not have sufficient power to detect a beneficial effect on AD. Also, 
in the view of health care cost-containment it may not be a very attractive outlook to 
expand the, already substantial, number of persons eligible for cholesterol lowering 
or antihypertensive treatment. This would lead to considerable increase in health care 
costs.69,70 Therefore, treatment with these drugs for the sole purpose of AD prevention 
would only by attainable if not merely proven effective, but also cost-effective.71 Also, if 
further primary prevention trials were to be conducted we should first focus on patient 
groups who are already eligible for treatment with these drugs or who at greater risk 
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of developing AD. Moreover, we could gain power and efficiency by using biologic and 
imaging markers that predict future risk of disease for the recruitment of participants as 
well as outcome parameters.72 
We described that antihypertensive use may prevent progression of WML. WML pro-
gression represents one of the most convincing and readily measurable markers of 
progressing vascular brain disease. WML changes are objective and quantifiable as 
compared to the more subjective clinical diagnosis of subsequent disease. Furthermore, 
WML changes can be detected early in the disease process and thus shorten the 
duration of follow-up which in turn is expected to reduce selection bias. The European 
Task Force on Age-Related White Matter Changes73 has suggested that trials on vas-
cular brain disease may use lesion load progression as a secondary outcome variable 
to evaluate therapeutic effects.74,75 Thus far, this endpoint has been adopted in several 
trials, including two trials on antihypertensives.76,77 
These trials provide the initial insights into the potential role of these therapeutic agents 
in prevention progression of WML. However, because these trials allowed for usual 
antihypertensive treatment in both treatment and control arms, it remains unclear 
whether the beneficial effect of antihypertensive treatment on WML progression was 
due to a stronger reduction in blood pressure in the treatment arms or whether some 
agents may provide (more) beneficial effects above others. Placebo-controlled studies 
of antihypertensives on WML-progression are thus needed to provide conclusive 
evidence. Clinical trials may also overcome some methodological issues encountered in 
current observational research investigating this association, such as confounding-by-
indication and selective attrition of study participants. 
The cross-sectional investigation of antithrombotic drugs and microbleeds that we report 
on showed that, in the general population, cerebral microbleeds were more prevalent 
in persons who had used, or were using, antithrombotic drugs. In view of broadening 
indications for antithrombotic medication in prevention of ischemic disease, we feel that 
our results justify further longitudinal research into this association. 
The research presented in this thesis illustrates that observational research on the 
effect of drugs on disease can also be used to provide us with clues on the pathway to 
disease which in turn can provide a basis for further basic scientific or clinical research. 
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The aging global population will create an unsurpassed burden of the age-related 
neurological conditions such as Alzheimer disease (AD), Parkinson disease (PD) 
and stroke. Despite intensive research in the last decades no effective therapy for 
the prevention or treatment of these disorders is currently available. On the basis of 
previously proposed risk factors and current knowledge of pathogenesis, we sought to 
investigate two drug groups as determinants of neurodegenerative and cerebrovascular 
disease and of potential imaging markers of these disorders. In Chapter 1 nonsteroidal 
anti-inflammatory drugs (NSAIDs) are studied in relation to the outcomes of stroke, TIA, 
PD and AD. NSAIDs are among the most widely used drugs by elderly persons, mainly 
employed for their anti-inflammatory and analgesic effects. In Chapter 2 we attend to 
cardiovascular medication as determinant of AD, and two markers of vascular brain 
disease as seen on magnetic resonance imaging scans (MRI), namely white matter 
lesion (WML) progression and cerebral microbleeds. We considered three chronically 
used cardiovascular drugs which are all essential drugs in vascular risk management, 
namely antihypertensives, cholesterol-lowering drugs and anti-thrombotics. The studies 
presented in this thesis are based on the prospective population-based Rotterdam 
Study which was initiated in 1990-1993 in 7,983 persons of 55 years and over, living 
in a well-defined suburb of Rotterdam, the Netherlands. Our final study also included 
a randomly selected sample from the first expansion of the Rotterdam Study cohort of 
persons 60 years and older. We had detailed information on prescription drug exposure 
from local automated pharmacy records from 1991 and during the complete follow-up.
Following the previous reports from clinical and observational research on the increased 
risk of thrombotic events with cyclooxygenase (COX)-2 selective NSAIDs we first 
examined the relation between NSAID use and stroke in Chapter 1.1. NSAIDs were 
grouped according to their relative selectivity for the two isoforms of cyclooxygenase-
enzymes as COX1-selective, non-selective and COX2-selective NSAIDs. We found an 
increased risk of stroke with current use non-selective and COX2-selective NSAIDs 
at time of the event. Using the same approach we also investigated the association 
between NSAID use and risk of TIA. Like for stroke, we found an increased risk of 
TIA with current use of NSAIDs that appeared not to be restricted to COX2-selective 
NSAIDs (Chapter 1.2). Our data contests the notion that the risk of thrombotic events, 
including risk of ischemic cerebrovascular events, is not restricted to the use of COX2-
selective NSAIDs.
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There is growing evidence for a role of inflammation in PD pathogenesis. Hence, it 
was hypothesized that NSAIDs may have a beneficial effect on PD risk. In Chapter 1.3 
we investigated whether NSAID use reduced the risk of PD. In this study we found no 
significant beneficial effect of NSAID use on the risk of PD. A drawback of this study 
was the limited power due to low case numbers. Consequently we were unable to 
investigate the effects of long-term use of these drugs or differences across subtypes of 
NSAIDs. These kinds of subanalyses are potentially interesting, as the protective effect 
may depend on the duration of use or differ across NSAIDs subtypes.
A leading hypothesis regarding AD pathogenesis postulates a central role for amyloid-
β42 (Aβ42) peptide, the major constituent of senile plaques observed in the AD 
diseased brain. Several lines of evidence suggest that certain NSAIDs interfere with 
Aβ42-processing and ultimately lower Aβ42 levels. In Chapter 1.4 we report that 
the reduced risk of AD associated with long-term use of NSAIDs was confined to the 
subgroup of NSAIDs that interfere with Aβ42-processing. Our observation corroborates 
in vitro and animal studies which suggest that this group of NSAIDs influence the risk 
of AD through an amyloid-processing related mechanism, rather than an inflammatory 
effect. Moreover, these data shed new light on the interpretation of recent trials for no 
beneficial effect of long-term treatment with NSAIDs on AD whilst the trial included 
only non-Aβ42-lowering NSAIDs. Further investigation of the role of Aβ42 in AD patho-
genesis is of importance, as it could prove a target for development of preventive 
treatment strategies in AD. 
Evidence from observational studies has suggested that cholesterol-lowering agents, 
including statins, may prevent against AD. High cholesterol-levels have been associated 
with AD risk as well. However, brain cholesterol is synthesized in situ and exchange 
over the blood-brain-barrier (BBB) is limited. Hence, it was suggested that only 
lipophilic statins, those that cross the BBB, would affect brain cholesterol. In Chapter 
2.1 we showed that the protective effect of statins was observed irrespective of their 
lipophilicity. Many other factors besides lipid solubility determine a drug’s distribution in 
different tissues, which may explain our findings. It may also be that brain penetration is 
not essential for statins to exert their effect on AD pathology.
 
Increased blood pressure has also shown to be a risk factor for the development of 
AD. Therefore, we investigate in Chapter 2.2 if the use of antihypertensives would 
conversely reduce the risk of AD. We found that the use of antihypertensive drugs was 
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associated with 8% risk reduction of dementia per year of use for persons below 75 
years of age. This is in line with the view with the view that increased blood pressure 
earlier in life increases the risk of dementia, whereas high blood pressure in older 
persons may not necessarily put persons at higher risk for dementia. 
Apart from the association between antihypertensives and AD, we also examined 
whether antihypertensive use would reduce the risk of WML-progression (Chapter 2.3). 
WML are established imaging markers of vascular brain disease, which have been 
related to an increased risk of stroke and dementia. Hypertension has been identified 
as a well known risk factor for the presence of WML and a potential target for treatment 
strategies. In a subset of 320 persons from the Rotterdam Study with follow-up MRI 
data, we found that users of antihypertensive use prior to baseline MRI had a reduced 
risk of WML progression at follow-up in persons younger than 70 years of age or with 
controlled blood pressure. Above 70 years of age, no benefit of antihypertensives was 
observed and our findings were subject to selective loss-to-follow-up. 
For our final study on antithrombotics and presence of microbleeds, described in 
Chapter 2.4, we also included a random sample from the first extension of the original 
Rotterdam Study of persons aged 60 years and over. By means of a cross-sectional 
study design we determined whether the use of antithrombotic drugs, between start of 
the Rotterdam Study in 1991 and first MRI scan (2005-2006), was related to presence 
of cerebral microbleeds. We show that use of antithrombotic drugs is related to a 
higher prevalence of cerebral microbleeds, thereby confirming our a priori hypothesis. 
The possible implications of our findings to clinical management in patients with 
cardiovascular or cerebrovascular disease, justifies longitudinal research into this 
relation. 
The research presented in this thesis illustrates that observational research on the 
effect of drugs on disease can be used to provide us with clues on the pathway to 
disease. This in turn can provide a basis for further basic scientific or clinical research 
and the development of new drugs. 
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De ‘vergrijzing’ van de wereldbevolking zal een ongekende toename in ziektelast 
van ouderdomsgerelateerde neurologische en cerebrovasculaire aandoeningen 
zoals de ziekte van Alzheimer (AD), de ziekte van Parkinson (PD) en beroerte tot 
gevolg hebben. Ondanks intensief onderzoek in de laatste decennia is tot op heden 
geen preventie van deze ziekten mogelijk of effectieve behandeling voorhanden. 
Op basis van eerder geïdentificeerde risicofactoren en kennis van de pathogenese, 
hebben wij twee groepen geneesmiddelen onderzocht als mogelijke determinanten 
van neurodegeneratieve en cerebrovasculaire aandoeningen en daaraan verwante 
afwijkingen in het brein zoals gezien op magnetic resonance imaging (MRI). Hoofdstuk 
1 omvat het onderzoek naar non-steroïde anti-inflammatoire geneesmiddelen (NSAIDs) 
in relatie tot beroerte, transient ischemic attack (TIA), PD en AD. NSAIDs behoren tot 
een van de meest gebruikte geneesmiddelen onder ouderen, voornamelijk toegepast 
bij bewegingsapparaat gerelateerde pijn en vanwege hun anti-inflammatoire effecten. 
In Hoofdstuk 2 besteden we aandacht aan cardiovasculaire medicatie in relatie tot 
AD en twee markers van vasculaire schade in het brein, namelijk wittestofafwijkingen 
(WML) en cerebrale micro-bloedingen zoals waargenomen op MRI scans. We richten 
ons op drie chronisch gebruikte cardiovasculaire middelen die veelal toegepast worden 
in vasculair risicomanagment, namelijk antihypertensiva, cholesterolverlagers en 
antitrombotica. De studies in dit proefschrift zijn uitgevoerd binnen het in 1990-1993 
gestartte prospectieve Erasmus Rotterdam Gezondheid Onderzoek (ERGO/Rotterdam 
Study) onder 7,983 mannen en vrouwen uit de algemene bevolking van 55 jaar en 
ouder, woonachtig in de Rotterdamse wijk Ommoord en, voor onze laatste studie, 
een willekeurige sample van de eerste uitbreiding van dit cohort onder mensen van 
60 jaar en ouder. Gedetailleerde informatie van voorgeschreven geneesmiddelen uit 
geautomatiseerde gegevens van de lokale openbare apotheken was vanaf 1991 en 
gedurende de complete looptijd beschikbaar. 
In navolging van eerdere publicaties over een verhoogd risico van thrombotische 
accidenten met het gebruik van cyclooxygenase (COX)-2 selectieve NSAIDs, in 
klinisch en observationeel onderzoek, onderzochten wij in Hoofdstuk 1.1 als eerste 
de relatie tussen NSAID gebruik en beroerte. NSAIDs werden aan de hand van hun 
relatieve selectiviteit voor beide isovormen van het COX-enzym gegroepeerd in COX1-
selectieve, niet-COX-selectieve en COX2-selectieve NSAIDs. We vonden een verhoogd 
risico van beroerte voor personen die ten tijde van het optreden van de beroerte 
gebruikers waren van niet-selectieve en COX2-selectieve NSAIDs. Op dezelfde wijze 
onderzochten wij tevens de relatie tussen NSAIDs en het optreden van TIA in Hoofdstuk 
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1.2. Net als voor beroerte hadden gebruikers van NSAIDs een verhoogd risico op TIA. 
Dit verhoogde risico leek eveneens niet beperkt te zijn tot COX2-selectieve NSAIDs. 
Onze bevindingen spreken de huidige opvattingen tegen dat het verhoogde risico van 
trombo-embolische incidenten, inclusief ischemische cerebrovasculaire incidenten, 
beperkt is tot de COX2-selectieve NSAIDs. 
Er zijn meer en meer aanwijzingen dat ontsteking een rol speelt in de pathogenese van 
de ziekte van Parkinson (PD). Derhalve bestond de hypothese dat NSAIDs mogelijk het 
ontstaan van PD zouden kunnen voorkomen. In Hoofdstuk 1.3 gingen wij na of NSAID 
gebruik het risico van PD zou verlagen. In dit onderzoek vonden we geen beschermend 
effect van NSAIDs bij PD. De studie werd beperkt door het kleine aantal personen 
met PD. Hierdoor was nader onderzoek, naar de lange termijn effecten van NSAIDs 
of verschillen tussen de diverse NSAIDs, niet mogelijk. Deze analyses zijn mogelijk 
interessant aangezien het beschermende effect af kan hangen van duur of het type 
NSAID. 
Een vooraanstaande hypothese met betrekking tot Alzheimer pathogenese stelt 
een centrale rol voor het amyloïd-β42-eiwit. Amyloid-β42 (Aβ42) is het voornaamste 
bestandeel van de seniele plaques kenmerkend voor de hersenen van AD patiënten. 
Resultaten van verschillende onderzoeksgebieden suggereren dat bepaalde NSAIDs 
interfereren met de amyloïd homeostase en de concentraties van dit eiwit verlagen. De 
resultaten van Hoofdstuk 1.4 laten zien dat het beschermende effect van langdurig 
gebruik van NSAIDs in AD beperkt is tot de NSAIDs met een Aβ42 verlagend effect. 
Onze bevindingen sluiten aan bij eerdere aanwijzingen uit in vitro en diermodel studies 
waaruit bleek dat deze groep NSAIDs het risico van AD middels een aan amyloïd 
gerelateerd proces beïnvloedden, in plaats van een via een anti-inflammatoir effect. 
De resultaten geven bovendien een andere kijk op de resultaten van recent klinisch 
onderzoek waarin werd geconcludeerd dat langdurig gebruik van niet-Aβ42 verlagende 
NSAIDs niet zou beschermen tegen AD. Additioneel bewijs voor een rol van Aβ42 in 
AD is belangrijk, aangezien het een interessant aanknopingspunt kan zijn voor de 
ontwikkeling van preventieve behandelingen voor AD. 
Uit eerder verricht observationeel onderzoek is gebleken dat cholesterolverlagers, 
waaronder statines, het risico op AD zouden kunnen verlagen. Tevens is er een verband 
aangetoond tussen concentraties van cholesterol en het risico van AD. Echter, de 
synthese van brein cholesterol vindt vrijwel geheel in situ plaats en cholesterol wordt 
 170
nauwelijks over de bloed-hersen-barriere (BHB) uitgewisseld. Daarom werd gedacht 
dat alleen lipofiele statins, degene die de BHB makkelijker zouden passeren, een 
effect zouden hebben op cholesterol in het centrale zenuwstelsel. In Hoofdstuk 2.1 
laten we zien dat statines het risico op AD verlagen, maar dat dit onafhankelijk is van 
de lipofiliteit van het statine. Naast dat veel andere factoren de verdeling van statines 
in verschillende weefsel bepaalt, kan het ook zo zijn dat passage van de BHB niet 
essentieel is voor statines om een effect te kunnen hebben op AD pathogenese hetgeen 
onze bevindingen zou kunnen verklaren. 
Net als cholesterol, is een verhoogde bloeddruk ook in verband gebracht met het 
risico op dementie. Daarom onderzochten wij in Hoofdstuk 2.2 of het gebruik van 
antihypertensiva het risico op dementie kon verlagen. Wij vonden dat het gebruik van 
antihypertensiva geassocieerd was met een 8% reductie van het risico op dementie per 
jaar gebruik bij personen van 75 jaar en jonger. Dit is in lijn met eerdere bevindingen die 
suggereren dat met name verhoogde bloeddruk op jongere leeftijd geassocieerd is met 
een verhoogd risico op dementie, terwijl op latere leeftijd het mogelijk andersom geldt. 
Naast het verband tussen antihypertensiva en het risico op AD bekeken wij tevens, 
in Hoofdstuk 2.3, of het gebruik van antihypertensiva het risico op progressie van 
cerebrale wittestofafwijkingen kon verlagen. Wittestofafwijkingen zijn erkende markers 
van vasculair hersenlijden en zijn in verband gebracht met een verhoogd risico op 
beroerte en dementie. Hypertensie is een bekende risicofactor voor de aanwezigheid 
en progressie van wittestofafwijkingen en daarmee een potentieel aanknopingspunt 
voor therapeutische preventie. In een subset van de ERGO onderzoeksgroep met 
MRI-scan data vonden wij dat gebruik van antihypertensiva in de periode tussen 
1991 en de eerste MRI-scan (1995-1996) minder kans hadden op progressie van 
wittestofafwijkingen bij personen jonger dan 70 jaar of met een gecontroleerde 
bloeddruk. Bij personen ouder dan 70 jaar bleken antihypertensiva de progressie van 
wittestofafwijkingen niet te voorkomen en werd meer non-respons geconstateerd onder 
gebruikers van antihypertensiva dan niet gebruikers hetgeen onze resultaten kan 
hebben beïnvloed. 
Onze laatste studie in dit proefschrift, beschreven in Hoofdstuk 2.4, is gebaseerd op 
een willekeurig geselecteerde subpopulatie van deelnemers van het originele ERGO 
cohort en een uitbreiding van het cohort onder personen van 60 jaar en ouder. Middels 
een cross-sectionele studie hebben wij in deze populatie onderzocht of gebruik van 
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antitrombotica, tussen aanvang van ERGO (1991-1994) en de eerste MRI scan in 
(2005-2006), gerelateerd was aan de aanwezigheid van cerebrale microbloedingen. 
We vonden dat gebruikers van plaatjes aggregatie remmers, middelen die de bloed-
stolselvorming remmen, een verhoogd risico hadden op deze microbloedingen 
hetgeen onze a priori hypothese bevestigde. Dezelfde relatie vonden wij niet voor 
anticogulantia, middelen die de stabilisatie van het stolsel tegengaan. Daarnaast zou 
er een verschil kunnen bestaan tussen de relatie van aspirine enerzijds en carbasalaat 
calcium anderzijds tot strikt lobaire microbloedingen. De mogelijke implicaties van 
deze bevindingen voor klinische besluitvorming bij patiënten met cardiovasculair en 
cerebrovasculair lijden illustreert de noodzaak voor verder longitudinaal onderzoek naar 
deze associatie. 
Het onderzoek gepresenteerd in dit proefschrift illustreert dat observationeel onderzoek 
naar de effecten van geneesmiddelen op een ziekte belangrijke aanwijzingen kan geven 
over een ziekteproces en een basis vormen voor verder basaal wetenschappelijk of 
klinisch onderzoek en ontwikkeling van nieuwe geneesmiddelen. 
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